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CHAPTER 1 
Introduction 

Renal transplantation and immunosuppression 
There are three treatment options for patients with end-stage renal disease: 
haemodialysis, peritoneal dialysis, and renal transplantation. None of these 
modalities of treatment has definitely been proven to be superior over the others in 
prolonging the life expectancy of a patient (1). Many studies have indicated 
however that quality of life is substantially higher after a successful renal 
transplantation than on dialysis therapy (2-4). In addition, after the first post­
operative year, treatment related costs of renal transplantation are much lower than 
those of any mode of dialysis (5). Therefore, renal transplantation is regarded as 
the treatment of choice for most patients with end-stage renal disease. During the 
past decades, outcome of renal transplantation has steadily improved with current 
one-year graft survival rates for cadaveric grafts amounting to 85% (6). 
After transplantation, recognition of foreign antigens elicits an immune response 
which potentially results in rejection of the allograft. Rejections are grossly divided 
in an acute and a chronic form whereas mixed pictures are also encountered. Acute 
rejection leads to rapid deterioration of renal function and is histologically mainly 
characterized by a cellular infiltrate. Treatment is possible with additional 
immunosuppression given as high doses of corticosteroids or antibodies against 
Τ lymphocytes, although complete resolution is not always achieved. Moreover, 
occurrence of an acute rejection episode may herald the onset of chronic rejection 
and it worsens the prognosis of long-term graft function (7-10). Chronic rejection 
proceeds more insidiously with a gradual decline of renal function. Histological 
examination in these cases shows vascular narrowing and interstitial fibrosis. 
Currently, there are no adequate therapeutic options to retard this process and 
chronic rejection is the most frequent cause of late allograft failure (11,12). 
To prevent the occurrence of acute and chronic rejection, renal allograft 
recipients receive life-long immunosuppressive therapy. The combination of 
prednisone and azathioprine has long been the standard baseline immunosuppressive 
regimen. A substantial improvement of graft survival rates was achieved after 
introduction of cyclosporine A (CsA) in the late seventies (13-17). Nowadays, 
CsA, often combined with prednisone, azathioprine, or both, forms the cornerstone 
of immunosuppressive therapy after renal transplantation. 
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Adverse effects of immunosuppressive drugs 
Unfortunately, all immunosuppressive drugs have considerable side-effects. 
Adverse effects common to the use of any immunosuppressive drug are the 
increased risk of infections and malignancies. In addition, each drug has its own 
array of possible complications. Prednisone can induce or aggravate osteoporosis, 
osteonecrosis, obesity, diabetes mellitus, cataract, peptic ulceration, hypertension, 
and hyperlipidaemia. The use of azathioprine is frequently complicated by bone 
marrow depression and hepatotoxicity. The most common side-effects of CsA are 
nephrotoxicity, hypertension, hyperlipidaemia, tremor, hypertrichosis, and gingival 
hypertrophy. Because CsA has a narrow therapeutic range, treatment with the drug 
is monitored by measuring its blood concentration. The daily costs of CsA amount 
more than tenfold those of prednisone or azathioprine. The effects of prednisone 
and CsA on lipid metabolism (18) are of particular clinical relevance, since 
cardiovascular diseases are a major cause of morbidity and mortality in the popula-
tion concerned (19,20). 
Of all side-effects of CsA, nephrotoxicity is the most important. Functional 
changes to the vascular and tubular system of the kidney are distinguished from 
structural changes leading to histologic injury (21). The functional effect on the 
renal vessels consists of vasoconstriction, especially of the afferent arteriole, 
leading to a decrease in glomerular filtration rate (GFR) after each individual dose 
of CsA (22). The pathophysiologic mechanisms mediating the renal 
vasoconstriction are not entirely clear. Stimulation of the renin-angiotensin system 
(23), increased activity of the sympathetic nervous system (24), an imbalance 
between vasoconstrictor and vasodilator eicosanoids (25), and enhanced endothelin 
action (26-28) all have been implicated to explain the increase in renal vascular 
tone. The functional tubular effects are reflected in altered tubular handling of 
urate, magnesium, bicarbonate, potassium, and N1 methylnicotinamide (29,30). The 
functional changes in blood vessels and tubules appear to remain reversible, even 
after prolonged treatment with CsA (31). Chronic use of CsA can lead to structural 
changes such as occlusion of the arteriole, glomerulosclerosis, and interstitial 
fibrosis, which are irreversible once established (32,33). It is this form of CsA-
induced nephropathy that is feared most, although recent studies suggest that CsA-
induced toxicity is not an important cause of late graft dysfunction or graft loss 
(9,17,34). 
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Optimal immunosuppressive drug regimen 
Especially because immunosuppressive therapy has to be used chronically, one 
would favour a drug regimen that couples an adequate immunosuppressive effect to 
a minimum of side-effects and costs. Finding such a regimen is not so easy, since 
an increase in the level of immunosuppression will inevitably result in more 
complications. Therefore, one has to weigh the frequency of rejections and graft 
losses on the one hand against the incidence and severity of adverse effects on the 
other hand. In this search for an optimal immunosuppressive regimen several 
strategies may be followed. 
1. Combination of low doses of CsA, prednisone and azathioprine (triple-drug 
therapy). 
This seems an attractive approach since all drugs are supposed to add to the 
immunosuppressive effect, while the side-effects of each drug may be reduced at 
the lower doses. Although triple therapy is widely applied, its superiority over 
other regimens, especially double therapy with CsA and prednisone has not been 
proven (35-37). Moreover, CsA impairs renal function even if given in low doses 
(38). 
2. Replacement of CsA by azathioprine at 3 to 12 months after transplantation. 
This concept is based on the impression that the improvement in graft survival by 
the use of CsA mainly results from a decrease in the number of rejection episodes 
during the first few months after transplantation. Switching from CsA to 
azathioprine at some time after transplantation with continuation of prednisone, 
takes advantage of this early decrease in immunological graft loss while it prevents 
a decline of graft function due to chronic exposure to CsA. In a recent meta-
analysis (39) it was documented that conversion from CsA to azathioprine is 
followed by an increased incidence of acute rejections. However, patient and graft 
survival rates were not adversely affected. Several studies have shown that 
conversion is followed by an improvement in renal function and blood pressure 
(40-44). 
3. CsA monotherapy. 
The strong immunosuppressive action of CsA allows this drug to be given as a 
single immunosuppressive agent after renal transplantation, thereby avoiding the 
complications of long term use of prednisone and azathioprine. In the earliest 
clinical trials, when high starting doses of CsA were used, CsA monotherapy was 
given from the day of transplantation (14,45). Afterwards, lower doses of CsA 
have usually been combined with prednisone during the first months after 
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transplantation, with subsequent attempts to discontinue the steroids. As reviewed 
in a meta-analysis (46), steroid withdrawal increases the risk of rejection, and is 
ultimately feasible in about half of the cases only. Despite the increased rejection 
rate however, cessation of steroid therapy does not appear to affect graft survival 
negatively (46). Moreover, when successful, steroid withdrawal has been reported 
to improve blood pressure and serum cholesterol levels (47-49). 
4. Pharmacological amelioration of the renal adverse effects of CsA. 
The renal vasoconstriction that acutely occurs after each dose of CsA may 
contribute to the irreversible graft damage associated with chronic use of the drug. 
Several agents have been studied for their potential to ameliorate CsA-induced 
renal dysfunction. In one study, fish oil was reported to improve renal function in 
CsA-treated renal transplant patients independently of its favorable effect on the 
incidence of acute rejections (50), although these results could not be confirmed by 
others (51). Dihydropyridine calcium antagonists appear to be more promising 
agents in this regard. They have repeatedly been shown to reduce the CsA-induced 
decrease in renal blood flow and GFR in renal transplant recipients (52,53). In 
addition they are able to lessen the incidence and duration of delayed graft failure 
(54,55). 
Outcome measures 
Several outcome measures can be employed to evaluate the degree to which 
these different strategies meet our goals. The effectiveness of immunosuppression 
is usually judged by the rate of immunological graft losses and the incidence of 
acute and chronic rejections. Depending on the type of adverse effect, more or less 
objective measures such as clinical signs and laboratory markers, are available to 
evaluate its presence or severity. Furthermore, it has been advocated to express the 
impact that a treatment has on the patient, in terms of quality of life (56,57). A 
common way to measure quality of life is to use validated questionnaires. An 
important characteristic of these quality of life measurements is that they assess the 
subjective perception by the patient of his physical as well as psychological and 
emotional state. The patient's appraisal of his condition has been demonstrated to 
influence compliance with the therapeutic regimen (58), which in turn is an 
important determinant of long term graft survival (59-61). Finally, concern about 
the costs of medical treatment is growing. Therefore, cost-effectiveness analysis 
(62) should complete the set of outcome measures that are used to compare 
alternative treatment strategies. 
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Outline of the thesis 
The studies described in these thesis concerned the following issues: 
A. Comparison of CsA monotherapy versus the combination of azathioprine and 
prednisone. 
In a prospective trial, patients were treated with the combination of CsA and 
prednisone during the first three months after renal transplantation. Subsequently 
they were randomized to withdrawal of steroids (resulting in CsA monotherapy) or 
replacement of CsA by azathioprine. With a follow-up of at least two years in all 
patients, we compared both treatment regimens with respect to patient and graft 
survival, occurrence of rejections, and graft function (Chapter 2). During the first 
year after transplantation we also measured the effects of both therapies on health 
care costs (Chapter 2) and on quality of life (Chapter 3). Using the pill count 
method we studied the compliance with immunosuppressive and antihypertensive 
medication, as well as factors affecting it, in the participants of the same trial 
(Chapter 4). 
B. The effect of CsA and prednisone on apolipoprotein and lipid metabolism after 
renal transplantation (Chapter 5). 
The design of our randomized trial allowed us to compare directly the effects of 
CsA and prednisone on the serum lipid profile. In addition, we were able to 
examine the supposed benefits of steroid withdrawal in CsA treated patients. 
C. The effects of CsA and the calcium antagonist nifedipine on renal function in 
renal transplant patients. 
Although substantial knowledge already exists on the renal effects of CsA, we 
studied some as yet less explored aspects. First, we performed a detailed 
investigation of the magnitude and time course of changes in various parameters of 
renal function after cessation of CsA at three months after transplantation (Chapter 
6). Second, in view of its known tubulotoxic properties, we questioned whether 
CsA might inhibit the tubular secretion of creatinine in addition to its effect on 
GFR. In chapter 7 we show how the drug Cimetidine can be used as a tool to 
quantify the tubular secretion of creatinine. Subsequently, we applied this method 
to determine the effect of CsA on tubular creatinine secretion (Chapter 8). Finally, 
we examined the acute renal effects of nifedipine in CsA-treated renal transplant 
patients. To investigate whether the effects of nifedipine are limited to patients on 
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CsA or whether they might also apply to those not treated with CsA, we repeated 
the measurements after replacement of CsA by azathioprine (Chapter 9). 
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CHAPTER 2 
Randomized, prospective trial of cyclosporine 
monotherapy versus azathioprine-prednisone from 
three months after renal transplantation 
L.B. Hilbrands, A.J. Hoitsma, and R.A.P. Koene 
Transplantation, in press 

ABSTRACT 
Cyclosporin (CsA) and prednisone (Pred) are the most widely used drugs for 
immunosuppression after renal transplantation, but both drugs have marked side 
effects. Either replacement of CsA by azathioprine (Aza) or withdrawal of 
prednisone (Pred) resulting in CsA monotherapy, can be employed to circumvent 
the adverse effects on the long run. Both treatment regimens were compared in this 
prospective randomized trial in patients who were treated with CsA and Pred 
during the first 3 months after renal transplantation (CsA: η = 64, Aza-Pred: η=63, 
median duration of follow-up: 3.9 years). Estimated graft survival rates at 5 years 
after transplantation (in patients with a functioning graft at 3 months) were 78% in 
the CsA group and 87% in the Aza-Pred group. The incidence of a rejection within 
3 months after start of steroid withdrawal or conversion from CsA to Aza was 30% 
and 25% respectively (NS). At 2 years after transplantation, serum creatinine levels 
were lower in the Aza-Pred group (126+35 μπιοΐ/ΐ) than in the CsA group 
(180+78 μίτιοΐ/ΐ; Ρ<0.001). There were no differences in blood pressure or 
incidence of infections between the treatment groups. Treatment-related costs were 
measured during the first year after transplantation and were lower in the Aza-Pred 
group (DFL 40,882 + 18,895 vs. DFL 53,484+44,828; P<0.05). In conclusion, 
CsA monotherapy and Aza-Pred treatment from three months after renal 
transplantation are comparably effective immunosuppressive treatment regimens, 
although Aza-Pred therapy results in better graft function. Both withdrawal of 
steroids and replacement of CsA by Aza, carry a substantial risk of rejection. The 
previously demonstrated cost-effectiveness of CsA-containing therapies seems to be 
limited to the first phase after transplantation. Conversion to Aza-Pred at three 
months after transplantation reduces costs. 
INTRODUCTION 
The combination of cyclosporine (CsA) and prednisone (Pred), frequently 
supplemented by azathioprine (Aza), is widely used as standard immunosuppressive 
drug regimen after renal transplantation. Although figures regarding graft survival 
with the use of these drugs are quite satisfactory, concern remains about their side 
effects, especially when they are used chronically. Pred is feared for its effects on 
bone metabolism and skin, its potential to induce hyperglycaemia, hyperlipidaemia, 
and cataract, and its contribution to hypertension (1,2). The nephrotoxic properties 
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of CsA are well known and long term use of this drug has been associated with 
irreversible loss of graft function due to vascular obliteration and interstitial fibrosis 
(3), although recent data on this issue are less worrisome (4,5). In addition, CsA 
importantly contributes to post-transplant hypertension (6) and has also been 
implicated in the pathogenesis of hypercholesterolemia in these patients (2). To 
reduce the incidence of these long term adverse effects in patients treated with CsA 
and Pred, two strategies may be followed. One is to withdraw the steroids, leading 
to CsA monotherapy. Alternatively, CsA can be replaced by Aza, a drug with a 
less impressive side effect profile, with continuation of Pred. Conversion from CsA 
to Aza at three months after renal transplantation has been our standard protocol 
during recent years. In different studies, both CsA monotherapy (7-9) and 
conversion from CsA to Aza (10-13) have been demonstrated to yield adequate 
results in terms of graft survival and graft function. In 1989, we initiated a 
randomized, prospective trial to compare these two treatment regimens with respect 
to efficacy, side effects, and costs. All patients were on CsA and Pred until three 
months after transplantation, when they were randomized to CsA monotherapy or 
Aza-Pred. With a duration of follow-up of at least two years in all patients, this 
paper describes the results with emphasis on rejection incidence, graft function, and 
costs. Detailed data on the effects of both therapies on quality of life (14) and lipid 
metabolism (15) during the first year after transplantation are published separately. 
PATIENTS AND METHODS 
Patient population and randomisation procedure 
From June 1989 to June 1992, all 236 adult patients who underwent a first or 
second cadaveric renal transplantation at our institution were candidates for this 
study. Patients were excluded when they fulfilled one or more of the following 
exclusion criteria: age above 65 years (n=10), history of psychiatric disease or 
alcohol abuse (n=14), history of malignancy (n=7), signs of active hepatitis or 
carriage of hepatitis В surface antigen (n=7), haemolytic uremic syndrome as 
original kidney disease (n=6), use of anti-epileptic drugs (n=5), and allergy to 
Aza (n=2). Quality of life measurements necessitated the exclusion of patients with 
poor knowledge of Dutch language (n=16). Finally, five patients refused to 
participate, resulting in a number of 185 patients who were eligible for the study. 
Patients received CsA and Pred during the first three months after 
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transplantation. Afterwards, they were allocated to CsA monotherapy or to the 
combination of Aza and Pred. Treatment allocation was carried out by the 
minimization method (16) with frequency matching for the following factors: sex 
and age (<40/>40 years) of the recipient, diabetes mellitus (yes/no), type of 
previous renal replacement therapy (hemodialysis/CAPD), previous transplantation 
(yes/no), number of rejections (0/1/>2), treatment with anti-thymocyte globulin 
during the first three months (yes/no), temporary interruption of CsA therapy 
(<10/>10 days), graft function (creatinine clearance <50/50-75/>75 ml/min), 
proteinuria (<0.1/0.1-1.0/> 1.0 g/1), number of antihypertensive drugs 
(0/l/2/>3), and age of the donor (< 10/ll-50/>51 years). At three months after 
transplantation, 58 of the 185 eligible patients could not be allocated to one of both 
treatment arms. Main causes were a relatively high incidence of patient death 
(n = 8) and graft loss (n=30), resulting in a graft survival rate of 79% at three 
months after transplantation. Other reasons to withdraw patients from 
randomisation were: loss of patient to follow-up (n=l), contraindication for CsA 
by clinical judgment (usually because of signs of CsA nephrotoxicity; n=17), use 
of Aza contraindicated because of bone marrow depression (n= 1), and use of Pred 
contraindicated because of severe osteoporosis (n=l). The remaining 127 patients 
made up our study population. 
Postulating a two year graft survival (starting with 100% at three months after 
transplantation) of 80% with our standard therapy, 80 patients on each treatment 
were required to provide 80% power of detecting a difference in graft survival of 
15%. Lower than expected patient accrual and a high incidence of graft loss before 
randomisation, resulted in ending up with somewhat less patients in each group 
after the three year accrual period. 
The most frequent causes of renal insufficiency in the study patients were 
chronic pyelonephritis (n=20), autosomal dominant polycystic kidney disease 
(n=13) and IgA nephropathy (n=9). Two patients (both in the CsA group) had 
diabetic nephropathy and in 22 patients the cause of renal failure was unknown. 
A prognostic index, a score including information on both the donor and 
recipient which was developed to predict graft survival, was calculated according to 
Thorogood et al. (17). 
Study protocol 
The surgical procedure included infusion of mannitol and a moderate hydration 
protocol as described previously (18). After surgery, CsA was given intravenously 
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(3 mg/kg/day) for the first three days, followed by 12 mg/kg/day in two divided 
oral doses during the first month. This was gradually reduced to 4 mg/kg/day at 
three months after transplantation, adjusting the dosage to maintain CsA trough 
blood levels between 200 and 400 ng/ml (monoclonal antibody assay). In case of 
signs of severe CsA nephrotoxicity, temporary replacement of CsA by Aza 
(3 mg/kg) was allowed. Prednisolone was given at a dose of 100 mg/day i.v. 
during the first two days, followed by an oral Pred dosage of 25 mg/day during the 
remainder of the first month and 20 mg/day during the second and third month 
after transplantation. In patients who were randomised to receive CsA 
monotherapy, CsA was continued in the same dosage with adjustments to reach 
trough blood levels between 100 and 200 ng/ml (monoclonal antibody assay). The 
daily Pred dosage was reduced by 5 mg every two weeks resulting in CsA 
monotherapy after six weeks. In patients allocated to Aza-Pred therapy, CsA was 
replaced without overlap by Aza in a dosage of 3 mg/kg. Their Pred dosage was 
temporarily increased from 20 to 25 mg/day and reduced by 5 mg every two weeks 
until a maintenance dose of 10 mg/day was reached. In the CsA group, Pred was 
restarted if more than one acute rejection or chronic vascular rejection occurred 
after randomisation. The same conditions led to replacement of Aza by CsA in the 
Aza-Pred group. In case of severe and persistent side effects, attributable to one of 
the drugs, patients were put on the alternative treatment regimen. 
The diagnosis of acute rejection was made on clinical grounds and histologically 
confirmed in 81 % of cases. During the first three months after transplantation acute 
rejection episodes were treated with methylprednisolone (1 g/day i.v. on three 
consecutive days) or antithymocyte globulin (ATG, RIVM Bilthoven, The 
Netherlands; 200 mg/day i.v. on alternate days for 10 d). An oral course of high-
dose Pred (initial dosage 200 mg/day tapering to 25 mg/day in 12 d) was given 
after failure of one or both of these treatments. From three months after 
transplantation (i.e. after randomisation) acute rejections were primarily treated 
with ATG in all cases. High-dose Pred courses were given in case of failure of 
ATG, bone marrow suppression, or previous treatment with ATG for rejection. 
Occasionally, acute rejections were treated with monoclonal anti-CD3 antibodies. 
Hypertension, defined as diastolic blood pressure above 95 mmHg on three 
consecutive occasions, was initially treated in a standard way using a /3-blocker 
(atenolol), followed by the addition of a calcium-antagonist (nifedipine) and a 
diuretic (chlorthalidone) when necessary. Beyond the first year after 
transplantation, when most patients were seen in different community hospitals, 
antihypertensive therapy reflected local practice. 
26 
Body weight and blood pressure as well as results from routine clinical 
chemistry were recorded at regular intervals as part of the usual post-transplant 
patient evaluation. A diagnosis of urinary tract infection was made when a positive 
urine culture prompted antibiotic therapy. Cytomegalovirus infection was defined 
by a fourfold rise in IgG antibody titer. The diagnosis of other infections was based 
on clinical judgment. Creatinine clearance was estimated with the formula given by 
Cockcroft and Gault (19). Proteinuria was defined as urinary protein concentration 
of 0.2 g/1 or more (24 hour urinary protein excretion was not measured routinely). 
Whole blood CsA levels were measured with a fluorescence polarization immuno-
assay (Abbott Laboratories, North Chicago, Illinois, USA), initially using 
polyclonal antibodies directed against the parent molecule of CsA and some of its 
metabolites. The majority of blood levels were measured with a modified kit, using 
monoclonal antibodies against the CsA parent molecule without cross-reactivity. A 
conversion factor of 0.5 was used to adjust the initial values to those currently 
measured. 
The study was approved by the Hospital Ethics Committee and all patients gave 
written informed consent. 
Cost analysis 
The health care costs directly related to either treatment regimen were 
calculated for the first year after transplantation. Costs of kidney-acquisition and 
indirect costs for society, e.g. costs related to disablement, were not considered. 
Two patients who died, two patients with graft loss, and one patient in whom 
insufficient data were available, were excluded from this analysis (death and graft 
loss were evenly distributed among both groups). The medical records were used 
as data source for number of admission days, number of visits to the outpatient 
clinic, and amounts of all kind of drugs that were used during hospital stays 
(except drugs used in the operating room) as well as on an outpatient basis. 
Similarly, the number of blood products administered and the number of CsA 
blood level measurements were counted. Our hospital financial administration 
service provided data on activities regarding the following items: clinical 
laboratory, operating room and anesthesia, diagnostic radiology, nuclear medicine, 
endoscopy, pathology, and physiotherapy. Prices current during 1993 or 1994, and 
expressed in Dutch guilders (1 DFL is about US$ 0.60) were used to calculate 
costs. The direct costs of hospital days and visits to the outpatient clinic were 
estimated on the basis of personnel costs and material expenses (excluding 
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medication and blood products) and amounted about DFL 300 and DFL 75, 
respectively. For the intensive care unit, costs were estimated at DFL 2,000 per 
day. The costs of other services were assessed in an analogous way and in case 
reliable estimations were not attainable (as for laboratory services), charges were 
used as a proxy for costs. 
Statistical analysis 
The results were analyzed on an intention-to-treat basis. Calculations were 
performed with the SAS system (SAS Institute Inc., Сагу, North Carolina, USA). 
Data are given as means with SD unless stated otherwise. Unpaired and paired 
comparisons of numerical data were performed with Wilcoxon's rank sum and 
signed ranks tests. Proportions were compared with chi-square analysis using 
continuity correction or with McNemars test when appropriate. Probabilities of 
survival were calculated by the Kaplan Meier product limit method and for 
comparison of survival curves the logrank test was used. A Ρ value smaller than 
0.05 was considered statistically significant. 
RESULTS 
The characteristics of patients and their kidney donors are given in Table 1. 
Except for a better degree of HLA-B matching in the Aza-Pred group, there were 
no significant differences between both treatment groups. In addition, the 58 
patients who initially were eligible for the study but could not be randomised at 
three months after transplantation, did not differ with regard to these base-line 
characteristics. At the time of randomisation, there were no differences between 
both groups in clinical data (Table 1). The median duration of follow-up in patients 
with still functioning grafts was 3.9 years (range: 2.7-5.6 years). 
Course of treatment 
Since the originally assigned treatment was changed for various reasons in a 
considerable number of patients, an overview of the course of treatment in all 
randomized patients is given in Table 2. In some patients, the immunosuppressive 
treatment regimen had to be changed for a second or third time. Despite the 
numerous changes, all data were analyzed according to the intention-to-treat 
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Table 1. Patient and donor characteristics m 127 study patients who participated in a 
randomized trial comparing Ciclosporine monotherapy (CsA) with a combination of 
azathioprine and prednisone (Aza-Pred). 
Data at time of transplantation 
Sex (male/female) 
Age (years) 
Time on dialysis (months) 
Number of graft (first/second) 
Cold ischemia time (hours) 
Age of donor (years) 
Highest % panel reactive antibodies (<5%/5-85%/>85%) 
Number of mismatches on HLA-A (0/ > 1) 
HLA-B (0/2:1) 
HLA-DR (0/ > 1) 
Prognostic index scoreb first transplants 
second transplants 
Clinical data at time of randomisation (3 months afli 
Requirement for dialysis after transplantation (%) 
Temporary interruption of CsA treatment (%) 
One or more acute rejections during first 3 months (%) 
Serum creatinine (μπιοΐ/ΐ) 
Estimated creatinine clearance (ral/min) 
Proteinuria > 0.2 g/1 (%) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Use of antihypertensive drug(s) (%) 
CsA 
(n=64) 
40/24 
43 + 13 
30 ±22 
52/12 
30±7 
42 + 16 
25/37/1" 
23/41 
19/45 
46/18 
0.87+0.37 
0.78+0.28 
Aza-Pred 
(n=63) 
41/22 
42 + 14 
27 + 17 
53/10 
30+7 
39 + 17 
30/30/2a 
33/30 
38/25c 
53/10 
0.76+0.36 
0.48+0.36 
er transplantation) 
22 (34) 
14 (22) 
17 (27) 
158+60 
55 + 19 
10 (16) 
154+26 
92 + 11 
45 (70) 
15 (24) 
12 (19) 
16 (25) 
151+39 
56 + 19 
10 (16) 
153+21 
92+8 
47 (75) 
No data available in one patient in each group. 
A higher prognostic index score indicates worse graft prognosis of a first or second 
graft respectively. The scores for first and second grafts are calculated by different 
formulas and cannot be compared. 
Ρ <0.001 for difference between both groups. 
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Table 2. Course of treatment in patients who were allocated to treatment with 
cyclosponne monotherapy (CsA) or azathiopnne and prednisone (Aza-Pred) 
Year after transplantation 
5th 
CsA -» Aza-Pred 
+ Aza-Pred 
CsA 
Patients with sufficient length of follow-up3 
Patient death / Graft failure6 c 
Reasons to deviate from originally assigned therapy ά 
+ Pred - > 2 acute rejections 
- chronic rejection 
- other reasons 
- CsA nephrotoxicity 
- other reasons 
- chronic rejection and CsA 
nephrotoxicity 
Immunosuppressive therapy at end of each year 
- continuously on CsA monotherapy 
- CsA monotherapy after interruption by other therapy 
- Pred 
- CsA-Pred 
- Aza-Pred 
- CsA-Aza-Pred 
Aza-Pred 
Patients with sufficient length of follow-up2 
Patient death / Graft failure11 
Reasons to deviate from originally assigned therapy d 
Aza-Pred -» CsA - > 2 acute rejections 
- bone marrow suppression 
- elevated liver enzymes 
- other reasons 
Immunosuppressive therapy at end of each year 
- continuously on Aza-Pred 
- Aza-Pred after interruption by other therapy 
- CsA 
- CsA-Pred 
64 
1/1 
4 
4 
4 
11 
1 
1 
37 
-
13 
11 
1 
63 
1/1 
2 
8 
4 
-
47 
2 
7 
5 
62 
2/1 
. 
3 
1 
2 
1 
1 
28 
1 
1 
13 
10 
6 
61 
2/1 
1 
4 
-
1 
40 
3 
6 
9 
52 
2/5 
_ 
2 
1 
-
-
-
21 
1 
13 
9 
1 
50 
-/-
-
-
1 
35 
3 
6 
6 
26 
-/1 
„ 
-
-
-
-
~ 
14 
1 
6 
3 
1 
28 
-12 
. 
-
-
-
19 
2 
3 
2 
8 
-/-
_ 
-
-
-
-
" 
4 
-
3 
1 
-
6 
-/-
_ 
-
-
-
6 
-
-
-
Patients who died or lost graft function during preceding years were excluded. 
The number of patients with a functioning graft at the end of each year equals the 
number of patients with sufficient length of follow-up minus the number of patients 
who died or returned to dialysis during that year 
One patient has died during the sixth year of follow-up 
Following the deviation of the originally assigned therapy, treatment was changed for 
a second or third time in some patients (e g conversion from CsA to Aza-Pred was 
sometimes followed by reconversion to CsA-Pred) 
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principle. In patients who died or in whom graft failure occurred (n=21), therapy 
had been changed previously in seven cases. Persistent symptoms of a steroid 
withdrawal syndrome (fatigue, arthralgia) necessitated temporary reinstitution of 
steroids in three CsA-treated patients, but eventually these patients received CsA 
monotherapy. In the CsA group, the CsA dose gradually decreased from 4.0±1.0 
mg/kg/day at the end of the first year to 2.9+0.9 mg/kg/day at the end of the fifth 
year after transplantation. Only CsA trough levels that were measured during the 
first nine months after allocation to CsA monotherapy were analyzed, since beyond 
this period most of the patients were seen in various community hospitals, that used 
different analytical techniques to determine CsA levels. The frequency of levels 
below the target range varied from 2% at 5 months after transplantation to 7% at 4 
months after transplantation. 
Patient and graft survival 
Estimated five-year patient survivals (in survivors at three months) were 92% 
and 95% in the CsA and Aza-Pred group, respectively. The death of six patients in 
the CsA group was caused by pneumonia (n=3, in one case caused by 
Pneumocystis Carinii), myocardial infarction (n=l), rupture of abdominal aortic 
aneurysm (n=l), and uterine cervix carcinoma (n=l). In the Aza-Pred, group 
three patients died. Causes of death were myocardial infarction, brain 
haemorrhage, and malignant lymphoma of the lungs. Kaplan Meier plots of 
probability of graft survival (death with a functioning graft was considered as graft 
failure) are given in Figure 1. Probabilities of survival with a functioning graft at 
five years after transplantation (again starting with 100% at 3 months after 
transplantation) were estimated on 78% in the CsA group and 87% in the Aza-Pred 
group (NS). In one patient a recurrence of focal glomerular sclerosis led to return 
to dialysis. All other graft failures in surviving patients (8 in CsA group and 3 in 
Aza-Pred group) were due to rejection. 
Rejections 
From the time of randomisation until end of follow-up, a total number of 68 
rejections were diagnosed in 46 patients. In the CsA group 43 rejections occurred 
in 27 patients (42% incidence of at least one rejection), whereas in the Aza-Pred 
group 25 rejections were found in 19 patients (30%; NS for difference with CsA). 
Thirty-five (76%) patients of those with at least one rejection after randomisation, 
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Figure 1. Kaplan-Meier graft survival curves of the two treatment groups 
had no rejection during the first three months after transplantation In the majority 
of cases, rejections became manifest within 3 months after start of steroid 
withdrawal or conversion from CsA to Aza randomisation (CsA 19/27, Aza-Pred 
16/19) For rejections occurring between randomisation and the end of the first 
year after transplantation, the interval between randomisation and rejection was 
significantly shorter in the Aza-Pred group (CsA [n=26] 12±8 weeks, Aza-Pred 
[n=18] 6+7 weeks, P < 0 01) Thus, the incidence of acute rejection within 
4 weeks after change of therapy was 3% in the CsA group as compared to 19% in 
the Aza-Pred group (P=0 01) A histologic diagnosis of chronic vascular rejection 
was made in 17 patients in the CsA group and in 12 cases in the Aza-Pred group 
(NS) Time from transplantation until the diagnosis of chronic rejection was 
comparable in both groups (median with range CsA 9 months [4-33], Aza-Pred 
7 months [4-42], NS) In all but 3 CsA-treated and all but 4 Aza-Pred treated 
patients, chrome rejection was preceded by one or more acute rejection episodes 
Patients in whom one or more rejections occurred after allocation to CsA or 
Aza-Pred treatment, did not differ from those without rejections with respect to 
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various clinical and immunological risk factors, prognostic index score, or 
proportion of patients with rejections in the first three months after transplantation. 
Likewise, the 11 patients in whom rejection ultimately resulted in graft failure were 
not characterized by extreme levels of HLA mismatches, percentage panel reactive 
antibodies, or prognostic index score. Remarkably however, nine of these patients 
had been free of any rejection episode at time of conversion or start of steroid 
taper, and in eight of the latter nine a rejection occurred between 4 and 20 weeks 
after the changes in therapy. Expressed in another way, in patients having a first 
rejection episode between 4 and 20 weeks after steroid withdrawal or conversion 
from CsA to Aza at three months after transplantation (n=31), the risk of 
subsequent graft failure due to rejection was 26%. 
When event-free survival was defined as survival with a functioning graft 
without diagnosis of acute or chronic rejection, the probability of this survival at 5 
years after transplantation was estimated to amount 48% and 65% in the CsA and 
Aza-Pred group, respectively (NS). 
Graft f unction and blood pressure 
As expected, conversion from CsA to Aza was followed by a sustained 
improvement in graft function (Table 3). During the first three months after this 
conversion, estimated creatinine clearance increased with 19±20% (P<0.001). 
After withdrawal of steroids in the CsA monotherapy group, a slight increase in 
serum creatinine was observed. This could not be attributed to the occurrence of 
rejection, since a rise in creatinine (7.5±13.9% between 3 and 6 months after 
transplantation, P<0.01) was still present after patients with a rejection or overt 
signs of CsA nephrotoxicity had been excluded. Restricting the comparison 
between both groups to rejection-free patients who were kept on their originally 
assigned therapy, resulted in one year serum creatinine levels of 148+40 μπιοΐ/ΐ 
and 122 + 30 μπ\ο\Ι\ in the CsA and Aza-Pred group respectively (P<0.05). Except 
for a transiently lower frequency of proteinuria at 6 months after transplantation in 
the CsA group, there were no differences in the incidence or degree of proteinuria 
(latter data not shown). Similar reductions in systolic as well as diastolic blood 
pressure were observed after withdrawal of steroids or conversion from CsA to 
Aza (change in systolic blood pressure between 3 and 6 months after 
transplantation: -6+13% vs. -6±14% [NS], change in diastolic blood pressure: 
-5 + 17 vs. -7 + 12% [NS]). Although diastolic blood pressure tended to be higher in 
the CsA group, the difference only reached statistical significance at four years 
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after transplantation. Antihypertensive therapy was considered necessary in about 
two-thirds of all patients during the first year after transplantation and the 
requirement for blood pressure reduction did not decline during subsequent years. 
There was no difference in the need for antihypertensive treatment between both 
groups. 
Infections 
During the universally completed follow-up period of two years after 
transplantation, there were no differences between both groups with regard to the 
number of patients with urinary tract infections, respiratory tract infections, 
cytomegalovirus infections, or the combined incidence of all other infections. 
Cost analysis 
Direct treatment-related costs during the first year after transplantation were 
higher in the CsA group (P<0.05, Table 4 and Figure 2). The majority of data 
Proportion of patients (%) 
60 -
40 -
20 
• CsA 
1 Aza-Pred 
In 
< 25,000 25,000-
50,000 
50,000-
75,000 
> 75,000 
Total costs (DFL) 
Figure 2. Proportion of patients in different categories of total treatment-related costs 
during the first year after transplantation. 
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allowed separate analyses for the periods before and after randomisation 
respectively. As expected, there were no significant differences between both 
groups before randomisation. After randomisation, the CsA group was 
characterized by significantly higher drug costs and costs of CsA level 
measurements. These differences as well as a tendency to higher costs of 
hospitalization in the CsA group, mainly accounted for the difference in total 
whole-year costs. In the CsA group, whole-year costs of CsA comprised 68% of 
all drug costs as compared to 48% in the Aza-Pred group. When only the period 
Table 4. Direct treatment-related costs per patient during the first year after 
transplantation in patients who were allocated to treatment with Ciclosporine monotherapy 
(CsA) or a combination of azathioprine and prednisone (Aza-Pred). When available, 
separate data are given for months 1-3 (i.e. before randomisation) and months 4-12 
respectively. Costs are expressed in Dutch guilders. 
A. Hospitalization 
B. Drugs 
C. Visits to outpatient clinic 
D. CsA level measurements 
E. Renal replacement therapy 
A + B + C + D + E 
F. Laboratory services (excl. 
months 1-3 
months 4-12 
entire year 
months 1-3 
months 4-12 
entire year 
months 1-3 
months 4-12 
entire year 
months 1-3 
months 4-12 
entire year 
months 1-3 
months 4-12 
entire year 
months 1-3 
months 4-12 
CsA levels) 
G. Other diagnostic and therapeutic activities 
H. Blood products 
Total costs 
CsA 
8,311+4,692 
10,520±30,609 
18,831 ±31,444 
5,641 ±2,598 
9,064±4,713 
14,706±5,361 
816 + 189 
1,554±597 
2,370±625 
965 ±365 
1,009 ±459 
1,975 ±675 
551±1,316 
109±788 
660 ±1,497 
16,285 ±7,023 
22,257±33,727 
9,453±7,352 
4,944±3,882 
545 ±1,168 
53,484±44,828 
Aza-Pred 
8,036±4,351 
5,579±8,925 
13,615±10,159 
5,829±2,677 
4,280±4,062a 
10,109±4,680a 
852 + 185 
1?499±449 
2,351 ±502 
1,020 ±387 
173 ± 347a 
l,194±495a 
374 ±881 
35 ±273 
409 ±908 
16,111 ±6,674 
ll,566±ll,878 a 
8,516±3,207 
4,335 ±4,425 
355±571 
40,882 ±18,895" 
Ρ <0.001, " Ρ <0.05 for differences between both groups. 
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after randomisation was included in the calculations (months 4-12), these figures 
were 67% and 19% respectively. When costs of standard immunosuppressive 
therapy (CsA, Aza, and Pred) and of CsA level measurements were not 
considered, mean costs per patient decreased to DFL 41,155 ±44,890 and 
DFL 33,655±18,919 in the CsA and Aza-Pred group respectively (NS). Exclusion 
of five patients who were admitted to the intensive care unit (CsA: 3, Aza-Pred: 2) 
resulted in a reduction of the mean costs of hospitalization by more than 20%. In 
the remaining patients, total costs did not significantly differ between both groups 
(CsA: DFL 44,311 ±17,159, Aza-Pred: DFL 39,624± 17,873). Not surprisingly, in 
patients who experienced one or more rejection episodes during the first year after 
transplantation, costs were significantly higher than in patients without any 
rejection (DFL 56,717±39,406 vs. DFL 37,333±26,250; P<0.001). Occurrence 
of a rejection after the time of allocation to either treatment group resulted in an 
increase of total costs by DFL 21,557 per patient in the CsA group and by DFL 
17,054 per patient in the Aza-Pred group. 
DISCUSSION 
This study demonstrates that CsA monotherapy and Aza-Pred treatment from 
three months after renal transplantation are comparably effective 
immunosuppressive treatment regimens in terms of patient and graft survival. 
Keeping in mind that survival curves departed from 100% at three months after 
transplantation, the observed patient and graft survival agree with the pooled results 
of other centers using CsA-based immunosuppressive regimens (20,21). However, 
the relatively small sample size of the current study may have obscured a 
difference in graft survival between both groups. 
One of our major findings was the rather high incidence of acute rejections after 
both steroid withdrawal and conversion from CsA to Aza. In several studies the 
risk of having an acute rejection episode has been shown to decrease with time, 
and most patients free of rejection at 3 months after transplantation remained so 
during the rest of the first post-transplantation year (22,23). In the current study 
however, the number of patients with rejections between 3 and 12 months after 
transplantation exceeded the number of patients with rejections during the first 
three months in both treatment groups. Acute rejections tended to be more frequent 
in the CsA group but the difference did not reach statistical significance. The 19% 
incidence of acute rejections within the first month after conversion from CsA to 
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Aza was relatively high as compared to our previous experience of only 6% (24). 
We do not have a clear explanation for this discrepancy since the same treatment 
schedule, including temporary increase of the prednisone dosage following 
conversion, was used. With either an overlap between CsA and Aza treatment of at 
least several weeks or a transient increase in the steroid dosage, other authors 
reported a rejection incidence during different time intervals following conversion 
of 15 to 40% (11,25-28). 
There are several reasons to assume that a considerable proportion of these 
rejections have been precipitated by the changes in immunosuppressive therapy at 
three months after transplantation. First, the majority of rejections occurred in the 
first three months after change of the therapeutic regimen. In the Aza-Pred group 
rejections occurred even earlier than in the CsA group which may be caused by the 
prompt switch of CsA to Aza as opposed to gradual tapering of the steroid dose in 
the latter group. Secondly, patients with a rejection following conversion or steroid 
withdrawal did not differ from non-rejecting subjects with respect to immunological 
risk factors or incidence of prior rejection episodes, which increases the likelihood 
of a treatment factor being involved. The low incidence of suboptimal CsA blood 
levels makes it unlikely that rejections in the CsA group were related to 
underdosing of this drug. Therefore, elective withdrawal of steroids and 
replacement of CsA by Aza at three months after transplantation appear to increase 
the risk of rejection, although we could not perform a proper comparison with a 
control group continued on CsA-Pred. Patients in whom rejection occurred shortly 
after steroid withdrawal or conversion were particularly prone to subsequent graft 
failure, which suggests that these reductions in immunosuppressive therapy may 
have contributed to graft loss in some cases. A higher risk of graft failure in late 
first-rejection episodes has also been observed by others (25). 
To our knowledge, only one clinical trial using the same design as the present 
study has been performed before (29). In contrast to our findings, the incidence of 
rejections in that study tended to be higher in 28 converted patients than in 40 
patients who remained on CsA monotherapy (29% vs. 18%). Numerous other 
studies on elective withdrawal of either cyclosporine or steroids have been 
published and the results of these studies were reviewed in two recent meta-
analyses (30,31). In accordance with our observations, it was concluded that both 
steroid withdrawal and discontinuation of CsA increase the risk of acute rejection. 
Nevertheless, there was no evidence from these meta-analyses that the higher 
incidence of rejections adversely affects patient or graft survival, although the 
duration of follow-up of the separate studies may have been too short to detect 
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significant differences. 
Although our data are presented as a comparison between CsA monotherapy 
and Aza-Pred (according to the intention-to-treat principle), the considerable 
incidence of treatment failures in both groups has to be noticed (Table 2). 
Resumption of Pred because of acute or chronic rejection and conversion from CsA 
to Aza-Pred because of CsA related nephrotoxicity were the main reasons to 
deviate from the originally assigned CsA monotherapy. At the end of the second 
year after transplantation, 28 of the 59 patients (47%) with a functioning graft had 
continuously been kept on CsA monotherapy and a similar rate of protocol 
adherence has been reported by others (32,33). Of these 28 patients on CsA 
monotherapy, 22 had remained free of acute or chronic rejection from the start of 
steroid taper. Thus, uncomplicated withdrawal of steroids was feasible in about one 
third of all cases. Return to CsA in the Aza-Pred group appeared necessary in 
about 25% of cases, mostly because of Aza related toxicity. 
Graft function was persistently better in Aza-Pred treated patients which may 
partly be explained by the somewhat lower incidence of rejections in this group. 
Nevertheless, after exclusion of patients in whom a rejection was diagnosed, the 
difference remained significant. Additional exclusion of patients who did not adhere 
to their original treatment left some 20% difference in graft function, which 
probably reflects the magnitude of CsA induced renal dysfunction. In accordance 
with recent data from literature (4,5), we found no evidence for a progressive 
deterioration of graft function during long term use of CsA. The interesting 
observation of a slight decrease in graft function after withdrawal of steroids in 
CsA-treated patients may mirror the rise in glomerular filtration rate which has 
been demonstrated in Pred-treated patients with Graves' ophthalmopathy (34). 
Other authors documented an increased incidence of CsA nephrotoxicity in patients 
treated with CsA monotherapy as compared with those treated with the combination 
of CsA and Pred (32). 
Somewhat unexpectedly, there was no substantial difference in blood pressure 
or use of antihypertensive drugs between groups. As reported before (35), there 
was a considerable reduction in blood pressure following withdrawal of steroids, 
which equalled that observed after conversion from CsA to Aza. The effect on 
blood pressure of a daily amount of 10 mg Pred therefore appears comparable to 
that of CsA in a dose of 4 mg/kg/day in the population of patients concerned. 
In another paper, we have reported that CsA monotherapy leads to a less 
favorable serum lipid and lipoprotein profile than Aza-Pred treatment (15). Use of 
CsA was associated with higher concentrations of serum triglycerides and 
39 
lipoprotein(a), and lower HDL cholesterol levels. Contrary to general belief, 
steroid withdrawal in CsA-treated patients had no beneficial effects on lipid 
metabolism. 
Regarding the important issue of quality of life as outcome measure after renal 
transplantation, we observed no major differences between both groups although a 
tendency for better scores on psychosocial items was found in patients successful 
taken off steroids (14). 
From an economic point of view, Aza-Pred was the most cost effective 
treatment regimen since it coupled lower costs with at least equal efficacy. Higher 
costs in the CsA group were partly caused by extremely high expenses for 
hospitalization in a few patients who were admitted to the intensive care unit. 
Nevertheless, the first-year costs of the drugs composing both immunosuppressive 
regimens differed by about DFL 4,500 per patient when analyzed on an intention-
to-treat basis. Previous studies had demonstrated the cost-effectiveness of CsA-
containing immunosuppressive regimens (36,37). However, in these studies control 
patients did not receive CsA at all, while in the current study all patients were 
treated with CsA during the first three months after transplantation. This initial 
treatment with CsA protected our patients from the high risk of rejection and 
associated costs of hospital readmissions, during the early phase after 
transplantation. Indeed, the finding of lower costs associated with the use of CsA in 
the study of Showstack et al. was confined to the direct post-transplantation 
hospitalization period, while total charges did not differ from those in the control 
group during the follow-up period (36). The costs that were related to late rejection 
episodes in our patients, indicate that strategies which reduce the incidence of late 
rejection episodes may result in important additional savings. 
Taken together, we conclude that with regard to graft survival, similar results 
can be achieved with CsA monotherapy and Aza-Pred as intentional treatment 
strategies from three months after transplantation. The majority of patients benefits 
from the discontinuation of either CsA or Pred without encountering major 
problems. While both regimens do not differ in their effect on blood pressure, Aza-
Pred has the advantages of better graft function, more favorable serum lipid and 
lipoprotein levels, and lower costs. On the other hand, successful withdrawal of 
steroid seems superior in terms of quality of life. An important drawback of both 
withdrawal of steroids and conversion of CsA to Aza however, is the considerable 
risk of subsequent rejection episodes. Aside from the chance of irreversible loss of 
graft function, treatment of these rejections will have to be paid for in terms of a 
higher incidence of infections, other side effects of the strong immunosuppressive 
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agents that are used, and money (1 course of ATG costs about DFL 5,000). 
Therefore, we believe that the treatment regimens employed in this trial are not 
ideal. 
How then to proceed if data indicate that indefinite continuation of both CsA 
and Pred to reduce the incidence of rejections probably means overtreatment in a 
substantial number of patients who consequently are exposed to the long term 
adverse effects of these drugs? We and others have not been able to identify 
patients in whom withdrawal of steroids or conversion is likely to be successful 
(11,35,38). Elective conversion of CsA to Aza at a longer interval after 
transplantation does not appear to reduce the rejection incidence (28,39,40). Some 
centres however, reported quite good results after reduction of immunosuppression 
in a subgroup of patients characterized by an uneventful course during the first year 
after transplantation (41,42). An alternative option is to replace Pred by Aza with 
continuation of CsA (35). The combination of CsA and Aza was recently shown by 
Opelz to provide excellent long-term graft survival rates (21). Currently we are 
performing a randomized trial comparing CsA-Pred with CsA-Aza from six months 
after renal transplantation. An important advantage of that trial, as compared to the 
study described in this paper, is the inclusion of a control group of patients who 
continue both CsA and Pred. This will allow a better appreciation of the possible 
occurrence of rejection episodes after replacement of Pred by Aza at six months 
after transplantation. 
In summary, CsA monotherapy and Aza-Pred from three months after 
transplantation both resulted in comparable graft survival rates. Either treatment 
had some advantages in terms of side effects and costs. However, the rather high 
risk of rejection associated with both regimens requires exploration of other 
strategies to minimize long term side effects of CsA and Pred. 
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THE EFFECT OF IMMUNOSUPPRESSIVE DRUGS ON QUALITY 
OF LIFE AFTER RENAL TRANSPLANTATION 
L U K A S В H I L B R A N D S , 1 2 A N D R I E S J . H O I T S M A , AND R O B E R T A Ρ K O E N E 
Department of Medicine, Division of Nephrology, University Hospital Nijmegen, NL 6500 HB Nijmegen, The Netherlands 
This prospect ive, randomized s t u d y i n v e s t i g a t e s t h e 
effect of two i m m u n o s u p p r e s s i v e t reatment r e g i m e n s 
o n qual i ty of life after renal t ransp lantat ion. At 3 
m o n t h s after t ransp lantat ion, p a t i e n t s t reated w i t h 
cyc lospor ine (CsA) and p r e d n i s o n e (Pred) w e r e allo­
cated to e i ther w i thdrawal of P r e d (n=60) or to con­
vers ion of CsA to azath iopr ine (Aza) (Aza-Pred, n = 6 0 ) . 
Qual ity of life w a s e v a l u a t e d jus t before randomiza­
tion, and at 6 and 12 m o n t h s after t ransp lantat ion 
u s i n g the S i c k n e s s Impact Prof i le (SIP), the Affect Bal­
a n c e Sca le (ABS), the Center for Ep idemio log ica l Stud­
ies D e p r e s s i o n Sca le (CES-D), m e a s u r e s of sat i s fact ion 
w i th several d o m a i n s of life e x p e r i e n c e , and a popula­
tion-specific phys ica l s y m p t o m s quest ionnaire . In 
both groups, t h e overal l S I P s c o r e a s wel l as t h e s c o r e s 
o n i ts physical and p s y c h o s o c i a l d i m e n s i o n s improved 
cont inuous ly after t ransp lantat ion, r e a c h i n g leve ls 
that are comparable t o t h o s e found in the genera l 
populat ion. The o c c u r r e n c e of a c u t e or chronic rejec­
t ion had a s igni f icant ly n e g a t i v e effect on S I P and 
CES-D scores. Intention-to-treat ana lys i s s h o w e d n o 
di f ferences b e t w e e n g r o u p s for s c o r e s on SIP, ABS, 
CES-D, and sat is fact ion m e a s u r e s . E x c l u s i o n of 41 pa­
t ients w h o did not str ict ly a d h e r e to the ir or ig inal ly 
d e s i g n a t e d therapy s h o w e d a t e n d e n c y for bet ter psy­
chosocia l SIP s c o r e s in CsA p a t i e n t s (P=0.05) , w h i c h 
mainly resu l ted from a di f ference o n t h e category of 
soc ia l in teract ion (P=0.01) . Th is di f ference o c c u r r e d 
desp i te a s imi lar re ject ion rate a n d w o r s e renal func­
t ion in CsA-treated pat ients . Short ly after s tero id 
withdrawal, a h i g h proport ion of CsA pat ients com­
pla ined of stiff or painful m u s c l e s (CsA: 74%, Aza-Pred: 
36%; P=0.002) . Our data ind icate that if success fu l ly 
completed, CsA m o n o t h e r a p y from 3 m o n t h s after 
t ransplantat ion may lead to a h i g h e r degree of psycho­
social well-being as c o m p a r e d w i th convers ion from 
CsA-Pred to Aza-Pred. It s e e m s l ike ly that th i s advan­
tage is re lated to t h e w i thdrawal of Pred. 
One of the primary goals of renal t ransplantat ion is to 
improve the quality of life of the pat ient with end-stage renal 
disease Traditional research efforts, however, have mainly 
been directed at prolonging patient and graft survival These 
survival rates have improved considerably during the last 
decades and any further progress will be hard to achieve 
Therefore, it is not surprising t h a t the quality of life of the 
patients with prolonged survival is receiving a growing 
amount of attention (/, 2) 
The type of immunosuppressive drug therapy is one of the 
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factors t h a t determine the quality of life after renal trans­
plantation First, an effective immunosuppressive regimen, 
leading to prolonged pat ient and graft survival, is a prereq­
uisite to reach an optimal level of quality of life Besides, 
t rea tment schedules may act more directly on quality of life 
by means of their adverse effects, which will differ according 
to the drugs t h a t are used Pat ients ' psychosocial function­
ing, which they will partly a t t r ibute to prescribed medica­
tion, will in turn have influence on the compliance with the 
therapeutic regimen (3) Eventually, compliance is one of the 
main determinants of long-term graft survival (4-7) 
Our aim was to investigate the impact of the currently 
most frequently used immunosuppressive drugs on changes 
in quality of life d u n n g the first year after renal t ransplan­
tation Health-related quality of life was therefore measured 
in part icipants in a randomized prospective trial comparing 
cyclosponne (CsA)* monotherapy with the combination of 
azathioprine (Aza) and prednisone (Pred) from 3 months 
after renal t ransplantat ion 
PATIENTS AND METHODS 
Patient population From July 19Θ9 to June 1992, all adult 
patients who underwent a first or second cadaveric renal transplan­
tation at our institution were invited to take part in this study 
Patients were excluded when they fulfilled one or more of the follow­
ing exclusion entena age above 65 years, history of psychiatric 
disease or alcohol abuse, history of malignancy, poor knowledge of 
Dutch language, signs of active hepatitis or carnage of hepatitis В 
surface antigen, hemolytic uremic syndrome as onginal kidney dis­
ease, use of anti epileptic drugs, and allergy to Aza After surgery, 
patients were treated with CsA and Pred for 3 months Afterward, 
Lhey were randomly allocated to CsA monotherapy or to the combi­
nation therapy of Aza and Pred At 3 months after transplantation, 
59 of the 186 patients who initially entered the study could not be 
randomized to a treatment arms for one of the following reasons 
patient death or graft loss in the first 3 months after transplantation 
(n = 39), loss of patient to follow-up (n=l), contraindication for CsA 
by clinical judgment (usually because of signs of СьА nephrotoxicity, 
n = 16), use of Aza contraindicated because of bone marrow depres­
sion (n-2), and use of Pred contraindicated because of severe 
osteoporosis (n = l) 
Study protocol CsA was given intravenously (3 mg/kg/day) for 
the first 3 days after surgery followed by 12 mg/kg/day in 2 divided 
oral doses dunng the first month This dosage was gradually reduced 
to 4 mg/kg/day at 3 months after transplantation The dosage was 
adjusted to maintain CsA trough blood levels between 200 and 400 
ng/ml Prednisolone was given at a dose of 100 mg/day ι ν during the 
first 2 days after surgery, followed by an oral Pred dosage of 25 
mg/day dunng the remainder of the first month and 20 mg/day 
* Abbreviations ABS, Affect Balance Scale, ATG, antithymocyte 
globulin Aza, azalhiopnne CES-D, Center of Epidemiological 
Studies Depression Scale, CsA, cyclosponne, Pred, prednisone, SIP, 
Sickness Impact Profile 
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during the second and third month after transplantation In patients 
who were randomized to receive CsA monotherapy, CsA was contin­
ued in the same dosage with adjustments to reach trough blood 
levels between 100 and 200 ng/ml The daily Pred dosage was re 
duced by 5 mg every 2 weeks resulting in CsA monotherapy after 6 
weeks In patients allocated to Aza Pred therapy, CsA was replaced 
without overlap by Aza at a dosage of 3 mg/kg Their Pred dosage was 
temporarily increased from 20 to 25 mg/day and reduced by 5 mg 
every 2 weeks until a maintenance dose of 10 mg/day was reached In 
the CsA group, Pred was restarted if more than 1 acute rejection or 
chronic vascular rejection occurred after randomization The same 
conditions led to replacement of Aza by CsA in the Aza Pred group 
In case of severe and persistent side effects, attributable to one ofthe 
drugs, patients were put on the alternative treatment regimen 
During the first 3 months after transplantation, acute rejection 
episodes were treated with methylprednisolone ( l g i v on 3 consec 
utive days) or antithymocyte globulin (ATG, RIVM Bilthoven, The 
Netherlands, 200 mg ι ν on alternate days for 10 days) An oral 
course of high-dose Pred (initial dosage 200 mg/day tapenng to 25 
mg/day in 12 days) was given after failure of one or both of these 
treatments 
From 3 months after transplantation (ι e , after randomization) 
acute rejections were treated primarily with ATG in all cases High-
dose Pred courses were given in case of failure of ATG, bone marrow 
suppression, or previous treatment with ATG for rejection 
Hypertension, defined as diastolic blood pressure above 95 
mmHg on 3 consecutive occasions, was treated in a standard way 
using a β blocker (atenolol), followed by the successive addition of 
a calcium antagonist (nifedipine) and a diuretic (chlorthalidone) 
when necessary 
Quality of life measurements (see below) were earned out at 3 
months (ι e , before randomization) as well as at 6 and 12 months 
after transplantation Body weight and blood pressure as well as 
results from routine clinical chemistry were recorded at regular 
intervals as part of the usual posttransplant patient evaluation 
Body mass (Quetelet) index was calculated as weight in kg divided by 
the square of the height in meters Creatinine clearance was 
estimated with the formula given by Cockcroft and Gault (8) 
The study was approved by the Hospital Ethics Committee and all 
patients gave written informed consent 
Quality of life assessment Questionnaires were administered by a 
single trained interviewer who was not aware of medical data ofthe 
patients, including their type of treatment The questionnaire con­
sisted of both generic measures and of questions rather specific for 
the population of renal transplant patients The genene measures 
comprised the Sickness Impact Profile (SIP), the Affect Balance 
Scale (ABS), the Center of Epidemiological Studies Depression Scale 
(CES D), and questions on satisfaction with several domains of life 
experience The SIP measures sickness related behavioral dysfunc 
tion and contains 136 items that can be divided into 12 categories (9) 
Three categories can be aggregated into a physical dimension (am­
bulation, mobility, and body care and movement), 4 categones make 
up a psychosocial dimension (social interaction, alertness behavior, 
communication, and emotional behavior), and 5 categones are inde 
pendent (eating, work home management, sleep and rest, and ree 
reation and pastimes) Total scores and scores on the vanous cate 
gones and dimensions are expressed on a scale of 0 to 100, with 
higher scores denoting worse state The Dutch version of the SIP that 
we used has been validated (10) The ABS contains 10 questions on 
positive and negative feelings dunng the past few weeks (11) Scores 
on the ABS can vary from 1 to 9, with higher scores indicating a more 
favorable grade of well being The CES D is another standardized 
measure of affect It is composed of 20 items that result in a score 
which increases along with a more depressive state from 0 to 60 {12) 
In addition to these composite scales, the questionnaire asked for 
overall life satisfaction and for satisfaction with 4 domains of life 
experience, denved from the study of Campbell et al (13) We added 
2 items questioning satisfaction with sexual activities and with the 
renal transplantation The complete list of domain satisfaction mea 
sures is given in Appendix A Finally, the questionnaire contained a 
set of physical symptoms, a number of them being rather specific for 
the population of renal transplant patients (Appendix B) Most of 
these items were gathered from vanous other studies Retesting of 
validity and responsiveness of this disease-specific questionnaire 
was not considered necessary (14) 
Statistical analysis All data were analyzed with the SAS system 
(SAS Institute Ine , Сагу, NC) Because the majonty of data were not 
normally distnbuted data are given as medians, with interquartile 
range in brackets Unpaired compansons of numencal data between 
2 groups at different time points were earned out with Wilcoxon's 
rank sum test Proportions were compared with chi square analysis 
using continuity correction Paired compansons of numencal and 
ordinal data within 1 group were performed with Wilcoxons signed 
rank test Simple correlations were assessed by calculating Spear 
man's correlation coefficient A P-value smaller than 0 05 was con­
sidered statistically significant 
RESULTS 
Full evaluation ofthe data was not possible in 7 ofthe 127 
patients who were allocated to the t rea tment groups Two 
patients (1 in each t r e a t m e n t group) died between 3 and 12 
months after t ransplantat ion Two patients (both in the CsA 
group) were not able to respond to the questionnaire a t 6 
months after t ransplantat ion because of severe illness Two 
more pat ients (1 in each group) discontinued their participa­
tion Finally, in 1 case (Aza-Pred group), the interviewer 
judged the answers as highly unreliable 
The demographic and clinical charactenstics of the re 
maining 120 pat ients are shown in Table 1 There were no 
significant differences between the t reatment groups 
Intention to treat analysis Graft loss occurred once in 
each group between 3 and 6 months after t ransplantat ion To 
perform an intention-to-treat analysis, these patients were 
not excluded and they completed the questionnaires while 
having returned to hemodialysis The main clinical results of 
the t ransplantat ion are given in Table 2 As expected, renal 
function improved after conversion from CsA to Aza in the 
Aza-Pred group This resulted in a significant difference be­
tween groups a t 12 months after transplantat ion The num­
ber of pat ients with 1 or more acute rejection episodes after 
randomization (ι e , between 3 and 12 months after t rans­
plantation) was 25 (42%) in the CsA group and 16 (27%) in 
the Aza-Pred group (NS) Chrome rejection was observed in 
15 pat ients (CsA 10, Aza Pred 5, NS) and was only twice not 
preceded by any acute rejection episode None of the other 
parameters t h a t may influence quality of life showed a sig­
nificant difference between groups The time course of scores 
on the SIP, ABS, and CES-D is given in Table 3 A continu­
ous, significant improvement of SIP scores took place be­
tween 3 and 12 months after t ransplantat ion in both groups 
Neither the actual values nor the degree of improvement of 
any score differed significantly between t rea tment groups 
Acute rejection, chronic rejection, or both were diagnosed in 
43 pat ients between 3 and 12 months after t ransplantat ion 
Their quality of life during this interval (i e at 6 months 
after t ransplantat ion) appeared worse than in nonrejecting 
patients (Table 4) In the whole group, there was a negative 
correlation between creatinine clearance and total SIP score 
(at 3 months Д = - 0 41, P < 0 001, at 6 months Д = - 0 21, 
P = 0 02, a t 12 months Д = - 0 24, P=0 009) After exclusion of 
patients who experienced acute or chronic rejection, this 
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TABLE 1 Characteristics of patients who were treated with CsA monotherapy or Aza and Pred from 3 months after renal 
transplantation" 
Sex(M/F) 
Age (yr) 
First/second Tx 
Time on dialysis (mo) 
Diabetes melli tus 
M a n t a ] s ta tus 
Unmarr ied, living alone 
MamecVhving together 
Widowed 
Divorced 
Living si tuat ion 
Alone 
Living with par tner / spouse 
Living in a family 
Otherwise 
Highest level of education 
Basic school 
Lower vocational t ra in ing 
Higher vocational t r a in ing 
only 
Lower general secondary education 
Higher general secondary educat ion 
College 
Salaried position 
All patients (n*120) 
76/44 
43(29-53) 
98/22 
23(13-38) 
1 
31 
83 
3 
3 
10 
38 
60 
12 
14 
45 
23 
16 
8 
14 
34 
CsA(n = 60) 
38/22 
43(32-53) 
48/12 
25(12-43) 
1 
12 
43 
2 
3 
4 
19 
31 
6 
5 
24 
10 
11 
3 
7 
18 
Aza Pred (n=60) 
38/22 
42(28-54) 
50/10 
23(14-38) 
0 
19 
40 
1 
0 
6 
19 
29 
6 
9 
21 
13 
5 
5 
7 
16 
1
 Numerical data are given as medians with interquartile ranges 
TABLE 2 Clinical results at 3 months (before randomization) and 12 months after renal transplantation in patients allocated to CsA 
monotherapy (n = 60) or treatment with Aza and Pred (n=60) 
CsA OBA 
At least 1 acute rejection 
Chronic rejection 
Antihypertensive therapy 
Body mass index (kg/m2) 
Weight gain after Tx (%) 
Creatinine clearance (ml/min) 
Hemoglobin (mmol/L) 
16(27) 
44 (73) 
23 7 
(21 3-25 6) 
33 
( -0 3-9 2) 
57 
(40-69) 
72 
(6 3-7 7) 
Aza Pred 
numbers (%) 
16 (27) 34° (57) 
— 10(17) 
44 (73) 39 (65) 
medians (interquartile range1;) 
23 3 25 5* 
(215-25 8) (22 6-27 1) 
4 3 10 0" 
(-0 1-7 7) (3 7-16 9) 
52 53 
(42-66) (43-67) 
70 8 1* 
(6 7-7 8) (7 3-8 8) 
° Including rejections that occurred during the first 3 months 
* P<Q 001 for difference with values of the same treatment group at 3 months after transplantation 
' P<0 001 for difference with CsA group 
29° (48) 
5(8) 
39 (65) 
25 0* 
(22 0-27 7) 
8 6* 
(4 1-12 8) 
6 4 " 
(53-84) 
8 1* 
(7 3-8 6) 
correlation remained significant a t 3 months ( ñ = - 0 37, 
P < 0 001), but had disappeared a t 6 and 12 months after 
transplantat ion 
Per-protocol analysts In 39 patients, the initially assigned 
t rea tment had to be changed for a variety of reasons Pred 
was added to CsA in 7 pat ients because of the occurrence of 
more than 1 acute rejection or chronic rejection episode after 
steroid withdrawal In another 6 patients, steroid with-
drawal was not completed for a variety of reasons CsA was 
replaced by Aza in 12 cases, all but once because of CsA-
induced renal dysfunction In 2 patients , Aza was replaced by 
CsA because the pat ients had a second acute rejection 
episode after prior conversion from CsA to Aza Bone marrow 
depression and liver function disturbances prompted switch-
ing from Aza to CsA in β and 4 additional patients, respec­
tively After exclusion of both this group of 39 pat ients and 
the 2 patients with graft loss, 79 pat ients (CsA· η = 3 4 , Aza-
Pred η=45) remained available for per-protocol analysis 
The clinical results of the t ransplantat ion in this subgroup 
of patients are given in Table 5 There was no significant 
difference between t r e a t m e n t regimens in the incidence of 
acute rejection episodes after randomization (CsA 10/34 
[29%], Aza-Pred 9/45(20%]) Regarding quality of life mea­
sures, the t r e a t m e n t groups did not differ significantly in 
actual values a t any time point nor in changes over time 
(Table 6) Nevertheless, there was a t rend toward a persis­
tently better score on the psychosocial dimension of the SIP 
in the CsA monotherapy group Of the 4 categories that make 
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TABLE 3 Scores on SIP ABS and CES D at 3 6 and 12 months after renal transplantation in patients allocated to CsA monotherapy 
(n = 60) or treatment with Aza and Pred (п~60Г 
S I P 
Total ' ' 
Physical* 
Psychosocial 0 
ABS 
C E S D * 
CsA 
9 1 
(5 5-16 4) 
5 7 
( 1 5 - 1 2 9) 
4 5 
( 1 6 - 1 4 7) 
7 
(6-8) 
2 
(0 5-7) 
3 Months 
Aza Pred 
8 7 
(3 6-16 5) 
4 1 
( 1 0 - 1 3 9) 
4 3 
( 1 9 - 1 4 4) 
6 
(5-8) 
2 
(0-6) 
6 Months 
CsA 
5 8 ' 
(3 7-11 4) 
1 91 
(0-10 1) 
19« 
(0-6 9) 
7 
(5 5-8) 
2 5 
(1-6) 
Aza Pred 
5 3 " 
(2 1-14 4) 
3 6 ' 
(0-10 7) 
4 8 
(0 12 3) 
7 
(5-8) 
2 5 
(0-9) 
CsA 
3 8' 
( 1 3 - 6 5) 
0 8' 
(0-4 4) 
1 3 ' 
( 0 - 1 0 ) 
7 5 
(6-8 5) 
Г 
(0-4) 
12 Months 
Aza Pred 
3 5 ' 
(0 5-10 4) 
1 2 е 
(0-6 7) 
3 1' 
(0-9 7) 
7 
(5 5-8) 
1 
(0-5 5) 
a
 Data are given as medians with interquartile ranges 
ь
 Lower scores on these indexes indicate better quality of life 
e
 P<0 001 for difference with values of the same treatment group at 3 months after transplantation 
d
 P<0 01 for difference with values of the same treatment group at 3 months after transplantation 
' P<0 05 for difference with values of the same treatment group at 3 months after transplantation 
TABLE 4 Scores on SIP ABS and CES D at 3 6 and 12 months after renal transplantation in patients with (n = 43) and without (n = 77) 
diagnosis of acute or chronic rejection between 3 and 12 months after transplantation irrespective of treatment group0 
S I P 
Total ' ' 
Physical ' ' 
Psychosocial* 
ABS 
C E S D * 
Yes 
9 5 
(4 5-16 0) 
5 9 
(2 2-14 4) 
4 2 
( 1 4 - 1 4 9) 
7 
(6-8) 
2 
(0-7) 
3 Months 
No 
8 7 
(4 8-16 4) 
3 8 
(0 8-12 3) 
4 6 
( 1 9 - 1 3 9) 
7 
(5-8) 
2 
(0-6) 
Acute/chrome rejection 3-12 mo 
Yes 
8 7 
(3 5 14 7) 
5 2 
(0-13 4) 
4 2 
(0-12 4) 
7 
(6-8) 
3 
(0-7) 
6 Months 
No 
4 4 ' " 
(2 0-10 7) 
1 2 " * 
(0-9 1) 
19* 
(0-8 1) 
7 
(5-8) 
2 
(0-6) 
12 Months 
Yes 
4 0 
(1 8-110) 
15^ 
(0-10 2) 
З У 
(0-8 3) 
7 
(5-8) 
2 
(0-6) 
No 
3 5"* 
(0 4-6 8) 
0 8* 
(0-3 9) 
1 3 r f 
(0-5 1) 
Τ 
(6-9) 
r 
(0-4) 
α
 Data are given as medians with interquartile ranges 
* Lower scores on these indexes indicate better quality of life 
' P<0 05 for difference with patients with rejection 
d P < 0 001 for difference with values of the same group at 3 months after transplantation 
' P<0 01 for difference with values of the same group at 3 months after transplantation 
f P<0 05 for difference with values of the same group at 3 months after transplantation 
up this psychosocial dimension, only the social interaction 
category showed different scores between groups at 6 months 
(CsA 0 [0-3 6], Aza-Pred 3 6 [0-15 2], P = 0 04) and 12 
months (CsA 0 [ 0 - 3 6], Aza-Pred 3 5 ( 0 - 7 9),P=0 01) None 
of the 20 individual items within the social interaction 
category displayed significant differences 
There were no differences in the ratings on the various 
satisfaction measures At 1 year after transplantation, only 1 
(CsA treated) patient was slightly dissatisfied with life in 
general Also, 1 (Aza-Pred) patient expressed some dissatis­
faction with his renal transplantation On the other hand, 8 
patients (CsA 3/31 [10%], Aza-Pred 5/37 [14%], NS) were to 
some extent (score 5 or higher) dissatisfied with their sex life 
For the evaluation of the incidence of physical symptoms, 
we interpreted a score of 1 as absence and a score of 2 or 
higher as presence of the concerning symptom Table 7 gives 
the incidence of the 10 most frequent complaints in either 
group at the various time points, completed by items at which 
significant differences were observed 
Subgroup analysis for males and females, respectively, did 
not demonstrate differences between treatment groups on 
any quality of life index Analysis of subgroups according to 
age, with the median age (41 years) as partition, disclosed a 
significant difference on the psychosocial dimension of the 
SIP for older patients at 1 year after transplantation (CsA 0 
[0-1 4], Aza-Pred 2 4 [ 0 - 9 3], P = 0 03) 
Finally, to avoid possible bias by an unequal rejection 
incidence in both groups, we analyzed the data after exclu 
sion of patients who experienced acute or chronic graft rejec 
tion after randomization (CsA 10/34, Aza-Pred 10/45) At 6 
months after transplantation, CsA-treated patients again 
tended to have better scores on the psychosocial dimension of 
the SIP (CsA 0 [ 0 - 4 3], Aza-Pred 4 9 [0-16 9], P = 0 06), 
with significant differences for its social interaction (CsA 0 
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TABLE 5 Clinical resul ts a t 3 and 12 m o n t h s 
At least 1 acute rejection 
Chronic rejection 
Antihypertensive therapy 
Body mass index (kg/m2> 
Weight gain after Tx И ) 
Creat in ine clearance (ml/min) 
Hemoglobin (mmol/L) 
after renal t r a n s p l a n t a t i o n in pat ients t rea ted 
CsA 
8 ( 2 4 ) 
— 
25 (74) 
23 6 
( 2 1 9 - 2 5 5) 
2 1 
( - 0 6-10 0) 
58 
(46-71) 
7 3 
(6 4-7 81 
Pred (n = 
3 Months 
45)° 
Aza Pred 
12(27) 
— 
35 (78) 
medians 
23 2 
( 2 1 6 - 2 5 6) 
4 3 
(0 3-9 5) 
51 
(42-64) 
7 0 
(6 6-7 7) 
- -
numbers 
with CsA monotherapy (n = 
СьА 
(Ir) 
16*(47) 
0 
19(56) 
(interquartile rängest 
25 5 r 
(22 8-26 9) 
9 6 
(4 8-13 3) 
55 
(48-64) 
8 2 
(7 7 -8 8) 
12 Months 
- — 
34) or Aza and 
Aza Pred 
20*(44) 
3 ( 7 ) 
29 (64) 
25 0 r 
(22 3 -27 7) 
9 4 r 
(4 1-12 5) 
69 r r f 
(56-85) 
8 Г 
(7 5-8 6) 
a
 Patients who deviated from their originally assigned treatment were excluded 
ь
 Including rejections that occurred during the first 3 months 
' P<0 001 for difference with values of the same treatment group at 3 months after transplantation 
d
 P<0 001 for difference with CsA group 
TABLE 6 Scores on SIP, ABS, and CES D at 3, 6 and 12 months after renal transplantation in patients treated with CsA monotherapy 
(n = 34) or Aza and Pred (n = 45)° 
S I P 
Total* 
Physical* 
Psychosocial* 
ABS 
C E S D * 
CsA 
7 5 
(5 3-10 1) 
4 0 
(0 8-10 2) 
3 5 
(0-9 9) 
7 
(6-8) 
2 
(0-5) 
3 Months 
Aza Pred 
9 4 
(4 8-17 7) 
4 7 
( 1 0 - 1 5 1) 
5 6 
( 3 0 - 1 7 1) 
6 
(5-8) 
2 
(1-7) 
CsA 
5 5 r 
(3 5-8 8) 
1 5 
(0-8 6) 
1 4 
(0-5 3) 
7 
(6-8) 
2 
(1-5) 
b Months 
Aza Pred 
5 2 d 
(2 1-12 1) 
1 9 ' 
(0-9 9) 
4 9 ' 
(0 10 1) 
7 
(5-8) 
3 
(0-9) 
12 Months 
CsA Aza Pred 
2 4d 3 2 a 
(0 5-5 4) (0 4 8 0) 
0a 0 8* 
(0-3 3) (0-4 0) 
0¿ з ] d í 
(0 -2 8) (0 -9 3) 
7 5 7 ' 
(6-8) (6-8) 
1* 1 
(0^1) (0-5) 
° Patients who deviated from their originally assigned treatment were excluded Data are given as medians with interquartile ranges 
* Lower scores on these indexes indicate better quality of life 
e
 P<0 05 for difference with values of the same treatment group at 3 months after transplantation 
d
 P<0 001 for difference with values of the same treatment group at 3 months after transplantation 
e
 P<0 01 for difference with values of the same treatment group at 3 months after transplantation 
'P=0 06 for difference versus CsA group 
* P=0 05 for difference versus CsA group 
[0 -3 6], Aza-Pred 3 6 [0-15 4], P = 0 02) and emotional 
behavior (CsA 0 [0 -0 ] , Aza Pred 0 [0-16 2], P - 0 04) 
categories 
DISCUSSION 
Our study population demonstrated an ongoing improve-
ment of quality of life during the first year after t ransplan 
tation, as measured with the SIP Previous, cross sectional 
studies established a higher quality of life in t ransplanted 
patients when compared with pat ients on hemodialysis or 
continuous ambulatory peritoneal dialysis (15-17), while a 
few prospective studies have reported a rise in health s ta tus 
after successful t ransplantat ion (18,19) Our results indicate 
that the figures obtained in renal graft recipients depend on 
the time elapsed after t ransplantat ion Assuming tha t the 
t ransplant procedure itself will have been responsible for a 
t ransient drawback in quality of life, it probably takes at 
least a year to reach the optimal post t ransplant level Al 
though a number of patients a t this t ime still obviously 
suffered from physical disabilities and complications, the 
achieved ratings for quality of life were extremely high Total 
SIP scores a t 1 year after t ransplantat ion were comparable to 
the mean score of 3 4 tha t was obtained in a sample of the 
general Dutch population (10) The majority of patients (77%) 
rated 1 or 2 on the 7-point scale for overall life satisfaction 
Similar observations were made before in renal (2, 15-17) 
and liver t ransplant pat ients (20,21) The favorable scores in 
these patient groups have been attributed to the feeling of 
being reborn after t ransplantat ion, to the desire to fulfill 
certain expectations, and to psychological defense mecha-
nisms against fear for rejection and complications (21) 
During the first year after transplantation, the occurrence 
of rejection episodes had a clear deteriorating effect on qual-
ity of life Physical complaints related to the rejection process 
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TABLE 7 Presence of physical complaints at 3, 6, and 12 months after renal transplantation in patients treated with CsA monotherapy 
(n = 34j or Aza and Pred (п=45Г 
Excessive h a i r growth 
Swollen face 
Need for res t 
Feel ing t ired 
Excessive appet i te 
Trembling h a n d s 
Too fat 
Feeling weak 
Stiff or painful muscles 
Tingling in h a n d s 
H e a d a c h e 
Swollen ankles 
Feel ing sick 
Problems to sleep on 
S h o r t n e s s of b r e a t h 
Problems to fall asleep 
Bruises 
H e a r t b u r n 
Dizziness 
CsA 
76 
62 
59 
59 
50 
56 
47 
35 
41 
26 
32 
24 
26 
24 
21 
21 
24 
15 
9 
3 Months 
Aza Pred 
64 
58 
58 
56 
58 
53 
44 
42 
42 
38 
27 
18 
24 
33 
24 
24 
20 
13 
16 
CsA 
59* 
12 a 
65 
65 
6" 
18" 
47 
35 
74* 
15 
18 
26 
24 
24 
18 
24 
15 
6 
0 
6 Months 
Aza Pred 
2 4 r " 
33 ' ' 
49 
4 4 ' 
3 1 " ' 
18" 
44 
27 
36' 
16 6 
31 
16 
29 
20 
31 
22 
29 
20 
20^ 
CsA 
3 2 a 
9" 
35 
47 
18" 
12" 
44 
15 
35 
12* 
18 
15 
15 
9» 
15 
21 
9 
9 
6 
12 Months 
Aza Pred 
T d 
20" 
42 
49 
18" 
4" 
42 
22* 
31 
9" 
18 
13 
20 
16 
16 
16 
33^ 
22 
13 
° Patients who deviated from their originally assigned treatment were excluded Data are given as percentages 
ь
 P<0 01 for difference with scores at 3 months after transplantation 
c
 P<0 01 for difference with CsA group 
" P<0 001 for difference with scores at 3 months after transplantation 
e
 P<0 05 For difference with scores at 3 months after transplantation 
fP<0 05 for difference with CsA group 
or worse graft function, side effects of antirejection treat­
ment, and being faced with a serious setback may all have 
been responsible for the impaired quality of life Unfortu­
nately, our data do not allow firm conclusions on the degree 
of reversibility of this phenomenon after successful treat­
ment of acute rejections 
We found no difference in quality of life between our 2 
treatment groups Both groups were similar on demographic 
variables that have been shown to correlate with total SIP 
score, such as age, sex, education, and length of time with 
end-stage renal disease (17) Theoretically, any difference 
should be caused by disparate effects of both treatment reg­
imens on factors such as graft survival, rejection rate, and 
graft function, or, more directly, by a different array of ad­
verse effects In our intention-to-treat analysis, especially the 
latter, possible cause of differences could be obscured by the 
fact that departure from the originally designated drug ther­
apy occurred in about one third of the patients Since both 
treatment regimens were explicitly designed to have no drug 
in common (CsA vs the combination of Aza and Pred), we 
excluded those patients who did not keep to their originally 
assigned treatment and subsequently performed a per-proto-
col analysis Again, no significant differences could be dem­
onstrated in the measured parameters of quality of life The 
slightly higher rejection rate and the worse renal function 
(both associated with a decline in quality of life) in the CsA 
monotherapy group did not result in a less favorable score on 
any measure In fact, there was a tendency for a more ben­
eficial score on the psychosocial dimension of the SIP in these 
patients, with statistical significance being reached in the 
older half of the population A significant difference on the 
social interaction category appeared to be mainly responsible 
for this finding We can only speculate about an explanation 
for this difference Lack of the steroid-related appearance 
may have offered the opportunity for the CsA-treated pa­
tients to visit their family and friends more frequently as 
well as feel themselves more comfortable in contacts with 
other people Based on existing knowledge of the effects of 
corticosteroids on affect and mood ("steroid high"), differ 
enees could have been expected on the CES-D and the SIP 
emotional behavior category Although improvements on 
these measures did not differ between groups, scores on the 
latter item were superior in the CsA monotherapy group 
after exclusion of patients with acute or chronic rejection 
Ratings on satisfaction measures were quite high in both 
groups Notably, the lowest levels of satisfaction were re­
corded in the sexual life domain Sexual problems are well 
recognized in dialysis patients (22), but this issue apparently 
deserves attention after renal transplantation too For sev 
eral physical symptoms, a marked improvement between 3 
and 12 months after transplantation was observed The 
higher incidence of hypertrichosis in the CsA group and the 
higher incidence of increased appetite and bruises in the 
Aza-Pred-treated patients were not unexpected A remark­
ably high number of CsA-treated patients complained of 
muscle pain and stiffness during the first few months after 
withdrawal of steroids In some of the patients, these com­
plaints were so severe as to urge extended continuation of 
low doses of Pred, which led to relief of symptoms 
To our knowledge, only once before has quality of life been 
reported as an outcome variable in a randomized clinical trial 
in renal transplant patients (2) In that study, comparing 
CsA-Pred with the regimen of antilymphocyte globulin fol 
lowed by Aza-Pred, quality of life was also assessed at 1 year 
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after transplantat ion, although baseline measurements were 
not performed. Pat ients on CsA-Pred appeared to fare better 
on indicators of physical, emotional, and social well-being, 
but the differences lost statistical significance after correc­
tion for the higher number of rejections and infections in the 
Aza-Pred group Nonetheless, there remained a tendency for 
a more favorable score on some measures of emotional well-
being in the CsA-Pred patients, who used lower Pred doses 
t h a n their counterparts in the Aza-Pred group Our finding of 
a slightly better score on the psychosocial dimension of the 
SIP in CsA patients, in spite of a rejection rate which at least 
equaled t h a t in Aza-Pred patients, adds to this observation 
Taken together, these results indicate t h a t lowering the dose 
or withdrawal of prednisone may improve ra ther t h a n 
worsen the quality of life after renal t ransplantat ion 
For both the changes over t ime as well as the effect of 
rejection on quality of life, the SIP appeared to be our most 
sensitive measuring ins t rument This fits in with the high 
figures for accuracy and reproducibility t h a t have been re­
ported for this questionnaire in various circumstances (9,23) 
Nevertheless, the discriminative capacity of the SIP, and of 
the ABS and CES-D as well, was impeded by the fairly high 
quality of life in this population Therefore, it can be ques­
tioned whether the lack of differences between the t r e a t m e n t 
groups may reflect a type II error, also in connection with the 
limited size of our pat ient population Because of little expe­
rience with this type of research in the field of t ransplanta­
tion, we did not have reliable information ( e g , on the ex­
pected distribution of the data and meaningful sizes of 
differences) needed to perform a proper power analysis before 
the s tar t of the study 
Although the importance of measuring the quality of life is 
generally appreciated U, 24), the skeptical reader may ask 
whether it adds any information to what can be derived from 
usual clinical judgment and laboratory figures In this re­
gard, it was instructive t h a t measured parameters of quality 
of life improved substantially in our CsA-treated patients 
between 3 and 12 months after transplantat ion, during this 
interval, 42% of them experienced one or more acute rejection 
episodes, and their renal function did not improve at all 
Therefore, we believe it is useful to incorporate quality of life 
measurement in future trials concerning the t r e a t m e n t of 
organ transplant recipients 
APPENDIX A 
Set of Satisfaction Measures 
Respondents were asked to rate their satisfaction with 
each item on a 7-point scale ranging from completely satis­
fied (1) to completely dissatisfied (7) If an item did not apply 
for the patient in case, it was skipped 
• In general, how satisfied are you with your life as a whole 
these days 7 
• How satisfied are you with the attention and support t h a t 
you receive from family or s u r r o u n d i n g s ' 
• How satisfied are you with your marriage or relation­
ship 9 
• How satisfied are you with your sexual life9 
• How satisfied are you with your daily pursuits and inter­
es t s 9 
• How satisfied are you with your physical condition 9 
• In general, how satisfied are you with the renal trans­
plantat ion 9 
APPENDIX В 
Set of Questions on Physical Complaints 
Respondents were asked to rate each item on a scale of 1 to 
4, with 1 = not a t all and 4 = very much 
Regarding the past week, 
• did you have a need for re s t 9 
• were you feeling sick 9 
• were you feeling weak 9 
• did you feel t i red 9 
• were you feeling physically well 9 
• did you have trouble with falling as leep 9 
• did you have problems to sleep o n 9 
• did you have loss of appet i te 9 
• did you suffer from n a u s e a 9 
• did you have to vomit 9 
• did you consider yourself too fat 9 
Regarding the past week, did you suffer from 
• stiff, tender, or painful muscles 9 
• a swollen face9 
• abdominal p a i n 9 
• d i a r r h e a 9 
• constipation 9 
• dizziness, feeling faint 9 
• loss of s ight 9 
• a skin disorder 9 
• shortness of b r e a t h 9 
• headache 9 
• swollen ankles 9 
• burning eyes 9 
• stomachache 9 
• h e a r t b u r n 9 
• excessive appet i te 9 
• trembling h a n d s 9 
• bruises 9 
• a tingling feeling in hands or fingers 9 
• excessive hair growth 9 
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CHAPTER 4 
Medication compliance after renal transplantation 
L.B. Hilbrands, A.J. Hoitsma, and R.A.P. Koene 
Transplantation, in press 

ABSTRACT 
Noncompliance is known to be an important cause of late graft failure after 
renal transplantation. We investigated prospectively the degree of compliance with 
immunosuppressive and antihypertensive drugs during the first year after renal 
transplantation by monthly pill counts. In addition, we examined whether 
noncompliance was related to a number of demographic and clinical variables or to 
the occurrence of rejections. The study population consisted of 127 patients who 
were involved in a randomized trial comparing cyclosporine monotherapy with 
azathioprine-prednisone treatment. Average compliance rates approximated 100%, 
although considerable variability within and between subjects was observed. Using 
an arbitrary limit to classify patients as compilers or noncompliers, the following 
frequencies of noncompliance were observed during the study year: cyclosporine: 
23%, azathioprine: 13%, prednisone: 23%, atenolol: 36%, and nifedipine: 32%. 
Average compliance scores for all immunosuppressive drugs were superior to those 
of antihypertensive medication (P<0.001). Except for a better compliance for 
prednisone in men as compared with women, we found no consistent relationship 
between compliance on the one hand and several demographic variables, graft 
function, or quality of life on the other hand. Patients who developed one or more 
acute rejection episodes showed a higher degree of undercompliance, especially for 
prednisone, than patients without rejections (P<0.01). Following the occurrence of 
a rejection episode, compliance scores improved significantly. 
Keeping in mind the limitations of the pill count method, we conclude that 
noncompliance with immunosuppressive drugs is not a huge problem during the 
first year after renal transplantation. However, it is likely that noncompliance 
contributes to a certain number of acute rejection episodes. 
INTRODUCTION 
Noncompliance with the therapeutic regimen is considered to be a major cause 
of graft failure after (organ) transplantation (1-3). Accordingly, efforts to 
encourage adherence to the medical regimen are regarded as an important aspect of 
posttransplant patient management (4,5). However, detailed data on the extent of 
medication noncompliance and on factors associated with it in renal transplant 
patients are scarcely available. 
We examined medication compliance during the first year after renal 
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transplantation by use of the pill count method, looking for an answer to the 
following questions: 1) What is the extent of noncompliance with 
immunosuppressive and antihypertensive drugs after renal transplantation? 2) Can 
the level of noncompliance be predicted from demographic or clinical variables? 
3) Does noncompliance increase the incidence of acute rejections? 4) Does the 
occurrence of an acute rejection alter the degree of compliance? 
PATIENTS AND METHODS 
Patient population 
The study population comprised 127 adult recipients of a first or second 
postmortal renal allograft who were involved in a prospective randomized trial 
comparing cyclosporine monotherapy with the combination of azathioprine and 
prednisone from three months after transplantation. Relevant exclusion criteria for 
that study were: history of psychiatric disease, alcohol abuse, and poor knowledge 
of Dutch language. 
Treatment protocol 
All patients received cyclosporine and prednisone during the first three months 
after transplantation. Patients with a functioning graft were then allocated to either 
cyclosporine monotherapy or conversion from cyclosporine to azathioprine. After 
surgery, cyclosporine was given in a dose of 12 mg/kg/day, which was gradually 
reduced to 4 mg/kg/day at three months after transplantation. In patients 
randomized to receive cyclosporine monotherapy, cyclosporine was continued in 
the same dosage with adjustments to reach trough levels between 100 and 
200 ng/ml, and the prednisone dosage was tapered to zero in six weeks. The 
prednisone dosage was 25 mg/day during the first month and 20 mg/day during the 
second and third months after transplantation. In patients allocated to azathioprine-
prednisone therapy, azathioprine was given in a dosage of 3 mg/kg/day and the 
maintenance dose of prednisone amounted to 10 mg/day. In the cyclosporine 
group, prednisone was restarted if more than one acute rejection or chronic 
vascular rejection occurred after randomization. The same conditions led to 
replacement of azathioprine by cyclosporine in the azathioprine-prednisone group. 
In case of severe and persistent side effects, attributable to one of the drugs, 
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patients were put on the alternative treatment regimen. Hypertension, defined as 
diastolic blood pressure above 95 mmHg on three consecutive occasions, was 
treated in a standard way using a /3-blocker (atenolol), followed by the successive 
addition of a calcium-antagonist (nifedipine) and a diuretic (chlorthalidone) when 
necessary. 
Data collection 
Patients were asked to bring along their medication boxes once monthly at 
regular control visits to the out-patient clinic, during the first year after 
transplantation. Counting of remaining pills was carried out in the presence of the 
patient for the following medications when applicable: cyclosporine (capsules of 25 
and 100 mg), prednisone (tablets of 5 mg), azathioprine (tablets of 25 and 50 mg), 
atenolol (tablets of 25, 50, and 100 mg), and nifedipine (slow release tablets of 10 
and 20 mg). The third antihypertensive drug, chlorthalidone, was used by a few 
patients only and data on this drug were therefore not analyzed. Hospital stays 
(during which drugs were handed out by nurses) and failures to carry medication to 
the outpatient clinic led to missing counts for one or more intervals in a number of 
patients. In such cases, the pill count following the missed one measured the 
compliance during both intervals together (i.e two months instead of one). The 
amounts of tablets for which prescriptions were written out (always more than 
required until the next visit) were recorded in the charts and in case of doubt 
additional information was obtained from the patient's pharmacy. 
Demographic data included information on level of education, living situation 
and job status. Creatinine clearance as a measure of graft function was estimated 
with the formula of Cockcroft and Gault (6). The diagnosis of acute rejection was 
made on clinical grounds and histologically confirmed in 81% of the cases. Quality 
of life measurements included the Sickness Impact Profile (SIP), the Affect Balance 
Scale (ABS), and the Center of Epidemiological Studies Depression Scale (CES-D), 
and were performed at 3, 6, and 12 months after transplantation as described 
elsewhere (7). 
Calculations 
Data on the counts of different strength formulations of the same drug 
(cyclosporine and azathioprine) were combined, with the appropriate conversion 
factors taken into account. For example, a surplus of one capsule of 100 mg of 
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cyclosporine would neutralize a shortage of four capsules of 25 mg. To express the 
degree of noncompliance (NC) we used the following three scores: 
, „ .. ~ . ,™,. number of tablets taken * 100% 
1. Compliance Rate (CR) = 
number of tablets prescribed 
2. NC±10 = 100 if CR deviates more than 10% (in either direction) from 100%; 
otherwise NC±,0 = 0. 
3. NC
 10 = 100 if CR is smaller than 90%; otherwise NC 10 = 0. 
CR was calculated for each monthly interval, for each quarter of the study year, 
and for the whole year. The monthly scores of NC±10 and NC.10 were averaged for 
each quarter and the mean of these quarter-scores gave the NC±10 and NC.W figures 
of the entire year. Separate scores for the different drugs were averaged to yield 
composite scores for immunosuppressive drugs, antihypertensive drugs, and all 
drugs, respectively. 
Some examples may clarify how to interpret these scores. Suppose that in a 
patient who used cyclosporine, CR for this drug was 85%, 95%, and 120% during 
months 1, 2, and 3 respectively. The resulting NC±10 for cyclosporine during the 
first quarter of the year would have been (100+0+100)/3 = 67. Roughly, such a 
figure indicates that the patient did not stick very well to the prescribed regimen 
during 67% of time. If in this imaginary case the simultaneously obtained NC±10 
for prednisone was 33, then the composite first-quarter score for 
immunosuppressive drugs would have been (67 + 33)/2=50. Analogous to the 
interpretation of NC±10, NC.W was used as a measure of the percentage of time 
during which too little of the drug was taken. For immunosuppressive drugs, we 
expected NC.10 in particular to be related to the occurrence of rejection episodes. 
Finally, a patient was regarded to be noncompliant for a given drug if the 
NC±10 of the entire study-year (i.e. the average of the four quarter scores) 
exceeded 20, or in other words, if the patient did not take the drug accurately 
during more than 20% of time. 
Statistical analysis 
Unless stated otherwise, data are given as means with SD. Proportions were 
compared with chi-square analysis using continuity correction. Unpaired 
comparisons of data were carried out with Wilcoxon's rank sum test. Paired 
comparisons of data on different drugs were performed with Wilcoxon's signed 
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ranks test. Correlations were assessed by calculating Spearman's correlation 
coefficient. All data were analyzed with the SAS system (SAS Institute Inc., Сагу, 
North Carolina, USA). A P-value smaller than 0.05 was considered statistically 
significant. 
RESULTS 
Two patients refused to bring their medication with them to the outpatient 
clinic; therefore, the results of these patients could not be analyzed. Initial analysis 
of the data revealed that a number of patients had very low or unduly high values 
of CR for one or more drugs at some time, while their mean values for the 
complete study period of a year closely approximated 100%. We presumed that 
these findings might be the result of accidental inaccuracies in transport of the 
drugs to the hospital in patients who actually were quite compliant with their drug 
regimen, or of errors made in pill counting. Therefore, we decided to exclude from 
analysis those patients in whom one or both of the following criteria for one or 
more drugs were met: a) presence of CR > 150% and CR < 50% at different 
times for the same drug, b) CR > 150% or CR <50% at any time, with whole 
year CR for the same drug between 95% and 105%. Actually, this could mean that 
we had strong evidence for an inaccuracy in counting for only one drug at only one 
of the twelve monthly pill-counts. At the same time, the remaining counts for the 
concerning drug and all counts for the other drugs might appear to have been 
carried out correctly. Nevertheless, one apparent mistake in counting prompted us 
to question the reliability of all other counts in the same patient and we thus 
decided to exclude 12 patients from our analysis. Of the remaining 113 patients, 
the mean age was 43 + 13 years (range 17-65), 62% were male, 75% had a first 
transplant, and the mean time on dialysis was 28+20 months. Fifty-one percent of 
the subjects had primary school or lower vocational training as their highest level 
of education, 26% had a salaried position, and 15% were living alone. The 14 
patients who were excluded from analysis did not differ with regard to these 
characteristics. Table 1 summarizes the numbers of patients who were using the 
various study drugs as well as the numbers of subjects in whom pill counts were 
carried out during each quarter of the study year. 
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Extent of noncompliance 
Noncompliance scores, as defined above, are given in Table 2. Mean 
compliance rates approximated 100%, suggesting a high degree of compliance for 
all drugs. However, as is shown by the frequency distribution of compliance with 
each drug (Figure 1, A and B), there is some variability between subjects with 
significant numbers of patients demonstrating underconsumption or 
overconsumption according to the whole year CR values. To get an impression of 
A Frequency (%) 
50 
40 
30 
20 
10 
У "*"Cyclosporine 
* Azathioprine 
'
T
'Prednisone 
40 60 80 100 120 140 160 
Compliance Rate (%) 
В Frequency (%) 
50 
40 
30 -
20 
10 
"*" Atenolol 
"* Nifedipine 
,1b*. • •<*>, ,»<*Γ*<*>5 
20 40 60 80 100 120 
Compliance Rate (%) 
Figure 1. Frequency distributions of compliance rates (number of tablets taken as a 
percentage of number of tablets prescribed) with (A) immunosuppressive and (B) 
antihypertensive drugs. The compliance rates concern the entire study period (one year). 
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the incidence of persistent nonadherence in either direction, we calculated the 
percentage of patients in whom CR was either < 90% or > 110% for more than 
50% of time. For each drug this analysis was confined to patients in whom at least 
3 pill counts for that particular drug were available. For the various drugs, the 
frequencies of persistent underconsumption and overconsumption respectively, were 
as follows: cyclosporine: 1% and 0%, azathioprine: 0% and 0%, prednisone: 2% 
and 1%, atenolol: 4% and 1%, and nifedipine: 6% and 0%. Differences in 
compliance rates at the various visits of one subject (intrasubject variability) were 
reflected in the following mean coefficients of variation of CR (defined as SD 
divided by the mean times 100%): cyclosporine: 5.5%, azathioprine: 5.8%, 
prednisone: 7.2%, atenolol: 10.8%, and nifedipine 11.8%. The paradoxical 
concurrence of NC± 1 0 (and NC.10) scores that substantially deviated from zero and 
CR scores near 100% (Table 2), is another manifestation of these observed 
between-subject and intrasubject variabilities. Using an arbitrary level for NC± 1 0 of 
20 to classify patients as compilers or noncompliers led to the following 
frequencies of noncompliance during the study year: cyclosporine: 23%, 
azathioprine: 13%, prednisone: 23%, atenolol: 36%, and nifedipine: 32%. Except 
for a tendency toward lower NC± 1 0 and NC.10 scores for cyclosporine toward the 
end of the year, there were no apparent changes in time. Mutual (paired) 
comparisons of the results for the three immunosuppressive drugs showed 
significant differences between cyclosporine and azathioprine for overall NC± ) 0 and 
NC. |0 scores (Table 2). In addition, scores for the combination of 
immunosuppressive drugs were more favorable than those for the combination of 
antihypertensive drugs. There was a weak correlation between the NC± 1 0 scores for 
immunosuppressive and antihypertensive drugs (R=0.30, Ρ<0.05), only during 
the fourth quarter of the year. Scores for patients randomized to cyclosporine 
monotherapy were not different from those for patients allocated to azafhioprine-
prednisone treatment. 
Factors associated with compliance 
We investigated whether the degree of compliance was related to demographic 
characteristics, graft function, or results of quality of life measurements (performed 
in 108 patients). The NC± 1 0 scores for the immunosuppressive drugs (separately 
and combined) were chosen as outcome variables on the following grounds. First, 
opposite to antihypertensive therapy, immunosuppressive medication was used by 
all patients. Moreover, generally worse noncompliance scores for antihypertensive 
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drugs would selectively affect overall drug scores in the subset of hypertensive 
patients. Finally, we considered the scores for the immunosuppressive drugs to be 
the most relevant from a clinical point of view. Explanatory variables that 
remained essentially unchanged during the study period were distinguished from 
those that could vary in time. The following explanatory variables were assumed to 
be constant: gender, age, level of education, employment status, living situation, 
and number of graft (first or second). Because a scatterplot of noncompliance 
scores versus age showed a U-shaped distribution, age was categorized into two 
additional variables, one indicating whether age was below or above the 25th 
percentile of the entire group (29 years) and the other indicating whether age was 
below or above the 75lh percentile (54 years). Correlation analysis revealed a 
significant correlation between overall NC±10 for prednisone and gender (P<0.05). 
Accordingly, NC±10 for prednisone was higher in women than in men (16±21 vs 
9 + 16, P<0.05). No other correlations between demographic variables or graft 
number on the one hand and noncompliance scores on the other hand were found. 
To examine the impact of quality of life indices and graft function on 
noncompliance scores, two methodological items had to be dealt with. First, by 
eliciting a rejection episode, noncompliance with immunosuppressive drugs might 
be related to quality of life and graft function in reverse direction. Therefore, we 
excluded patients with one or more rejection episodes from this part of the 
analysis. Second, since these explanatory variables varied in time, we looked for a 
correlation of quality of life parameters and graft function (assessed at 3, 6, and 12 
months after transplantation) with noncompliance scores obtained during the 
preceding or following quarter of the year. The combined NC±10 for 
immunosuppressive drugs during the second quarter of the year was correlated with 
the CES-D score at three months after transplantation. Somewhat unexpectedly, 
patients in a more depressive state had a better compliance score (R=0.38, 
P<0.01). Furthermore, the combined NC±10 for immunosuppressive drugs during 
the third quarter was more unfavorable in patients with higher SIP-scores 
(indicating worse quality of life) at six months after transplantation (R=0.36, 
P<0.01). We found no significant relationship between graft function and the 
degree of compliance at any time. 
Relationship between noncompliance and subsequent rejection episodes 
Noncompliance scores for immunosuppressive drugs were compared in 57 
patients with and 56 patients without one or more acute rejection episodes during 
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the first year after transplantation Since the occurrence of a rejection itself 
appeared to affect compliance (see below), noncompliance scores in rejecting 
patients were calculated up to and including the quarter of the year during which 
the first rejection episode occurred The means of the available quarter-scores 
resulted in the overall values which are given in Table 3 Patients who developed 
an acute rejection showed a worse degree of compliance with a higher incidence of 
underconsumption, especially of prednisone Two patients lost their graft due to 
irreversible rejection One of these patients was clearly noncomphant on the basis 
of the pill count results (mean NC±10 [NC ,0] cyclosponne 100 [100], 
azathiopnne 0 [0], prednisone 100 [100]), while the other appeared to adhere well 
to the treatment regimen (mean NC±10 [NC 10] cyclosponne 0 [0], prednisone 
0 5 [0]) 
Effect of experiencing a rejection on compliance 
To examine the influence of being faced with a rejection episode on compliance 
behavior, patients who had their first rejection episode during the first month after 
transplantation (n=17) were excluded because pill counts before rejection had 
occurred were obviously not available Figure 2 shows the time course of NC±W 
(combined score for all drugs) during the three months before and three months 
Table 3. Compliance rates and noncompliance scores for patients with and without one or 
more acute rejection episodes 
> 1 rejection 
(n=57) no rejection (n=56) 
Cyclosponne 
Azathioprine 
Prednisone 
All immunosuppressive drugs 
CR (%) 
NC±10 
NC,0 
CR (%) 
NC±10 
NC,0 
CR(%) 
NC±10 
NC,0 
CR (%) 
NC±10 
NC,0 
99 0±4 7 
15 ±24 
9 ±22 
100 4±5 2 
9±14 
3±9 
98 7±6 0 
15±21 
10±20 
99 2±3 4 
11±11 
7±10 
98 7±5 1 
11±23 
7±18 
101 3±8 0 
11 ±23 
1±4 
100 3±3 3 
8±14 
3±9 
99 9±3 2 
7±11 
3±5 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
<0 05 
<0 01 
NS 
<0 05 
<0 01 
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NC 
30 
±10 
20 - ^ 
10 
23 28 29 27 27 27 31 
- 3 - 2 - 1 0 1 2 3 
time from acute rejection (months) 
Figure 2. Non compliance scores for all drugs (NC±W ; for calculation see text) from 
three months before until three months after the month during which an acute rejection 
occurred. Data are given as means with SEM. The numbers in the bars denote the 
numbers of patients in whom pill counts could be carried out. 
after the month during which a first acute rejection episode occurred. There was a 
deterioration of compliance just before the occurrence of rejection. Notably, this 
was followed by a return of noncompliance scores to baseline levels. When mean 
scores of the two months before and two months after the month with rejection 
were compared, there was a borderline significant change in NC±10 (19±19 vs. 
13+22, P=0.05), while NC.,0 improved substantially (12±18 vs. 6+20, 
P<0.01). The course of compliance scores was similar in patients with and 
without subsequent rejection episodes (data not shown). 
DISCUSSION 
The importance of medication compliance after organ transplantation is beyond 
dispute. Several authors have demonstrated noncompliance to be a major 
determinant of late graft failure (1,3,8). Usually, medication noncompliance was 
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documented by the finding of low cyclosporine levels (1,9), or by information on 
drug taking behavior provided by the patient or family members (1,5,8). 
Sometimes medication compliance and compliance with the follow-up regimen were 
considered together (8), and in one study a definition of compliance was lacking 
(3). All of these, mostly retrospective, studies have in common that noncompliance 
is treated as a yes or no phenomenon. In reality, different patterns and degrees of 
noncompliance can be observed (10). In addition, studies using information 
provided by the patient may have been subject to recall bias, with patients in whom 
a rejection episode had occurred being more likely to report noncompliance. 
The current prospective investigation used the pill count method to assess 
compliance. It provided quantitative information that enabled us to express 
compliance on a numerical scale. We have to admit however, that this technique 
has its limitations too (11). Comparison of a sophisticated compliance monitoring 
device with the standard pill count in hypertensive patients, demonstrated 
substantial overestimation by the latter method (12). Tablet counts do not provide 
information about the pattern of day-to-day drug intake, nor will they reveal 
whether some or all of the tablets were not taken but discarded. Apparent 
compliance rates > 100% may indicate that patients took more than they were 
supposed to take (either on purpose or by mistake), but may also result from the 
loss of tablets. Finally, the pill count method is subject to possible errors being 
made by the person who counts the pills. As reported by others (13), our data 
show that near-optimal average compliance rates may mask considerable variability 
within and between subjects. Since it has been demonstrated that compliance may 
just as well be poor when an excessive number of tablets seems to have been taken 
(14), we used the frequency of counts yielding deviations from the prescribed 
amount of at least 10% in either direction as one of our outcome measures. 
On the whole, our results indicate a high degree of compliance during the first 
year after renal transplantation. Defining compliance arbitrarily as adhering to the 
prescribed regimen at least 80% of the time, the incidence of noncompliance 
ranged from 13% to 36% for the various drugs. These figures compare quite 
favorably with those reported earlier in studies on antihypertensive and other types 
of drugs (12,15). Factors that are known to be associated with medication 
compliance include the type of condition or disease, properties of the treatment 
regimen such as side-effects, and demographic as well as psychological patient 
characteristics (16). Knowledge of the fact that strict adherence is required to 
prevent graft rejection probably encouraged compliance in our patients. 
Accordingly, immunosuppressive drugs were more accurately taken than 
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antihypertensive drags, despite probably being more feared for their adverse 
effects. Several features of our study design may have contributed to the observed 
degree of compliance. First, more compliant behavior in response to repetitive pill 
counts can easily be imagined. Second, failure to carry medication to the outpatient 
clinic, resulting in missing values, may have occurred more often in noncompliant 
patients. Likewise, the exclusion of patients with a history of substance abuse or 
psychiatric disease potentially introduced some selection bias. 
With regard to the treatment regimen as a determinant of compliance, frequent 
changes in the dosage of the drags may have influenced compliance negatively. In 
this respect, a distinction between understanding the regimen and following the 
regimen would have been helpful. Of the three immunosuppressive drugs, 
azathioprine ranked higher on the scale of compliance than the others, with the 
difference with cyclosporine being statistically significant. Poorer compliance with 
cyclosporine may be caused by side effects, as well as by the size, taste, and daily 
amounts of the capsules. The use of prednisone is generally feared because of its 
wide array of adverse effects. 
Demographic factors that have been reported to influence compliance after renal 
transplantation include race, gender, age, socioeconomic level, and employment 
status (1,3,9,17). We found only slightly lower levels of compliance with 
prednisone in female patients. A challenging issue was to examine the association 
between medication compliance and quality of life, which was assessed thrice 
during the study period by means of interviews using three instruments. We were 
not able to demonstrate a consistent relationship between perceived quality of life 
and compliance scores, although some weak correlations emerged. To our surprise, 
and opposite to data from others (9), patients who were more depressed at three 
months after transplantation as measured with the CES-D scale, tended to be more 
compliant with immunosuppressive drags during the following quarter of the study 
year. Furthermore, patients in whom the Sickness Impact Profile indicated a better 
quality of life at six months after transplantation, showed a higher degree of 
compliance with immunosuppressive drags during the following months. The 
impact of quality of life on medication compliance has been put forward before 
(9,18,19) and is especially interesting in light of our data on the varying influence 
of immunosuppressive drag regimens on quality of life (7). Taken together, it can 
be speculated that different immunosuppressive drug therapies may vary in their 
effect on graft survival because they have a different effect on quality of life and 
thus on compliance. 
Patients experiencing one or more acute rejection episodes during the first year 
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after transplantation had worse compliance levels for immunosuppressive drugs, 
especially prednisone, prior to the occurrence of the first rejection episode. This 
finding indicates that the established relationship between noncompliance and late 
graft failure may originate at an early stage after transplantation. The current data 
do not allow inferences on an association between early and late noncompliance. It 
seems reasonable that such a connection exists. On the other hand it can be argued 
that early noncompliance is related mainly to side effects and their effect on quality 
of life while late noncompliance just as well may occur in patients who are feeling 
very well and who become convinced that they do not need their drugs anymore. 
In the case of acute rejection, compliance scores appeared to worsen just before 
its occurrence. Afterward however, compliance scores immediately returned to 
baseline levels. Experiencing a rejection apparently acted as an incentive to restore 
or enhance adherence with the medical regimen. 
Our study had a descriptive character and did not address the important issues 
of how to improve compliance. Strategies to modify noncompliant behavior in renal 
transplant patients have been developed (4,5), but proof of their efficacy is still 
awaited. 
In summary, using the pill count method we found a high degree of medication 
compliance during the first year after renal transplantation. Patients adhered better 
to their immunosuppressive therapy than to antihypertensive medication. Poor 
compliance with prednisone was associated with the subsequent occurrence of a 
rejection episode, which in turn appeared to correct noncompliant behavior. 
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ABSTRACT 
Disturbances of lipid metabolism are frequently en­
countered after renal transplantation and have been 
ascribed to the use of cyclosporine (CsA) and corti­
costeroids but the individual contribution of each of 
these drugs remains uncertain The individual effects 
of CsA and prednisone (Pred) on serum lipid and 
(apo)lipoprolem levels were compared in a prospec­
tive randomized trial All patients received CsA and 
Pred during the first 3 months after transplantation 
Subsequently they were allocated to either with­
drawal of Pred or conversion from CsA to azathioprme 
(Aza) Serum lipids and (apo)hpoprotelns including 
lipoprotein(a) (Lp(a)), were measured at regular In­
tervals during the first year after renal transplantation 
Analysis of variance for repeated measures of the first 
year results showed higher values for serum triglycer­
ides (P < 0 001) and lower high-density lipoprotein 
(HDL) cholesterol levels (P < 0 05) in the CsA mono­
therapy group (Λ/ = 59) as compared with the Aza-
Pred group (N = 63) At 1 yr after transplantation, 
CsA-treated patients had significantly higher Lp(a) 
levels (CsA median, 105 (interquartile range 42 to 
340) mg/L Aza-Pred 46 (25 to 176) mg/L, Ρ < 0 05) 
The withdrawal of Pred in the CsA group resulted in a 
large fall In HDL cholesterol (27 ± 30% at 5 months 
after transplantation) and an increase in triglycerides 
(49 ι 73% at 6 months) A reversion of these changes 
was observed in patients who were retreated with 
Pred Multiple linear regression analysis showed an 
independent correlation between the use of Pred and 
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HDL cholesterol level whereas the use of CsA was 
independently associated with the concentration of 
Lp(a) The results indicate that with respect to risk for 
hyperlipldemia after renal transplantation, Aza-Pred 
treatment may be preferred above CsA mono­
therapy These data do not support the general belief 
that the withdrawal ol steroids In CsA-treated patients 
improves the serum lipid and lipoprotein profile 
Key words Serum cholesterol lipoprotein(a) hyperlipldemia 
atherosclerosis renal transplantation 
A therosclerosis is a major cause of morbidity and mortality after renal transplantation One of the 
main risk factors for atherosclerosis is hyperlipld­
emia and many studies have demonstrated that hv 
perllpldemla Is frequently encountered In renal trans 
plant recipients (1) Elevated levels of serum total 
cholesterol low-density lipoprotein cholesterol (LDL 
С) and triglycerides (TG) are frequently observed (1-
3) High density lipoprotein cholesterol (HDL C) levels 
have been variously reported as high normal or low 
In recent years, elevated lipoproteln(a) [Lp(a)l concen 
tratlons have been reported in renal transplant pa­
tients treated with cyclosporine (CsA) (4) In addition 
to other factors there is strong evidence for a patho 
genetic role of Immunosuppressive drugs in post 
transplant hyperlipldemia The adverse effects of cor­
ticosteroids on serum cholesterol and TG levels are 
well established (2 5 6) The withdrawal of prednisone 
(Pred) in patients on CsA and azathioprlne (Aza) led to 
significant decreases In total cholesterol levels (6-8) 
Numerous studies documented that treatment with 
CsA alone or in combination with steroids was asso 
elated with Increased levels of total and LDL С and 
serum TG (6 9-12) although there are also studies in 
which these effects of CsA could not be demonstrated 
(13 14) The individual contribution of either drug to 
disturbances in lipid metabolism as well as their 
distinct effects on the various lipoprotein subclasses 
are not clear 
To clarify this issue we measured serum lipids and 
lipoproteins in patients who participated In a random­
ized prospective trial comparing CsA monotherapy 
with the combination of Aza and Pred from 3 months 
after renal transplantation Because Aza Is not known 
to influence lipid metabolism this actually meant a 
comparison of the effects of CsA and Pred In addition 
to most of the previous studies on this subject we also 
measured apolipoprotein (apo) Α-I apo В and Lp(a) 
Apo Α-I and apo В are the major protein components 
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within high dens i ty lipoprotein (HDL) and low densi ty 
l ipoprotein (LDL), respectively Lp(a) resembles LDL 
b u t h a s a n addi t ional apollpoprotein (apo(a)] tha t is 
s t ruc tu ra l ly homologous to p lasminogen In epidemi-
ologic s t ud i e s . a p o B (L5)and Lp(a)(16) were positively 
and apo A-I (15) was negatively associa ted with the 
risk for a therosclerot ic cardiovascular d i sease Be-
cause the initial t r ea tmen t in all of our s t udy pa t ien ts 
cons is ted of CsA and Pred. the design of the trial also 
allowed the examina t ion of the changes in lipid and 
apohpopro te ins occurr ing after the wi thdrawal of Pred 
in CsA-treated pa t ien t s , which we expected to be 
beneficial. 
PATIENTS AND METHODS 
Patient Population 
All patients underwent a first or second cadaveric renal 
transplantation at our institution Postoperatively they were 
treated with CsA and Pred for 3 months Afterwards they 
volunteered to participate in a randomized prospective trial, 
comparing CsA monotherapy [N ^ 64) with the combination 
therapy of A/a and Pred [N = 63) Two patients with diabetes 
mellitus (both in CsA group) were excluded from this analy-
sis and another three patients in the CsA group could not be 
evaluated because of lacking data The remaining 122 pa-
tients made up the study population 
Study Protocol 
CsA was given iv (3 mg/kg per day) for the firsl 3 days 
postoperatively, followed by 12 mg/kg per day in two divided 
oral doses during the firsl month, gradually reduced to 4 
mg/kg per day at 3 months after transplantation The dosage 
was adjusted to maintain CsA trough blood levels between 
200 and 400 ng/mL Prednisolone was given at a dose of 100 
mg/day iv during the first 2 days postoperatively, followed by 
an oral Pred dosage of 25 mg/day during the remainder of 
the first month and 20 mg/day during the second and third 
months after transplantation In patients who were random-
ized to receive CsA monotherapy. CsA was continued In the 
same dosage with adjustments to reach trough blood levels 
between 100 and 200 ng/mL The Pred dosage was reduced 
by 5 mg/day every 2 wk, resulting m CsA monotherapy after 
6 wk In patients allocated to Aza-Pred therapy, CsA was 
replaced without overlap by A¿a in a dosage of 3 mg/kg Their 
Pred dosage was temporarily increased from 20 to 25 mg/day 
and reduced by 5 mg/day every 2 wk until a maintenance 
dose of 10 mg/day was reached In the CsA group, Pred was 
restarted if more than one acute rejection or chronic vascular 
rejection occurred after randomization The same conditions 
led to the replacement of Aza by CsA in the Aza-Pred group 
In case of severe and persistent side effects attributable to 
one of the drugs, patients changed over to the alternative 
treatment regimen 
During the first 3 months after transplantation, acute 
rejection episodes were treated with methylprednlsolone ( 1 g 
iv on three consecutive days) or antihymocyte globulin (ATG. 
RIVM Billhoven. The Netherlands 200 mg iv on alternate 
days for 10 days) An oral course of high-dose Pred (initial 
dosage 200 mg/day tapering to 25 mg/day in 12 days) was 
given after the failure of one or both of these treatments 
From 3 months after transplantation (Í e . after randomiza-
tion) acute rejections were primarily treated with ATG in all 
cases High-dose Pred courses were given in case of the 
failure of ATG. bone marrow suppression, or previous treat-
ment with ATG for rejection 
Hypertension defined as diastolic blood pressure above 95 
mm Hg on three consecutive occasions, was treated in a 
standard way with a ß-blockcr (atenolol) followed by the 
successive addition of a calcium antagonist (nifedipine) and a 
diuretic (chlortalidone) when necessary None of the patients 
were treated with lipid-lowering drugs There were no dietary 
recommendations given except for caloric restriction in pa 
tients with a large weight gain after transplantation 
Blood samples for the measurement of serum total choles-
terol, HDL-C TG and plasma glucose were collected after an 
overnight fast at 2 and 3 months (baseline values) as well as 
at 5 6. 9. and 12 months after transplantation Apo Α-I and 
apo В were measured in the samples obtained at 3 6. and 12 
months whereas Lp(a) was measured at 3 and 12 months 
after transplantation In the samples obtained at 12 months, 
very low-density lipoprotein (VLDL) cholesterol and TG were 
determined 
Body weight and blood pressure as well as results from 
routine clinical chemistry were recorded at regular intervals 
as p.irl of the usual positransplant patient evaluation Body 
mass index was calculated as weight In kilograms divided by 
the square of the height in meters Creatinine clearance was 
estimated with the formula given by Cockcroft and Gault 
(17) Proteinuria was defined as a urinary protein concentra 
lion of more than 0 1 g/ L (24-h urinary protein excretion was 
not measured routinely) The study was approved bv the 
Hospital Ethics Committee and all patients gave written 
informed consent 
Analytical Procedures 
Cholesterol and TG were measured by enzymatic methods 
(CHOD-PAP cholesterol reagent. Boehringer-Mannhcim. 
Mannheim. Germany, and SERA-РАК TG. Miles. Italy with a 
centrifugal analyzer (Multistat 111 Instrumentation Labora 
lory Ine . Lexington. MA) HDL-C was measured as described 
(18) LDL-C was calculated by the Fnedewald formula (19) 
VLDL was isolated by ultraccntrlfugatlon at d = 1 006 g/mL 
with a Kontron TFT 45 6 rotor (Kontran Instruments AG 
Miles Italy) for 16 h at 168 000 x g at 14DC in a Beekman 
L7 55 ultracentrifuge (Beekman Instruments Ine , Palo Alto, 
CA) (20) Serum samples to be analyzed for apollpoprotelns 
were stored at -20°C constant temperature until assay Apo 
Α-I and apo В were measured by immunonephelometry (21). 
and the results were International Federation of Clinical 
Chemistry (IFCC) standardized by recalculation on the basis 
of an exchange of 40 serum samples with Dr S Marcovlna 
(North-West Lipid Research Laboratory Seattle WA), who 
uses a radioimmunoassay Lp(a) was measured by a com­
mercial lmmunoradiometric assay [apo(a) IRMA. Pharmacia. 
Uppsala, Sweden) Accuracy was confirmed by analyzing the 
human Lp(a) reference standard no 4395006. provided by 
Immuno GMBH (Vienna Auslrla) 
Serum creatinine and glucose levels were measured by 
standard techniques The urine dipstick was used as a 
screening test for proteinuria In samples with a positive 
result the protein concentration was measured by a colon-
metric assay Whole-blood CsA levels were measured with a 
fluorescence polarization immunoassay (Abbotl Labóralo 
nes. North Chicago. IL) Initially with polyclonal antibodies 
directed against the parent molecule of CsA and some of Its 
metabolites The majority of blood levels was measured with 
a modified kit. with monoclonal antibodies against the CsA 
parent molecule without cross-reactivity A conversion factor 
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of О 5 was used to adjust Ihe InftlaJ vaJues lo those currently 
measured 
Statistical Analysis 
All data were analyzed with the SAS system ISAS Institute 
Ine . Сагу NC) Data are given as means - standard devia 
(Ions, unless staled otherwise The logarithmic conversion of 
Lp(a) was performed to normalize the distribution Compar 
lson of the changes after randomization between both treat­
ment groups was performed by analysis of variance for 
repeated measurements Wllhtn-group comparisons and be 
tween-group comparisons at different times were carried out 
with paired or unpaired t tests Proportions were compared 
with χ2 analysis Simple correlations within each treatment 
group were assessed by calculating Spearman's correlation 
coefficient Multiple linear regression analysis was used to 
examine the relative Independent contributions of the use of 
CsA and Pred as well as of several other clinical variables, to 
lipid levels at 1 yr after transplantation A Ρ value of less than 
0 05 was considered statistically significant No correction 
for the comparison of multiple outcomes was applied 
RESULTS 
Between 3 and 12 months after transplantation, one 
patient died in each treatment group (CsA. 4 months, 
Aza-Pred, 6 months after transplantation) In addi­
tion, graft loss occurred once In each group (CsA, 6 
months; Aza-Pred. 7 months after transplantation) 
The results obtained until the lime of death or graft 
loss were included for analysis In 37 patients, the 
initially assigned treatment had to be changed for a 
variety of reasons Pred was added to CsA in eight 
patients because of the occurrence of more than one 
acute rejection or chronic rejection after steroid with­
drawal (one of these patients received triple therapy) 
In another six patients, steroid withdrawal was not 
completed for a variety of reasons CsA was replaced 
by Aza-Pred in nine cases, all but once because of 
CsA-lnduced renal dysfunction (in one of these pa­
tients, CsA was substituted for Aza again, with the 
continuation of Pred) In two patients, Aza was re­
placed by CsA because they had a second acute 
rejection episode after prior conversion from CsA lo 
Aza Bone marrow depression and liver function dis­
turbances prompted switching from Aza to CsA In 
eight (in one of these temporarily) and four additional 
patients, respectively Seven of the latter 12 patients 
were off Pred at 1 yr after transplantation To deter­
mine the clinical effect of the two therapeutic ap­
proaches on lipid metabolism and cardiovascular risk, 
the data of all patients were analyzed on an intention-
to-treat basis 
Intention-ToTreat Analysis 
The demographic and clinical characteristics of the 
patients are shown in Table 1 There were no differ­
ences in these parameters between both groups The 
values for serum lipids and (apo)lipoprotelns mea­
sured at 3. 6. and 12 months after transplantation are 
given in Table 2 In the CsA monotherapy group, total 
cholesterol and LDL-C did not change between 3 and 
TABLE 1. Characteristics of patients assigned to 
treatment with CsA monotherapy or combination 
therapy of Aza and Pred from 3 months after renal 
Iransplantatlon" 
Parameter 
Sex (M/F) 
Age (yr) 
First/second transplantation 
Body mass index (kg/m2) 
Creatinine clearance 
(mL/min) 
Patients with proteinuria 
Patients using antihypertensive 
drugs 
CsA 
(W = 59) 
38/21 
42 ι 12 
48/11 
23 7 * 3 2 
57 ± 18 
8 (14%) 
45 (76%) 
Aza-Pred 
(fV-63) 
41/22 
42 ± 14 
53/10 
24 3 ± 3 9 
56 ± 19 
10(16%) 
47 (75%) 
a
 Data at 3 months after transplantation 
12 months after transplantation however, the con­
centration of HDL С decreased considerably, with a 
maximal reduction of 27 ± 30% at 5 months after 
transplantation, whereas TG levels increased signifi­
cantly (maximal change of 49 ± 73% at 6 months) In 
the Aza-Pred group, there was also a significant de­
crease of the serum level of HDL-C (- 13 ± 25% at 6 
months) Analysis of variance showed that the 
changes after randomization differed significantly be­
tween both groups Tor HDL-C (a larger decrease in the 
CsA group, Ρ < 0 05), for TG (an increase in the CsA 
group uersus no change in the Aza-Pred group, Ρ < 
0 001), and for the ratio of total cholesterol to HDL-C 
(a larger increase In the CsA group, Ρ < 0 01) At 1 yr 
after transplantation, VLDL cholesterol was higher in 
the CsA group (CsA. 1 15 ± 0 82 mmol/L, Aza-Pred 
0 68 ± 0 42 mmol/L. Ρ < 0 01) as was the ratio of 
cholesterol to TG In the VLDL Traction (CsA. 0 76 ± 
0 21 Aza-Pred, 0 6 1 ± 0 1 5 . P < 0 001) The concen 
tration of apo Α-I was highly correlated with that of 
HDL-C (R = 0 72, 0 69. and 0 72 at 3, 6. and 12 
months, Ρ < 0 001) Likewise, the level of apo В 
showed a strong correlation with that of LDL-C (R = 
0 82, 0 80, and 0 64 at 3. 6. and 12 months, Ρ < 
0 001) Consequently, significant decreases in apo A-I 
were observed In both groups. Lp(a) concentration 
Increased in the CsA monotherapy group and did not 
change after replacing Csa-Pred by Aza-Pred, result­
ing in a significant difference between both treatment 
groups at 1 yr after transplantation 
Table 3 summarizes the values of other clinical and 
laboratory parameters that could have influenced li­
poprotein metabolism As expected, Aza-Pred-treated 
patients had higher creatinine clearances Except for 
a negative correlation between creatinine clearance 
and apo Α-I at 12 months after transplantation In the 
Aza-Pred group (R = - 0 28, Ρ < 0 05), there were no 
significant correlations between creatinine clearance 
and lipid or (apo)llpoproteln levels at 6 or 12 months In 
either group Proteinuria was more frequent in the 
Aza-Pred group at 6 months after transplantation A 
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TABLE 2 Lipid a n d ( a p o ) l i p o p r o t e i n c o n c e n t r a t i o n s a t 3, 6, a n d 12 m o n t h s after r e n a l transplantation in 
patients a s s i g n e d to t r e a t m e n t with CsA m o n o t h e r a p y or with Aza-Pred 
CsA 
Parameter 
3 months 6 months 12 months 3 months 
Aza-Pred 
6 months 12 months 
Serum cholesterol (mmol/L) 
Serum TG (mmol/L) 
LDL-Cholesterol (mmol/L) 
HDL-C (mmol/L) 
Total/HDL-C 
apol Α-I (mg/L) 
apol В (mg/L) 
Lp(a) (mg/L)' 
6 31 ± 1 63 
1 91 ± 0 97 
4 23 ± 1 51 
1 31 ± 0 38 
5 23 - 2 05 
1,538 ± 325 
6 19 - 1 40 
2 53 ± 1 4 2 a 
4 12 ± 1 16 
1 01 ± 0 3 4 a 
6 82 ± 2 78° 
1,350 »328= 
1,295 ± 3 9 9 1,314 ± 3 4 7 
61 (25-168) 
6 28 ± 1 86 
2 37 ± 1 29° 
4 22 ± 1 67 
1 06 = 0 38° 
6 72 ± 3 3 3 a 
1,426 ± 326 
1,386 ± 409= 
105(42-340)° 50(25-244) 
6 14 ± 1 33 
2 03 ± 0 94 
3 97 ± 1 08 
1 32 ± 0 48 
5 11 ± 1 82 
5 85 ± 1 31 
1 90 ± 0 9 9 b 
4 02 ± 1 23 
1 13 ± 0 45° 
5 69 » 1 9 0 a d 
1,477 ± 2 7 1 1,398 ± 2 8 5 
1,228 ± 3 3 2 1,257 ± 3 3 6 
591 ± 1 43 
1 78 ± 0 83° 
4 04 ± 1 30 
1 12 ± 0 37= 
5 73 ± 2 09= 
1,378 ± 232 е 
1,247 ± 3 3 8 
46(25-176)° 
a
 Ρ 0 001 for difference versus 3 monfhs 
D P ' 0 01 for difference with CsA group 
c
 Ρ ' 0 01 for difference versus 3 months 
a
 Ρ ' 0 05 for difference with CsA group 
ϋ
 Ρ < 0 05 for difference versus 3 months 
f
 Given as median with interquartile range 
TABLE 3 Cl inical a n d b i o c h e m i c a l p a r a m e t e r s a t 3, 6, a n d 12 months after r e n a l transplantation in patients 
a s s i g n e d to t r e a t m e n t with CsA m o n o t h e r a p y or with Aza-Pred 
Parameter 
Weight (kg) 
Creatinine clearance (mL/min) 
Plasma glucose (mmol/L) 
Patients with proteinuria (%) 
Patients using a ß-blocker (%) 
Patients using a calcium antagonist (%) 
Patients using a diuretic (%) 
CsA trough level (ng/mL) 
3 months 
7 0 - 1 1 
57 · 18 
4 9 ι 1 0 
14 
76 
48 
5 
220 ± 82 
CsA 
6 months 
72 ± 12 
54 ± 15 
5 0 ± 0 7 
14 
76 
39 
3 
197 ± 8 7 
12 months 
74 ± 13 
54 ± 18 
5 1 ± 0 7 
22 
64 
41 
12 
177 ± 5 0 
3 months 
70 ± 12 
56 ± 18 
5 8 ± 2 8= 
16 
75 
33 
5 
244 ± 124 
Aza-Pred 
6 months 
72 ± 13 
65 ± 2 1 = 
5 1 ± 1 1 
32° 
62 
27 
6 
12 months 
73 ± 13 
67 ± 20° 
5 2 ± 14 
27 
62 
32 
10 
Ί
 Ρ ^ 0 01 for difference with CsA group 
' Ρ ··' 0 001 for difference with CsA group 
" Ρ < 0 05 for difference with CsA group 
comparison of patients with and without proteinuria 
revealed a difference for LDL-C at 12 months in the 
CsA group (5 23 ± 2 72 uersus 3 97 ± 1 88 mmol/L, 
Ρ < 0 05) A significant correlation between changes m 
creatinine clearance or urinary protein excretion on 
the one hand and changes in lipid or (apo)lipoprotein 
levels on the other hand was only observed In the CsA 
group for the change In creatinine clearance between 
3 and 6 months and the concurrent change in TG (R = 
- 0 32, Ρ < 0 051 Body weight increased to the same 
extent in both treatment groups Although plasma 
glucose was slightly higher in the CsA group at 3 
months, there were no significant differences in 
plasma glucose after randomization The use of the 
different classes of antihypertensive drugs was com­
parable CsA blood levels tended to decline over time 
and showed no significant correlation with lipid or 
(apo)hpoprotein levels at 3, 6, or 12 months after 
transplantation The number of acute rejection epi­
sodes during the first year after transplantation did 
not differ between both groups (CsA mean, 0 83 
[range 0 to 4], Aza-Pred 0 65 [0 to 3]), nor did the 
number of patients who received a methylpred-
nisolone course (CsA, N = 9, Aza-Pred N - 11) The 
cumulative dose of Pred was higher in the Aza-Pred 
group (5.747 ± 845 versus 4,169 ± 1910 mg: Ρ < 
0 001) 
Multiple linear regression was performed to assess 
the independent effects of immunosuppressive treat­
ment and other clinical variables on lipid and (apo)h-
poprotein levels at 1 yr after transplantation Because 
a number of patients did not keep to their originally 
assigned treatment, the actual use of CsA and of Pred 
(0 if the patient did not take the drug and 1 if he/she 
did) instead of group membership formed explanatory 
variables Other independent variables were age. sex 
(0 = male, 1 = female), body mass Index, creatinine 
clearance, proteinuria (0 = absent, 1 = present), 
cumulative doses of corticosteroids (arbitrarily de­
fined as the cumulative dose of Pred plus 0 1 times the 
cumulative dose of methylprednisolone), and use of 
ß-blockers and calcium antagonists Table 4 gives 
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TABLE 4 Results of multiple linear regression analysis of data obtained at 1 yr after transplantation0 
Dependent Variable 
Serum cholesterol 
Serum TG 
VLDL cholesterol 
LDL-C 
HDL-C 
apo A-l 
apo В 
Log (Lp(a)) 
Predictor Variable 
Sex (Iemale = 1) 
Use of calcium-antagonist 
Age (yr) 
Use of calcium antagonist 
Creatinine clearance (mL/mm) 
Sex (female = 1) 
Body mass index (kg/m2) 
Use of Pred 
Creatinine clearance (mL/mm) 
Age (yr) 
Sex (female - 1) 
Use of CsA 
Use of Pred 
Use of calcium antagonist 
Body mass index (kg/m2) 
Use of CsA 
Partial 
Regression 
Coefficient" 
0 86 
0 79 
0 026 
053 
-0009 
0 35 
- 0 028 
0 23 
0 0045 
0 0058 
282 
178 
181 
163 
-13 
0 86 
Ρ 
0 022 
0044 
0 049 
0 043 
0 048 
<0 001 
0 002 
0 046 
0 046 
0 032 
Ό 0 0 1 
0019 
0044 
0 008 
0 047 
0 036 
a
 Only the variables thai showed a significant independent correlation with a particular lipid outcome are shown 
ь
 The regression coefficient shows the expected change in Ihe dependent variable each time the prediclor variable increases by 1 и noiding the 
values of the olher predictor variables constant 
those explanatory variables that showed an Indepen 
dent association with the respective lipid outcome 
variables The use of Pred retained a significant rela­
tionship with HDL С and apo A-l. whereas the use of 
CsA was an Independent prediclor of (log-normalized) 
Lp(a) and apo Α-I Somewhat surprisingly the use of a 
calcium antagonist (nifedipine) was independently 
correlated with serum cholesterol, serum TG, and apo 
A-I 
Additional information on the individual effects of 
CsA and Pred on serum lipid and lipoprotein levels 
was obtained In patients who received steroid courses 
for acute rejection In seven patients who were treated 
with high doses of Pred for acute rejection after prior 
steroid withdrawal blood samples were obtained be 
fore and within 3 months after restarting treatment 
with Pred The effects on serum lipid patterns are 
shown in Figure la The cessation of Pred at 3 months 
after transplantation was followed by a decrease in 
HDL-C and an Increase In TG resembling the results 
mentioned above The steroid course was accompa­
nied by a reversion of HDL-C and TG levels to values 
observed during previous Pred treatment In contrast 
the treatment of acute rejection with ATG in patients 
on CsA monotherapy was not followed by comparable 
changes (Figure lb | In 10 of the 23 patients who were 
switched to the other treatment group, the blood 
sampling schedule allowed the evaluation of the 
changes In the serum lipid profile after conversion 
from CsA monotherapy to Aza-Pred treatment or vice 
versa (Table 5) The decrease In HDL-C and the rise in 
TG characteristic of steroid withdrawal disappeared 
after the cessation of CsA and the reinstitution of Pred 
in all cases In addition the data presented in Table 4 
suggest that both treatment regimens have opposite 
effects on the levels of LDL-C 
Our trial was not designed to measure parameters 
of atherosclerosis in depth, but of both patients who 
died one patient died from an acute myocardial in­
farction (Aza Pred) and the other died from Pneumo­
cystis carinii pneumonia (CsA) None of the remaining 
patients developed clinical signs of cardiovascular 
disease during the first year after transplantation 
Continued-on-Therapy Analysis 
To Investigate the separate effects of maintenance 
doses of CsA and Pred on lipid and (apo)lipoproteln 
levels, as well as the changes In lipid levels after 
steroid withdrawal, we analyzed the data again after 
the exclusion of patients who died or experienced graft 
loss [N = 4), patients who did not strictly adhere to 
their assigned treatment protocol (¡V = 37), and pa-
tients who were treated with high-dose steroids for 
acute rejection (CsA, N = 6, Aza-Pred, JV = 6) The 
demographic and clinical characteristics of the re-
maining 69 patients were not different from those of 
the whole study population given in Table 1 The 
course of the concentrations of serum lipids and 
(apo)llpoproteins is shown in Table 6 Differences 
between both groups are more pronounced In this 
subgroup analysis especially for HDL-C and Lp(a) 
The proportion of patients with a Lp(a) value above 
300 mg/L (generally used as a cut-off point for in-
creased risk) was 36% in the CsA group and 10% in 
the Aza Pred group (P < 0 01) In the CsA group, the 
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TABLE 5. Direction of changes in serum lipids a n d 
l ipoproteins after c o n v e r s i o n f r o m CsA m o n o t h e r a p y 
t o Aza-Pred or v i c e v e r s a 
HDL-C TQ 
Figure 1. Effects on serum lipids a n d lipoproteins of steroid 
withdrawal a n d subsequent treatment with steroids or ATG 
for rejection. M e a n (±SE) values of serum lipids a n d l ipopro­
teins before the withdrawal of Pred at 3 months after renal 
transplantation (Tx), after cessation of Pred, a n d either after 
treatment with high doses of Pred for a c u t e rejection in seven 
patients (a) or after treatment with ATG for a c u t e rejection in 
five patients (b). Data are presented as percentages with a n 
index value of 100% for the first lanes. TC. serum total 
cholesterol; * Ρ < 0.05 for differences with values at 3 months 
after transplantation. 
relative decrease In HDL-C after steroid withdrawal 
was larger than the accompanying decrease in apo 
Α-I, resulting in a significant reduction in the HDL-C-
to-apo Α-I ratio. 
DISCUSSION 
This study demonstrates that CsA monotherapy 
and Aza-Pred treatment markedly differ in their effects 
on serum lipid and (apo)lipoprotein levels during the 
Parameter Increase/ decrease 
CsA -» Aza-Pred -
Aza-Pred CsA 
( N = 5) (W = 5) 
Total cholesterol 
LDL-C 
HDL-C 
ΤΘ 
Î / I 
Î / J 
t / I 
f /1 
1/4 
1/4 
5/0 
0/5 
2/3 
4/1 
2/3 
3/2 
first year after renal transplantation. Because the 
influence of Aza on serum lipid levels has not been 
demonstrated (22), the design of our study allowed a 
direct comparison of the effects of CsA and Pred on 
lipid metabolism. During the first 3 months after 
transplantation, all patients received both CsA and 
Pred, which was followed by the cessation of either 
drug. Concentrations of total cholesterol and LDL-C 
remained elevated in both groups and were compara-
ble to those reported earlier in posttransplant patients 
on various immunosuppressive regimens (12,13). 
However, significant differences between both groups 
were noted for HDL-C, serum TG. and Lp(a). Differ-
ences In HDL-C or TG were not observed in previous, 
relatively small studies comparing the effects of CsA 
monotherapy and Aza-Pred treatment on lipid metab-
olism (9,10). 
Diabetic patients were excluded from this study 
because preexisting secondary hypertriglyceridemia 
as well as the influence of Pred on already disturbed 
glucose metabolism would hamper the interpretation 
of the data obtained in these patients. The results may 
therefore not apply to diabetics, who represent a 
substantial part of the renal transplant recipients in 
some countries. 
One of our most striking findings was the consider-
able decrease in HDL-C concentration, especially in 
CsA-treated patients. The fall in HDL-C may in part 
have been secondary to the rise in serum TG, but in 
the Aza-Pred group, both HDL-C and TG appeared to 
decrease, which suggests that other mechanisms are 
involved. In general, low HDL-C levels can result from 
a decreased hepatic synthesis or from an increased 
removal from the circulation. The urinary loss of HDL 
has been suggested to occur in patients with the 
nephrotic syndrome (23). It is, however, not a likely 
cause of low HDL levels in our patients because there 
were only a few patients with proteinuria and there 
was no correlation between the degree of proteinuria 
and HDL levels. The time course of the alterations in 
HDL-C and serum TG on CsA monotherapy, with the 
most dramatic changes between 3 and 5 months after 
transplantation, suggests a relation with the cessa-
tion of Pred during exactly the same period. This was 
supported by the normalization of reduced HDL and 
increased TG levels in patients treated with steroid 
courses for acute rejection after prior steroid with-
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TABLE 6 Continued-on-therapy analysis of lipid and (apo)lipoproteln concentrations at 3. o, and 12 months 
after renal transplantation in patients treated wilh CsA monotherapy ( N = 2Θ) or with Aza-Pred ( N = 41) 
Parameter 
Serum cholesterol (mmol/L) 
Serum TG (mmol/L) 
LDL-C (mmol/L) 
HDL-C (mmol/L) 
Total/HDL-C 
apo Α-I (mg/L) 
HDL-C/apo Α-I (mmol/g) 
apo В (mg/L) 
Lp(a) (mg/L)' 
3 months 
6 I 6 1 1 53 
1 70 ± 0 84 
4 20 ± 1 32 
1 35 ± 0 36 
4 86 1 1 53 
1,568 ±277 
0 85 ± 0 17 
1.313 ±389 
84(38-378) 
' Ρ ' 0 05 for difference versus 3 months 
CsA 
6 months 
5 90 ± 1 06 
2 54 ± 1 57b 
3 93 ± 0 80 
0 90 ± 0 25b 
7 00 ± 2 24b 
1,316 ± 247b 
0 68± 0 13b 
1,236 ±241 
° Ρ · 0 001 for difference versus 3 months 
"· Ρ ' 0 01 for difference versus 3 months 
d
 Ρ <~ 0 01 for difference with CsA group 
* Ρ < 0 05 for difference with CsA group 
' Given as median with interquartile range 
drawaJ (Figure 1) The lack of a similar response to 
treatment with ATG argues against a role of the devel­
oping or resolving rejection process itself in the pro­
duction of these changes Comparable observations 
on the effects of the reinslitulion of Pred after previous 
steroid withdrawal were made in patients who 
switched from CsA monotherapy to Aza Pred treat­
ment Finally, multiple linear regression analysis re­
vealed that the use of Pred was an independent pre­
dictor of HDL-C and ofthe major protein component of 
HDL apo Α-I at 1 yr after transplantation 
The literature lacks agreement on HDL-C levels after 
renal transplantation, but increased HDL levels have 
been reported more than once In earlier years when 
immunosuppressive regimens without CsA contained 
higher Pred dosages (24) An effect of steroids on 
HDL-C is supported by a previously noted decrease in 
HDL-C after steroid withdrawal (Θ) and by the rise in 
HDL-C observed after the short-term administration 
of corticosteroids in healthy men (25,26) or in patients 
with various disorders (27,28) The increase in HDL-C 
was often not accompanied by a significant increase In 
apo Α-I, resulting in an Increased lipid-to-proteln ratio 
In HDL (24.26,27) Our finding of a significantly lower 
ratio of HDL-C to apo Α-I In patients who stopped 
taking Pred (CsA group), as compared with those In 
whom the dosage was reduced (Aza-Pred group), is in 
accordance with these observations 
The mechanism by which corticosteroid administra­
tion increases HDL-C levels is not clear Animal stud­
ies have shown Increases in the hepatic production of 
nascent HDL-C after corticosteroid administration 
(29) Furthermore, Increased activity of lipoprotein 
lipase during the administration of Pred has been 
associated with a rise in HDL-C and may also contrib­
ute to a decrease In TG (25.26) Alternatively, de­
creased activity of hepatic Upase, enhanced activity of 
lecithin-cholesterol acyltransferase (24). or changes in 
Aza-Pred 
12 months 
5 85 * 1 17 
2 19 ± ι iec 
3 94 ± 1 01 
0 99 ± 0 36b 
6 77 ; 2 87" 
1,383 ±251° 
0 7 0 ± 0 17c 
1,288 ±297 
166(71-479)° 
3 months 
6 26 ± 1 37 
2 10 ± 0 9 7 
406 ± 1 12 
1 32 ± 0 45 
5 17 ± 1 89 
1,510 ±275 
0 88 ± 0 18 
1,257 ± 327 
72 (25-277) 
6 months 
584 ± 1 21 
1 81 ± 0 86 
3 9 9 ± 1 17 
1 16 ± 0 44° d 
5 47 ± 1 64c d 
1,437 ± 302 
081 ± 0 18 c d 
1.251 ± 269 
12 months 
5 86 ± 1 17a 
1 76 ± 0 83е 
3 96 ± 1 02 
1 16 ± 0 39 
5 49 ± 1 96е 
1,388 ± 237a 
0 82± 0 18d 
1,218 ± 282 
38(2l-176)d 
cholesteryl ester transport could be involved In pa­
tients with nephrotic syndrome, corticosteroid ther­
apy has been associated with a reduction In plasma 
cholesteryl ester transfer protein (CETP) (30) CETP 
mediates the transfer of cholesteryl esters from HDL to 
apo B-contalning lipoproteins, and patients with ge­
netic CETP deficiency have increased HDL-C levels 
(31 ) A reduction in CETP activity by Pred therapy as a 
possible cause of increased HDL-C levels is supported 
by our observation of a significantly smaller choles­
terol content of VLDL in Aza-Pred-treated patients as 
compared with their CsA-treated counterparts 
Taken together, we have strong arguments to as­
sume that in our CsA treated patients, the reduction 
ofthe Pred dosage from 20 mg/day to 0 contributed to 
the observed fall in HDL-C The persistence of high 
levels of total cholesterol, LDL-C. and TG is probably 
related to treatment with CsA In accordance with this 
view, the moderate decrease in HDL-C that occurred 
in the Aza-Pred group may be caused by the reduction 
of the Pred dosage from 20 to 10 mg/day The ten­
dency for decreases in total cholesterol and TG In 
these patients is in line with the observations in 
previous conversion studies (32,33) and may be at­
tributed to either the discontinuation of CsA or again 
to the reduction of the Pred dosage 
The remarkable increase in Lp(a) levels in CsA-
treated patients, but not in Aza-Pred-treated patients, 
is in keeping with the results of several recent studies 
(4.34), although opposite data have been reported too 
(35) Multiple linear regression analysis showed an 
Independent relationship between the use of CsA and 
(log normalized) Lp(a) The mechanism by which CsA 
increases the concentration of Lp(a) is unknown Lp(a) 
levels were demonstrated to be related to the geneti­
cally determined apo(a) phenotype (36) Although 
apo(a) phenotyplng was not performed in our study, 
the results Indicate that In renal transplant patients. 
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Lp(a) levels are not only a function of the p h e n o t y p e 
b u t also of the i m m u n o s u p p r e s s i v e t r e a t m e n t regimen 
t h a t is u s e d A recent s t u d y showed d e c r e a s e s In Lp(a) 
levels d u r i n g t r e a t m e n t with glucocorticoids in pa­
t ient s with r h e u m a t i c d i seases (28), b u t the use of 
Pred a p p e a r e d not to be a n I n d e p e n d e n t predictor of 
Lp(a) levels m our mult ivar iate analys is 
What is the clinical significance of our f indings 9 
Atherosclerosis is a c o m m o n problem in renal t r a n s ­
p lant recipients, with coronary h e a r t d i sease being the 
m a i n c a u s e of d e a t h in this p o p u l a t i o n (37) Hyperllp-
ldemia plays a n i m p o r t a n t role in the p a t h o g e n e s i s of 
a therosc leros i s , a n d from large epidemiologic s tudies , 
it is k n o w n t h a t low HDL-C levels, a s well a s high total 
cholesterol a n d LDL-C levels, a re i n d e p e n d e n t risk 
factors for coronary h e a r t d i sease (15,38,39) Hyper­
triglyceridemia h a s been found to be a n i n d e p e n d e n t 
r isk factor in s o m e s tud ies (40) Kasiske d e m o n s t r a t e d 
a n i n d e p e n d e n t associat ion between s e r u m choles­
terol a n d ischemic h e a r t d i sease m a large popula t ion 
of rena l t r a n s p l a n t recipients (41) Regarding the mag­
n i t u d e of the effect of a decrease in HDL-C, it w a s 
e s t imated from the F r a m i n g h a m Heart S tudy that a 
decrease of 10 mg/dL (0 26 mmol/L) w a s associated 
with a n increase in the r isk for mortal i ty d u e to 
coronary h e a r t d i sease of 18 9 a n d 28 1% for m e n a n d 
women, respectively (39) Similarly, in the Physician 's 
Heal th Study, a c h a n g e of 1 U in the rat io of total 
cholesterol to HDL-C, like t h e difference between the 
m e a n s of our s t u d y g r o u p s a t 1 yr after t r a n s p l a n t a ­
tion, was associated with a 5 3 % change in the risk of 
myocardia l Infarction (15) Despite these persuas ive 
figures for the general populat ion, we have to be 
c a u t i o u s in concluding t h a t a decrease in HDL-C after 
steroid wi thdrawal will equally worsen the cardiovas­
cular r isk in renal t r a n s p l a n t p a t i e n t s If s teroids 
would alter the composi t ion of HDL in a nonbeneficial 
way, the improved composi t ion of HDL after steroid 
wi thdrawal could outweigh the potential ly negative 
effects of lower HDL-C levels. However, the rise in the 
lipid-to-protein rat io of HDL, a s well a s previously 
observed increases in t h e H D L 2 subfract ion (26,42), 
p o i n t s to favorable c h a n g e s in the composi t ion of HDL 
after the a d m i n i s t r a t i o n of Pred (15) Lp(a) is n o t only 
positively associa ted with coronary h e a r t d i sease b u t 
m a y also have de t r imenta l effects on h e m o s t a s i s a n d 
t h r o m b o s i s (16) 
In conclus ion, the resul t ing lower HDL-C, higher 
s e r u m TG, a n d higher Lp(a) levels suggest t h a t CsA 
m o n o t h e r a p y is a less at tract ive i m m u n o s u p p r e s s i v e 
t r e a t m e n t s trategy t h a n Aza-Pred t r e a t m e n t in t e r m s 
of r isk for coronary h e a r t d i sease Moreover, the 
c h a n g e s in HDL-C a n d TG t h a t we observed after the 
cessa t ion a n d r e s u m p t i o n of Pred in CsA-treated pa­
t ients Indicate t h a t t h e widespread a s s u m p t i o n that 
steroid withdrawal improves the s e r u m lipid p a t t e r n 
after rena l t r a n s p l a n t a t i o n m a y be false In this re­
gard, Pred m a y even exert s o m e protective effect in 
CsA-treated p a t i e n t s Current ly, we are performing a 
prospective s t u d y to c o m p a r e t h e effects of CsA-Aza 
t r e a t m e n t with t h a t of CsA-Pred t r e a t m e n t on s e r u m 
lipids a n d l ipoproteins 
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CHAPTER 6 
Detailed study of changes in renal function 
after conversion from cyclosporin e to azathioprine 
L.B. Hilbrands, A.J. Hoitsma, J.F.M. Wetzels, and R.A.P. Koene 
Submitted for publication 

ABSTRACT 
The renal dysfunction induced by cyclosporine (CsA) has been demonstrated to 
>e at least partially reversible after cessation of CsA therapy. The time course and 
nagnitude of changes in various parameters of renal function after CsA withdrawal 
lave not been studied in detail. We examined 12 renal transplant patients 
mmediately before and 1, 2, and 4 weeks after replacement of CsA by 
izathioprine at 3 months after transplantation. Nine patients in whom CsA was 
;ontinued during this period served as a control group. A significant increase in 
Glomerular filtration rate ([GFR] 15 + 17%, Ρ < 0.01) occurred already in the first 
veek after discontinuation of CsA. From 1 to 4 weeks after conversion, GFR did 
lot significantly increase any further. A fall in serum creatinine (-7+9%, NS) 
paralleled the rise in GFR (R= -0.78, p<0.01), but there was a further decrease 
if creatinine in the second to fourth week after conversion. Withdrawal of CsA 
nduced a rise in serum magnesium in all patients (0.73+0.13 vs 0.86+0.12 
Timol/1, Ρ < 0.001) as well as a marked decrease in the serum level of urate 
Ό.39 ±0.09 vs 0.33+0.07 mmol/1, Ρ < 0.01) within one week. None of the 
observed changes took place in the control group. In conclusion, a major 
mprovement of GFR occurs within one week after cessation of CsA-therapy. 
Changes in the serum levels of magnesium and urate appear to be the most 
'esponsive markers of the renal effects of CsA. 
INTRODUCTION 
The immunosuppressive drug cyclosporine A (CsA) contributes greatly to the 
successful treatment of transplant recipients and patients with auto-immune 
diseases. An important side effect of CsA is the impairment of renal function. 
Although long term use of the drug may result in irreversible renal injury, 
discontinuation of CsA is usually followed by considerable recovery of renal 
function (1). This reversible component of CsA-induced renal dysfunction has been 
ascribed to preglomerular vasoconstriction (2,3), a functional effect that should 
cease immediately after CsA withdrawal. Several human studies provide 
information on the degree of improvement in creatinine clearance or glomerular 
filtration rate (GFR) that can be expected after cessation of CsA (1,4). However, 
comprehensive data on the time course of these changes are not available. We 
therefore performed a prospective study to examine the rate of changes in renal 
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function during the first four weeks following conversion from CsA to azathioprine 
at three months after renal transplantation. In addition to GFR, various other 
indices of renal function (such as tubular handling of sodium and uric acid) were 
measured in order to identify the most sensitive markers of the renal effects of 
CsA. 
METHODS 
Subjects 
The study group consisted of 12 renal transplant patients (10 M, 2 F; age 
41 + 14 years) in whom elective conversion from CsA to azathioprine was carried 
out at three months after transplantation as part of another study protocol 
(randomized prospective trial comparing conversion from CsA to azathioprine with 
CsA monotherapy from three months after renal transplantation). Nine patients 
(7 M, 2 F; age 42 + 12 years) who were allocated to continuation of CsA served as 
the control group. Patients were eligible for this study if renal function was stable 
(variation in serum creatinine of less than 15% in two weeks prior to the study) 
and diastolic blood pressure was below 110 mmHg. Patients who were using 
diuretics, xanthine derivatives, or nonsteroidal anti-inflammatory drugs were 
excluded. Furthermore, two patients were excluded during the four weeks study 
period because an acute rejection episode was diagnosed (the study and control 
population initially consisted of 13 and 9 patients respectively). During the first 
three months after transplantation, immunosuppressive treatment consisted of CsA 
(initial oral dose of 12 mg/kg/day, tapered to approximately 4 mg/kg/day in two 
divided doses) and prednisone (20 mg/day at the time of the study) in all patients. 
In the conversion group, CsA was replaced by azathioprine in a dosage of 
3 mg/kg/day. The prednisone dosage was temporarily increased from 20 to 25 
mg/day during the first two weeks after conversion but was back on 20 mg/day 
during the following two weeks. In patients who continued on CsA, the dose of 
CsA was not changed and according to our treatment protocol, the prednisone 
dosage was reduced from 20 to 10 mg/day during the four weeks study period. Six 
patients (4 in the conversion group and 2 in the control group) used atenolol (50 to 
100 mg once daily) and 11 patients (4 in the conversion group and 7 in the control 
group) received the combination of atenolol and nifedipine (10 or 20 mg slow 
release tablets twice daily) as antihypertensive therapy. The dose of these drugs 
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was not changed during the study period. The study was approved by the Hospital 
Ethics Committee and all patients gave written informed consent. 
Study protocol 
In the conversion group, measurements were carried out on the day before 
discontinuation of CsA (at three months after transplantation) and 1, 2, and 4 
weeks afterwards. Patients in the control group underwent the same measurements 
only at the first and last occasion of this series, i.e. at 3 and 4 months after 
transplantation. All experiments were performed from 9.00 a.m. till noon. The 
patients were on a regular diet but were advised to avoid the use of coffee, alcohol, 
liquorice, or tobacco during the last nine hours preceding the measurements. The 
evening preceding each experiment, 300 mg of lithium carbonate (8.1 mmol of 
lithium) was given orally. A light breakfast on study days was allowed and if 
applicable, antihypertensive drugs were taken with breakfast. Upon arrival in the 
ward, a blood sample was drawn for determination of the CsA trough level. 
Immediately thereafter, the patients ingested their regular morning dose of CsA. A 
sufficient diuresis was attained by an initial oral water load of 10 ml per kg body 
weight, followed by i.v. infusion of a solution of 0.25% NaCl (to compensate for 
expected sodium losses in the urine) in 3.3% glucose at a rate of 400 ml/hr. 
Urinary fluid losses in excess of the infused volume were replaced orally by tap 
water. Except for spontaneous voiding in upright position, patients remained 
supine. 
Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured 
using a continuous infusion technique. Renal clearances of inulin (polyfructosan, 
InutestR, Laevosan-Gesellschaft, Linz, Austria) and para-aminohippuric acid (PAH) 
were used as markers of GFR and RPF, respectively. After an equilibration period 
of 90 min, urine was collected at 30 min intervals. Blood samples were drawn at 
the midpoint of each urinary collection period. Blood pressure and heart rate were 
recorded every three minutes with an automatic device (Dinamap model 1846P, 
Critikon Inc., Tampa, FL, USA). The mean values of five consecutive readings 
around the midpoint of each clearance period were used for analysis. 
The filtration fraction (FF) was calculated as GFR/RPF χ 100% and renal blood 
flow (RBF) was estimated using the formula RBF=RPF/(l-haematocrit). Renal 
vascular resistance (RVR) was defined as mean arterial pressure (MAP) divided by 
RBF and expressed in arbitrary units. Fractional excretions of sodium and uric acid 
(FENa and FEUr) were calculated as their respective renal clearances (CNa and CUr) 
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divided by GFR and expressed as percentage. Using the lithium clearance (C
u
) as 
an approximate marker of proximal tubular sodium and water reabsorption (5,6), 
the fractional proximal sodium reabsorption (FPRNa) and fractional distal sodium 
reabsorption (FDRNa) were estimated by the following calculations: 
FPRNa = (1-CU/GFR) χ 100% and FDRNa = (l-CNa/CLI) χ 100%. 
Clearances of the various parameters were calculated for each of the three 30 
min intervals and these values were averaged subsequently. The resulting clearance 
values were adjusted to a standard body surface area of 1.73 m2. 
Analytical procedures 
In serum or urine samples, PAH, inulin, creatinine, sodium, potassium, 
magnesium, uric acid, and bicarbonate were measured by standard techniques. 
Lithium was determined by atomic absorption spectrophotometry. In blood samples 
the haematocrit was determined by routine Coulter counter and whole blood CsA 
levels were measured with a monoclonal antibody against the CsA parent molecule 
using Abbott TDx (Abbott Laboratories, North Chicago, IL, USA). 
Statistical analysis 
Data are reported as means ± SD unless stated otherwise. Results were 
analyzed with Wilcoxon's test for paired or unpaired observations when 
appropriate. Correlations were assessed by calculating Spearman's correlation 
coefficient. A probability value less than 0.05 was considered statistically 
significant. No correction for comparison of multiple outcomes was applied. 
RESULTS 
Baseline values of blood pressure, renal hemodynamic parameters, and other 
indices of renal function did not differ between the conversion and control group 
(Tables 1 and 2). 
There were no differences between patients who used atenolol as the sole 
antihypertensive drug (n=6) and patients without antihypertensive therapy (n=4) 
with respect to baseline values of the parameters given in Tables 1 and 2. 
However, when all patients who used nifedipine (n=ll) were compared to those 
who did not (n=10), the former group was characterized by a higher FENa 
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(6.5+2.8% vs 3.3±0.8%, P<0.01), a lower FPRNa (53.2 + 11.3% vs 66.6+7.1%, 
P<0.01), and a lower FDRNa (86.4+4.1% vs 90.0+2.1%, P<0.05) at week 0. In 
the control patients, who continued to use CsA, the CsA trough levels remained 
constant (week 0: 161+48 ng/ml, week 4: 176 + 52 ng/ml; NS). Patients in the 
conversion group had similar CsA levels at week 0 (176 + 59 ng/ml; NS for 
difference versus control group). 
One week after discontinuation of CsA, GFR had improved in all but one 
patient. During the next three weeks, a slight and statistically non-significant 
further increase in GFR was observed (Table 1). After four weeks, the change in 
GFR in the conversion group significantly differed from that in the control group. 
RPF and RVR showed an increase and decrease respectively, but statistical 
significance was not achieved for the difference with the control group. Conversion 
from CsA to azathioprine was not followed by a change in the filtration fraction 
(0.22, 0.20, 0.20, and 0.22 at 0, 1, 2, and 4 weeks respectively). A fall in serum 
creatinine during the first week after conversion was followed by a further decrease 
during the subsequent 3 weeks, resulting in a significant difference from baseline 
from 2 weeks after conversion. At 1 and 4 weeks after conversion, serum 
creatinine had decreased in 9 and 11 of all 12 cases respectively. Blood pressure 
tended to decline after CsA withdrawal, although the difference did not reach 
statistical significance. 
The time course of other potential indices of the renal effects of CsA are given 
in Table 2. The most common change during the first week after conversion was a 
rise in the serum magnesium level, which occurred in all patients. In addition, 
there was a rapid and marked decrease in the serum level of urate. The fractional 
excretion of uric acid did not change after conversion from CsA to azathioprine 
(17+8% at baseline vs 16 + 8% at 4 weeks). There was a slight decrease in FENa 
which appeared to be due to an increase in the fractional distal reabsorption of 
sodium. However, as mentioned above, tubular handling of sodium and lithium 
were influenced by the use of nifedipine. To circumvent this potential source of 
bias, we repeated the analysis on tubular sodium handling after exclusion of 
4 nifedipine users from the conversion group. As is shown in Table 3, in the 
remaining 8 patients there was a slight decrease in FPRNa at one week after 
conversion, while a significant increase in FDRNa was lacking in this subgroup of 
patients. Meaningful comparisons with the control group were not possible since 
only two members of this group did not use nifedipine. 
The relative change in serum creatinine showed a significant correlation with 
the relative change in GFR (at 1 week: R = -0.76, P<0.01; at 4 weeks: R=-0.57, 
95 
Table 3. Tubular handling of sodium in 8 renal transplant patients who were converted 
from CsA to azathioprine and did not use nifedipine; baseline values (week 0) and 
absolute changes from baseline. 
FENa 
FPRNa 
FDRNa 
(%) 
(%) 
(%) 
0 
3.4±0.8 
65.9±7.7 
89.7±2.2 
1 
+0.1±0.9 
-7.3±8.0a 
+ 1.6±2.1 
Weeks 
2 
-0.3 + 1.4 
-4.8±6.9 
+2.2+4.0 
4 
-0.2 + 1.0 
-5.7±10.5 
+ 1.8±3.2 
a
 Ρ < 0.05 for difference versus baseline value. 
For abbreviations see text. 
P=0.055). Although the improvement in renal function and the decrease of serum 
urate were of equal magnitude, there was no significant correlation between both 
changes. Likewise, the change in serum magnesium was not correlated with the 
change in either GFR or serum creatinine. 
DISCUSSION 
This controlled study of the changes in renal function that occur after 
discontinuation of CsA demonstrates that these changes largely take place during 
the first week following cessation of the drug. At one week after conversion, GFR 
had improved with 15% and in the ensuing weeks only a minor, non-significant, 
further increase in GFR was observed. As expected from literature data, the 
increase in GFR was accompanied by a rise in RPF and a decrease in RVR (7,8). 
Accordingly, our findings support the conclusion by others that renal 
vasoconstriction is involved in the reversible form of CsA induced renal 
dysfunction (2,3). The fall in serum creatinine lasted slightly longer than the rise in 
GFR, which may partly be due to the time needed to achieve a new steady state of 
the serum creatinine level after a change in creatinine clearance. The relevance of 
these findings is that in clinical practice as well as in investigational circumstances 
the outcome of CsA withdrawal with regard to renal function can already be judged 
reliably after two weeks. When the interval between cessation of CsA and the time 
of evaluation becomes longer, the chance increases that measurement of the effects 
of CsA withdrawal becomes disturbed by other factors. One of these confounding 
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factors in renal transplant patients can be a change in renal function due to an acute 
rejection episode which sometimes occurs already in the first month after 
conversion from CsA to azathioprine (9). 
Generalization of the results may be limited by the fact that the study was 
carried out in CsA-treated patients with rather well functioning grafts. Some 
selection-bias may have occurred in this respect since it has been our policy to 
replace CsA by azathioprine prematurely in patients in whom poor graft function 
was suspected to be worsened further by CsA-related nephrotoxicity. In addition, 
the fluid load and the supine position of the patients may have raised the measured 
GFR to some extent. 
In previous studies, a decrease in the fractional clearance of lithium (FELl) has 
been suggested to be a sensitive marker of CsA induced renal dysfunction 
(10,11,12). At first sight, we were not able to confirm these findings as the 
fractional proximal sodium reabsorption (which was calculated by the formula 100-
FELl) did not change after discontinuation of CsA. However bias appeared to be 
introduced by treatment with the calcium antagonist nifedipine in four patients. Use 
of nifedipine during CsA therapy was associated with higher levels of FENa and 
FEL| which agrees with the known effects of this drug (13,14). Indeed, analysis of 
the data after exclusion of the four nifedipine using patients, revealed a decrease in 
the FPRNa (corresponding to an increase in FELl) at one week after conversion. The 
tendency of the fractional distal sodium reabsorption to increase may reflect a 
reversal of the CsA-induced hyporeninemic hypo-aldosteronism (15). The observed 
increase in serum bicarbonate as well as the decrease in serum potassium also fit 
with recovery from a hypo-aldosteronemic state. 
Hypomagnesemia and hyperuricemia are well known side effects of CsA. 
Nevertheless, we were surprised to find that the rise in serum magnesium as well 
as the fall in serum urate levels were the most consistent changes already occurring 
during the first week following conversion from CsA to azathioprine. The serum 
magnesium level rose in all patients and the urate concentration decreased in all but 
one patient in whom it remained constant. Thus, in our hands the magnesium and 
urate levels were the most sensitive markers of the acute renal effects of CsA. The 
mechanisms by which CsA changes the serum levels of magnesium and urate are 
not quite clear. Theoretically, hyperuricemia may result from a decrease in the 
filtered load of urate with impaired GFR, from an independent effect of CsA on 
tubular urate transport, or from both of these factors. The lack of correlation 
between the decrease in serum urate and the increase in GFR in our patients 
suggests that the improvement of renal function is not the sole explanation for the 
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reduction of urate levels after conversion from CsA to azathioprine. Moreover, in 
other studies it was found that urate levels were higher in CsA-treated patients than 
in those receiving azathioprine for any given degree of renal function (1,16,17). It 
has therefore been suggested that CsA specifically decreases tubular secretion or 
increases tubular reabsorption of urate (17,18). Since we did not observe an 
increase in FEUr after cessation of CsA, our data do not support this hypothesis, 
although an irreversible change in the tubular handling of urate due to CsA 
treatment, as suggested by Noordzij et al. (18), cannot be excluded An increased 
renal clearance of magnesium in CsA-treated patients has been demonstrated 
repeatedly (19,20,21), but the tubular site and mechanism of altered magnesium 
transport remain unknown. 
In summary, the improvement in GFR that can be expected after discontinuation 
of CsA is largely attained within one week. A rapid and marked increase in serum 
magnesium and decrease in serum urate level are the most consistent other 
biochemical changes following conversion from CsA to azathioprine in renal 
transplant patients. 
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Cimetidine improves the reliability of creatinine as a marker of 
glomerular filtration 
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Cimetidine improves the reliability оГ creatinine <is a marker оГ 
glomerular filtration. Τυ investigale whether the administration ul 
Cimetidine can improve ihe reliability of creatinine as a marker of GFR 
we compared the creatinine clearance (CCr) ю the clearance of the true 
nitration markers *'Cr EDTA ( C t u r A l and inulin (C,n) after oral 
ingestion of Cimetidine in 10 healthy men and 29 patients with varying 
degrees of renal dysfunction After administration of Cimetidine for 
three to six days serum creatinine level rose in all participants while 
C t D T A and C l n remained stable in a subgroup of 14 subjects in whom 
they were measured before as well as after ihe administration of 
Cimetidine The mean (± SD) ratios of C ( r to C E D T A (iV = 39) and of C t r 
to C,„ (N = 19) after ingestion of Cimetidine were 1 02 ± 0 13 and I 01 
± 0 13 respectively and did not differ significantly from unity This 
high degree of accuracy of the Cimetidine aided C t I was present over 
the entire range of renal function in the sludy population Our results 
also indicated an improved precision of the Cimetidine aided measure 
ment of CC r resulting in a variability that did not differ significantly 
from that of the measurement of С
Ь О
Т А
 О Г
 C|n We conclude that after 
oral administration of Cimetidine the creatinine clearance can be used 
as a reliable measure of GFR within a broad range of renal function 
In routine clinical practice, serum creatinine and creatinine 
clearance are commonly used to assess renal function How­
ever, the use of creatinine as a marker of the glomerular 
filtration rate (GFR) has several pitfalls [1.2] The ratio of 
creatinine clearance to GFR therefore exceeds unity and may 
even rise above 2 0 in patients with severe renal insufficiency 
[3] Tubular secretion of creatinine is the major cause of 
overestimation of the true GFR by the creatinine clearance [3. 
4] The contribution of tubular secretion to the overall renal 
clearance of creatinine is unpredictable and variable It has 
been shown that tubular secretion increases as renal function 
decreases [3], and that it may vary with time [5] Therefore, no 
fixed relationship between the creatinine clearance and GFR 
exists, and the creatinine clearance is a rather unreliable marker 
of GFR Furthermore, the "adaptive' increase of tubular 
secretion of creatinine when renal function deteriorates, pre­
vents serum creatinine to be used as a marker of early renal 
dysfunction Lastly, together with the variability of other 
factors such as extrarenal excretion and creatinine generation, 
the unpredictability of tubular secretion limits the use of the 
reciprocal value of serum creatinine as marker of GFR in 
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studies on the progression of renal disease [2) To circumvent 
these problems. GFR can be measured with the aid of "true 
filtration markers" such as inulin ':M-iolhalamate, W m Tc-
DTPA (diethylenetnaminepenla-acetic acid) or '"Cr-EDTA 
(ethylenediaminetetra-aceuc acid) The major disadvantages of 
these techniques are their inconvenience and high cost in 
comparison with measurement of the creatinine clearance 
Secretion of creatinine by the tubular transport system can be 
inhibited by several anionic and canonic substances [1] One of 
these is the frequently used drug Cimetidine, which has been 
shown to reduce creatinine clearance without impairing GFR 
[6-10] Limiting the tubular secretion of creatinine by the 
administration of Cimetidine might thus improve the validity of 
creatinine as a marker of GFR To test this hypothesis we 
compared the clearances of creatinine to that of two true 
filtration markers C'Cr EDTA and inulin) after the administra­
tion of Cimetidine in healthy persons and in patients with 
varying degrees of renal dysfunction 
Methods 
Selec nun oj the partit ipants 
The study was performed in 10 healthy volunteers and in 29 
patients with varying degree of renal dysfunction, who were 
selected from our outpatient population Their calculated 
endogenous creatinine clearance (ECO according to the for 
mula of Cockroft and Gault [11] had to exceed 20 ml/mm. as 
measurement of the plasma clearance of MCr EDTA is not 
reliable when ECC falls below this value [12] Other exclusion 
criteria were pregnancy, diabetes mellitus, use of H,-receptor 
antagonists or antiacids. allergy for Cimetidine, use of drugs of 
which the metabolism can be influenced by Cimetidine, use of 
drugs which are known to interfere with creatinine secretion, 
and unstable renal function The study protocol was approved 
by the Hospital Ethics Committee and informed consent was 
obtained from all participants 
Stud\ design 
The 39 participants of the study visited the outpatient clinic 
on two separate occasions During the interval between both 
study days they used oral Cimetidine (Tagamet") in a dosage 
described below The principal measure of evaluation was the 
ratio of the creatinine clearance (CCr-S) to the simultaneously 
measured clearance of "Cr-EDTA (C E D T A ) after administration 
of Cimetidine In a subgroup of 19 participants the inulin 
clearance (C ln) was used as a second reference method To 
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investigale a possible effect of Cimetidine on GFR clearances of 
M C r EDTA and of inulin were measured before as well as after 
administration of Cimetidine in a subgroup of 14 subiecls In 
addition we studied in all participants the effect of Cimetidine on 
the validity of the 24 hour creatinine clearance ( C C r 2 4 ) and 
1 5 hour creatinine clearance ( C C r I 5) as these methods are 
more practical in ambulatory patients 
Clearance measurements 
The above mentioned clearance measurements using the 
standard clearance formula UX*V/PX for calculations were 
performed in the following way 
a I Determination of 24 hour ciealimnt clearance tCCr24) 
The 24 hour excretion of creatinine was obtained by the mean ot 
the creatinine excretions in the 24 hour urine collected during 
the last two days preceding each visit Serum creatinine con 
centration was determined in the first drawn serum sample at 
each visit (SC r) 
b ) Determination of I 5 hour treatimnt clearance (C
c
 I 5) 
Upon arrival m the outpatient clinic an oral water load of 10 
ml/kg in one hour was given and the urine was collected during 
90 minutes The mean of the serum creatinine concentrations at 
the beginning and end of this period was used for calculation of 
the clearance 
с ) Simultanious measurement of the eh агате of creatinine 
tClrS) "Cr EDTA and Im applicable саіец malin during 
three (omecutne half hour inters als Following the measure 
ment of the C t 1 5 (see in b ) and after an equilibration period 
of at least 75 minutes C C r S and C,„ were determined during 
three clearance periods of 30 minutes Inulin (InutestK Lae 
vosan GmbH) was administered as a continuous ι ν infusion 
with priming and maintenance dose Satisfactory urinary output 
during this period was maintained by replacing urinary losses 
by an oral load of tap water The means of the serum concen 
trations of creatinine or inulin in blood samples at the beginning 
and end of each period were used for clearance calculations 
Subsequently the clearance values of the three half hour pen 
ods were averaged and the mean was used for statistical 
analysis The M C r EDTA clearance was derived from the 
plasma disappearance curve of M C r EDTA using plasma sam 
pies obtained at 150 180 210 and 240 minutes (points of time 
bracketing the 3 clearance periods) after a single ι ν injection of 
" ' C r E D T A [13 14J We used the formula described by 
Brochner Mortensen and Rodbro to calculate the renal clear 
ance of " C r EDTA [15] The dose of " C r EDTA was 100
 M Ci 
if ECC exceeded 30 ml/min and 50 μ & if ECC was less 
During the clearance measurements the participants were in 
a supine or sitting position All measurements were earned out 
between 9 00 a m and 2 00 ρ m On the morning of both study 
days a standard breakfast containing only two slices of bread 
with jelly and two glasses of water were allowed before starting 
the measurements to exclude a possible rise in creatinine by 
dietary intake 
Apart from the clearance measurements whole blood counts 
liver function tests and analyses of the urinary sediment were 
performed to monitor possible side effects of Cimetidine 
Laborators methods 
Serum and unne concentrations of creatinine were deter 
mined by an enzymatic method (Boehnnger Mannheim GmbH) 
table I Daily dose and dosing scheme of Cimetidine for different 
levels of renal function 
Dally dose and Last morning 
dosing schemeb dose 
ECC' _ 
ml mm mf> 
>7S 2000 400 400 400 8(X) 800 
50-7S 1600 400 400 400 400 600 
30-SO 1400 400 400 600 600 
20-10 1200 400 400 400 400 
" ECC endogenous creatinine clearance according to the Cockroft 
G lull equalion 111] 
ь
 The first dose was taken on waking up the last dose al bedtime and 
interjacent doses at regular intervals 
Ingested at home before visit lo the outpatient clinic 
permitting accurate quantitation of the creatinine concentration 
and eliminating measurement of spurious non creatinine chro 
mogens as occurs with the conventional alkaline picrate 
method Inulin concentrations were determined by a semi 
automated technique (centrifugal analysis Multistat) using en 
zymatic degradation of inulin [16] 4 C r EDTA was measured in 
plasma samples with a gamma counter (LKB Wallace) Other 
measurements were performed according to standard labora 
tory techniques 
Dosage of Cimetidine 
To obtain maximal inhibition of tubular secretion of creati 
nine we prescribed the maximally allowed oral daily dose of 
2000 mg in case of normal renal function As Cimetidine is 
cleared largely by the kidney the dose was adjusted according 
to the degree of renal dysfunction in an attempt to achieve 
approximately equal blood Cimetidine levels in all participants 
The prescribed doses tor the different levels of renal function 
are given in Table I Compliance was checked by pill counting 
Duration of Cimetidine intake 
After administration of Cimetidine a rise in serum creatinine 
concentration can be expected In such a case a new steady 
stale which is necessary to perform clearance studies will be 
reached after four elimination half times (T, -,) of serum creat 
mine The kinetics of creatinine are multi compartmental b u m 
has been demonstrated that the error arising from applying a 
one compartmental model is negligible [17] In that case the 
turnover time ( T E L ) is equal to the quotient of the volume of 
distribution (VD) and the clearance (C) of a substance which can 
be defined as the sum of the renal and extrarenal clearance (C R 
+ C N R ) 
T E L = V D / ( C R + C N R ) 
Based on a VD of creatinine of 0 5 x body weight [ 17-20] and an 
extrarenal clearance of 0 04 liter/day/kg [21] T t I can be 
expressed as a function of body weight (BW in kg) and 
endogenous creatinine clearance (ECC in ml/min) 
T E L (in hours) - 500 χ BW/(60 χ ECC + 1 67 x BW ) 
Since Τ, τ - ln2 x T E l 
Τ , , (in hours) = 5 78 x BW/(ECC + 0 028 χ BW) 
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Since daily measurements of creatinine were not feasible in this 
outpatient population we estimated the number of days (four 
times T , , ) required to reach a steady state for any combination 
ol body weight and creatinine clearance using the above for 
mula In every participant 24-hour urine collection prior to the 
second visit only started after the duration of Cimetidine intake 
had been long enough to attain the predicted new steady stale 
The duration of Cimetidine intake thus equalled the number of 
days required to achieve steady state plus two days 
Statnlical anahus 
All values are expressed as means ± SD For comparison of 
the renal function parameters before and after the administra 
lion of Cimetidine Student s I test and Wilcoxon s test for 
paired observations were used when appropriate Differences 
from unity of the ratios between clearances measured bv lest 
and by reference method, were analyzed by Student s Mest for 
paired data Differences between more than two subgroups 
were evaluated by the Kruskal Wallis test Comparison of the 
SDS of the C t r S to GFR ratios before and after administration 
and comparison ot the variances of clearance values obtained 
by different methods, were performed by analysis of the Pear 
son correlation coefficient between sum and difference of paired 
data A zero correlation coefficient means equal variances or 
SDS A /"-value smaller than 0 05 was considered statistically 
significant 
Results 
Characteristic ч of the study population 
The 10 healthy persons were all men with a median age of 24 
years (range 19 to 30) Their median calculated ECC was 111 
ml/min/l 73 m2 (range 92 to 141) The 29 persons (21 men 8 
women) with impaired renal function who participated in the 
study had a median age of 48 years (range 25 to 66) and a 
median ECC of M ml/min/l 73 m2 (range 20 to 97) Five of 
them had undergone unilateral nephrectomy to donate for 
living-related kidney transplantation and four were renal al 
logran recipients The remaining patients had the following 
renal disorders chronic glomerulonephritis (10), chronic pyelo 
nephritis (4) polycystic kidney disease (2), bilateral renal artery 
stenosis (I), status after malignant hypertension (I), partial 
nephrectomy of single functioning kidney ( I ), and unknown ( I ) 
The calculated duration of Cimetidine intake required to achieve 
steady state for serum creatinine varied from one to four days 
with the following distribution one day, /V = 17, two days N = 
16, three days, iV = 5, four days N - 1 Since collection of two 
24-hour urine samples was started after steady state was 
supposed to be reached, Cimetidine was administered during the 
last three to six days preceding the second visit For practical 
reasons, the interval between the two clearance measurements 
usually was longer than this latter period and varied from six to 
fifteen days The prescribed dosage of Cimetidine was 2000 
mg/day in 15 subjects, 1600 mg/day in 11 subjects, 1400 mg/day 
in nine subjects, and 1200 mg in four cases One of the 
participants used 1000 mg of Cimetidine per day instead of the 
prescribed dosage of 1400 mg/day Another participant had left 
three tablets of 400 mg in excess, while it was not clear when he 
had forgotten to ingest them All participants were included for 
evaluation of the results 
Table 2 Ratios between the creatinine clearance and the 
simultaneously measured clearance of MCr EDTA or inulin before 
and after administration of Cimetidine 
Ratio before Cimetidine Ratio after Cimetidine 
C< S/C t D T A 1 02 * 0 IV (0 98-1 06) 
(iV = 39) 
Q., S/CLUTA 1 1 9 * 0 13(111-126) I 01 ± 0 I I a " (0 94-1 07) 
( V = 14) 
Q , S/C,„ I 01 ± 0 13" (0 95-1 07) 
(N = 19) 
C
c
 S/C,„ I 21 * 0 20(1 12-1 3S) 0 96 ± 0 08"* (0 92-1 01) 
(N = 14) 
C „ n / C „
m
 0 97 * 0 12" (0 91-1 01) 
</V = 39) 
t , , 24/СцугА 0 85 ± 0 I6U (0 80-0 90) 
(rV = 19) 
Values are expressed as means * SD (9S% confidence interval) 
Abbreviation·, are in ihe lexl 
α
 Not significant vs unity 
r
 Η < 0 001 lor comparison wilh pre Cimetidine value 
ь
 /' < 0 001 lor difference from unity 
Eflecti oj < imelidim 
Administration of Cimetidine resulted in a clear-cut rise in 
serum creatinine concentration in all participants Mean S C l ( ± 
SD) increased from 144 ± 77 μπιοΐ/liter to 176 ± 94 μιτιοΐ/liter 
the mean rise being 23 ± I \c/c (P < 0 001) In agreement with 
this observation we found a substantial fall in C C r -24 from 74 ± 
36 to 59 * 30 ml/min (/· < 0 001 ) and in CC r-1 5 from 89 ± 44 to 
68 ± 33 ml/min (P < 0 001) As expected, no statistically 
significant effect of the administration of Cimetidine on the 
clearance of '"Cr-EDTA or inulin could be d e m o n s t r a t e d 
C F D T A "V - 14) was 86 ± 37 ml/mm before administrat ion of 
Cimetidine and 82 ± 34 ml/mm afterwards (NS) For C I n (N = 
14) the corresponding values were 86 ± 41 ml/min and 88 ± 40 
ml/mm (NS) 
By blocking tubular secretion of creatinine, Cimetidine will 
reduce the difference between the creatinine c learance and 
GFR measured by the clearance of a true filtration m a r k e r 
Consequently the ratio of the creatinine clearance to G F R 
should approximate I 0 Table 2 gives an overview of the rat ios 
of C
c r
 to the clearance of true filtration markers before and after 
the administration of Cimetidine After the participants had used 
Cimetidine their mean CC r-S to C F D T A was 1 02 ± 0 1 3 This 
value is not significantly different from unity, rendering the 
cimetidine-aided measurement of the creatinine c learance an 
accurate method of estimation of GFR Using inulin as a second 
marker of GFR. the finding of a C C r S lo C,„ rano of I 01 ± 0 13 
(NS vs unity) pointed to a similar conclusion In a subgroup of 
participants (N - 14 median ECC - 86 ml/min/l 73 m 2 ) the 
ratios of C t r - S to C F „ r A and of CC r-S to C, n were obta ined 
before as well as after administration of Cimetidine Both rat ios 
showed a significant decrease after administration of Cimetidine 
(Table 2) 
Next we classified the 39 participants in three groups accord­
ing to their renal function ( C E D T A < 40 ml/min/l 73 пГ, C h D T A 
40 to 80 ml/min/l 73 m 2 , C E D T A > 80 ml/min/l 73 m
2 ) A s 
expected, absolute and relative nse of serum creatinine were 
larger in the patients with more severe renal dysfunction (Table 
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Table 3 Effect of Cimetidine on serum creatinine (S t r) CCr S to 
C E D Í A r d t l ° an t^ ^ -c S to C,n ratio for various levels of renal 
function 
•-40 
t mlimmll 71 ι 
40-80 >80 
II 17 II 
60 * 28J 26 ± II* 16 r V 
26 * 14" 21 ± 10" 19 ± Τ 
1 01 ± 0 21 h I 01 χ 0 07b I 01 ± 0 08" 
Absolute rise of S t r ¿imol/l 
Relative rise of SCr 7c 
CC r S /C r D T A after 
Cimetidine 
Λ 
С , , S/C, after Cimetidine 
Values are expressed as means ± SD Abbreviations are in the text 
J
 Ρ < 0001 
h
 Not significant vs unilv and no significant differences for С
ь о 1 > 
< 4 0 v s C t m A 40-80 C E l ) , A < 4 0 v s C M ) T A > 8 0 and C, D T A 40-80 vs 
C,DTA >80 
I 08 » 0 I8h 0 99 * 0 I I ' 0 97 ± 0 I0b 
1 6 
1 4 
1 2 
1 0 
08 
06 
04 
Fig 1 Rutto oj C
c
 S to С?
п 
udmmtstralum of titneltdint 
40 60 80 100 120 
CEDTA тНттП 73 тг 
(¡corame of 5'Cr EDTA after 
3) M o r e notably after administ rat ion o f Cimetidine no signif 
leant di f ferences in the CCr S l o С,
 т л
 rat io nor in the C C r S lo 
C|„ r a t i o between the three subgroups, were found (Table 1) In 
a d d i t i o n the mean C C r S to C L l v r A rat io after administrat ion of 
Cimet id ine o f the 10 patients w i t h p r i m a r i l y g lomerular diseases 
(1 03 ± 0 14) d id not differ signif icantly f r o m that of the four 
pat ients w i t h pr imar i ly tubulotnterstt t ia l diseases (0 94 ± 0 02) 
T h e c o n c l u s i o n that C ( , S after use of Cimetidine reflected 
G F R o v e r a broad range o f renal funct ion in the study popula 
l i o n is i l lustrated in Figure I 
T o lest whether the use o f Cimetidine besides i m p r o v i n g the 
a c c u r a c y was also able to improve the precis ion of the creati­
nine clearance as a measure of G F R we compared the SDS of 
t h e rat ios o f C ( r-S to С М ) Г Ч and o f C t r S to C l n before 
a d m i n i s t r a t i o n of Cimetidine and the SDS of the same ratios after 
a d m i n i s t r a t i o n of Cimetidine in the subgroup of part icipants who 
u n d e r w e n t these clearance measurements t w i c e The s o o f the 
C C r - S to C l n rat io decreased markedly f r o m 0 20 to 0 08 (P < 
0 0 5 ) . w h i l e Ihe SD o f the C C l - S to C E D T A rat io d i d not change 
s ign i f icant ly (0 13 vs O i l NS) The precision of the c imet i -
d ine-aided creat in ine clearance was fur ther evaluated by c o m 
p a r i n g the var iab i l i ty of the C C r -S w i t h the var iabi l i ty of C, n and 
C i m л l n 'he group o f 19 subjects in w h o m all three measure 
ments were performed simultaneously N o significant differ 
enees c o u l d be demonstrated between the variances of C C r - S 
a n d C, (1321 vs 1158) on the one hand or between the 
var iances o f C C r - S and C,„ (1321 vs 1560) o n the other hand 
Since the measurement of the creatinine clearance as carr ied 
o u t in o u r simultaneous study ( C t r - S ) may stil l be impract ical 
w e also tested the accuracy of C C r 1 5 and C C r 24 after admin­
i s t r a t i o n o f Cimetidine The mean C c r-1 5 to C, „ r A rat io again 
c l o s e l y a p p r o x i m a t e d 1 0 whi le the C C r - 2 4 to C E D T A rat io was 
s ign i f icant ly less than uni ty (Table 2) 
Adverse effects 
N i n e part ic ipants ment ioned the f o l l o w i n g complaints dur ing 
use o f Cimetidine dizziness (three cases, Cimetidine dosage 
2000 mg/day I600mg/day and 1400 mg/day) muscle weakness 
( t w o cases, Cimetidine dosage 1600 and 1200 mg/day) dyspep­
sia ( t w o cases, Cimetidine dosage 2000 and 1600 mg/day) 
diarrhea lone case Cimetidine dosage 1400 mg/day) and insom­
nia (one case Cimetidine dosage 1600 mg/day) A l l symptoms 
resolved after stopping drug intake at the end of the study 
None of the participants had elevations of l iver enzymes 
leucocytopema or thrombocytopenia or signs of interst i t ial 
nephritis in their ur inary sediments 
Discussion 
The rise in scrum creatinine and the fall in creat inine clear­
ance due to the inh ib i tory effect of Cimetidine o n renal tubular 
secretion of creatinine have been regarded as impediments to 
the routine cl inical evaluation o f renal funct ion Yet we tr ied to 
make use of this action o f Cimetidine in order to improve the 
val idity of creatinine as a marker o f GFR The results of our 
study suggest that this goal can be achieved Use of Cimetidine 
in a dosage and durat ion which were adjusted to renal funct ion 
resulted in ratios ot the creatinine clearance to the simulta­
neously measured clearance of M C r - E D T A and o f inuhn w h i c h 
closely approximated unity 
For an adequate interpretat ion o f the results, three important 
questions have to be dealt w i t h First does Cimetidine have any 
effect on G F R per se'' In agreement w i t h extensive data f r o m 
the literature [6-10 22 23] we could not demonstrate a signif­
icant effect o f administrat ion of Cimetidine on G F R Second 
does the finding of a rat io of creatinine clearance to G F R o f 
approximately I 0 apply to all levels o f renal f u n c t i o n 9 Since 
o u r study populat ion was composed o f individuals w i t h a broad 
range o f renal funct ion the answer seems yes Nevertheless, 
deviations o f t h e rat io f r o m 1 0 in patients w i t h different degrees 
o f renal dysfunct ion could theoret ical ly have neutral ized each 
other Analysis o f t h e results after subdiv iding the part icipants 
in three groups according to renal f u n c t i o n , showed no signifi­
cant differences in Ihe C t r S to C t D T A and C C r S to C,„ rat io 
between the three subgroups L i k e w i s e we found no significant 
difference between the mean C C r - S to C E D T A rat io o f patients 
w i t h pr imari ly glomerular disorders and of those w i t h pr imar i ly 
tubulomterst i t ia l diseases although the number o f patients in 
the latter group was too small to draw a firm conclusion Since 
patients w i t h an endogenous creatinine clearance less than 20 
ml/mm were excluded f rom the study no statement can be 
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made about the reliability of the Cimetidine aided creatinine 
clearance in patients with more severe renal dysfunction In the 
third place what is the magnitude of the variability of the ratio 
of C
c r
 to GFR9 In other words are the ratios of all individuals 
lying within a narrow range ' Administration of Cimetidine 
resulted in a decrease in the SD of the ratio of CC r S to CIn and 
thus appeared to improve the precision of the creatinine clear 
ance as a measure of GFR The decrease in SD might even have 
been larger if the concerning subgroup had consisted of patients 
with more severe renal dysfunction since the variability of С
Г г 
to GFR due to tubular secretion of creatinine rises with decreas 
mg renal function [3] In that case we also might have been able 
to demonstrate a significant decrease in the SD of the ratio of 
CC r S to C E D T A We also compared the variance of the data 
trom measurement of C
c r
 S and the variances of the data from 
simultaneous measurement of C E D T A and CIn respectively ina 
subgroup of 19 subjects The variance of the data obtained by 
any technique equals the variance in the study population plus 
the variance introduced by the measuring error of that tech 
nique Since the three different methods of clearance measure 
ment were performed in the same individuals comparing the 
variances comes to comparing the measuring errors Thus if one 
of these methods would be less precise a larger variance of the 
data from that particular method would be expected From the 
results it is clear that estimation of the GFR by measurement of 
the Cimetidine aided creatinine clearance had about the same 
extent of precision as measurement of the clearance of inulin or 
of MCr EDTA 
For daily clinical practice it would be very helpful to have 
available a reliable yet feasible method of estimation of GFR 
Our data indicate that after the administration of Cimetidine the 
easily performed CC r 1 5 is a quite accurate measure of GFR as 
determined by the clearance of MCr EDTA The underestima 
tion of this GFR value by CC r 24 may partly be explained by 
errors in the collection of 24 hour urine In addition from the 
presence of a arcadian rhythm for the GFR with higher values 
during daytime [24) one might expect that GFR measured in 
the late morning hours will be higher than the 24 hour creatinine 
clearance Finally since creatinine clearance has been reported 
to depend on urinary flow rate [25] lower urinary flow rates 
during the night may have contributed to the underestimation of 
GFR (in this case C E D T A ) by CC r 24 
No serious adverse effects of Cimetidine were noted which is 
of special importance for this situation where Cimetidine is used 
for a non therapeutical purpose The report of subjective com 
plaints by a number of participants could have been influenced 
by the fact that in accordance with ethical guidelines informa 
Hon about possible side effects was provided In a recent 
meta analysis of randomized clinical trials with Cimetidine the 
rate of adverse effects was found to be equal in Cimetidine and 
placebo groups even with dosages as high as 2000 mg/day [26] 
Previous studies concerning the effects of Cimetidine on renal 
function reported mean ratios of creatinine clearance to GFR 
after administration of Cimetidine varying from 0 89 [8] to 1 35 
[6] Since the inhibition of tubular creatinine secretion is 
thought to be a competitive process [22] the effect of Cimetidine 
on the ratio of the creatinine clearance to GFR would be 
expected to vary with the blood concentration of Cimetidine 
The variation in the reported results may thus be related to 
differing dosage schedules and ways of administration of Cimet 
ldine The fall of the mean creatinine clearance to GFR ratio 
below I 0 in some studies raises the question of whether tubular 
reabsorption ol creatinine might exist In that case the mean 
ratio of about I 0 in our study could have been achieved by 
incomplete inhibition of tubular secretion in part of the subjects 
and domination of reabsorption of creatinine over more com 
plete inhibited secretion in others Tubular reabsorption ot 
creatinine has been demonstrated in rats [27] but in humans 
sufficient proof is still lacking 
Our study extends recent observations by Roubenoff et al 
who demonstrated improved accuracy and precision of the 
creatinine clearance by use of oral Cimetidine [28] Their study 
population consisted of 13 patients with lupus nephritis and 
near normal renal function The mean ratio of the creatinine 
clearance to the GFR simultaneously determined by measure 
ment of the clearance of DTPA was reduced to 1 14 (compared 
to a C t t S to C E D r A ratio of I 02 in our study) Somewhat 
unexpectedly serum creatinine did not rise in 4 of their 13 
patients The dosing scheme of Cimetidine differed slightly from 
ours with a lower total daily dose (1600 mg) and a lower 
morning dose (400 mg) just before clearance measurements 
were performed Moreover in all patients clearance studies 
were performed within 48 hours after starting Cimetidine intake 
whereas we estimated the number of days required to reach 
steady state for each individual Based on these calculations all 
but one of our participants was expected to be in steady state 
after receiving Cimetidine for 72 hours We believe that future 
studies including daily measurements of creatinine will be 
needed to actually determine the time needed for a steady state 
to be achieved after starting Cimetidine 
It should be stressed that before use of the Cimetidine aided 
creatinine clearance can be promoted as an exact measure of 
GFR the reproducibility of this technique has to be investi 
gated Reproducibility of any method for determining GFR is 
best established by temporally separated determinations in 
individual subjects with stable renal function If the reproduc 
ibility would prove to be high there are many situations in 
which measurement of the Cimetidine aided creatinine clear 
ance or serum creatinine concentration may furnish a useful 
assessment of renal function First in certain instances it may 
replace classical measurement of GFR with a true filtration 
marker as the latter is more expensive and less convenient As 
such it can offer prospects in studies concerned with long term 
follow up of renal function [29] Moreover monitoring of the 
progress of renal deterioration by plotting the reciprocal values 
of serum creatinine against time [30] might become more 
reliable when serum samples are obtained after use of cimeli 
dine Finally administration of Cimetidine might improve the 
sensitivity of serum creatinine in detecting small degrees of 
renal dysfunction by restoring the inverse relationship between 
serum creatinine and GFR which is actually blunted by the 
increase of tubular secretion with reduction of GFR [3] 
In summary oral administration of Cimetidine improved the 
reliability of the creatinine clearance as a measure of the 
glomerular filtration rate The ratio of the Cimetidine aided 
creatinine clearance to GFR approximated unity over a broad 
range of renal function Moreover the variability of the method 
was comparable to that of standard methods For daily practical 
use the Cimetidine aided 1 5 hour creatinine clearance seems a 
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v a l u a b l e tes t of rena l f u n c t i o n S t u d i e s inves t iga t ing t h e r e p r o 
ducib i l i ty of t h e Cimet id ine a i d e d c r e a t i n i n e c l e a r a n c e are re 
q u i r e d 
A c k n o w l e d g m e n t 
The authors (hank Mr A Theeuwes for statistical help 
Reprint requests to L В Htlbrands Department of Internal Medi 
cine Division of'Nephrotoms Uni\erstt\ Hospital Nijmegen PO Box 
9101 N1 6500 HB \ijmegen The Netherlands 
References 
1 W E T Z E L S J F M HU.VSMANS F T H M K O E N E RAP Creatinine as a 
marker of glomerular filtration rate \itli J Mid 31 144-151 1988 
2 L E V E Y AS Measurement of renal function in chronic renal disease 
Kidne\ Im 18 167-184 1990 
1 S H E M E S H 0 G O L B F T Z H K R I S S JP MYERS BD Limitations of 
creatinine as a filtration marker in glomerulopathy patients Kidne\ 
Int 28 810-818 1985 
4 T O M I ANOvicH S G O L B E T Z H Pi RLROTH M S T I N S O N F MYERS 
BD Limitations of creatinine in quantifying the seventy of cyclos 
porrne induced chronic nephropathy Am J Kidne\ l)i\ 8 332-317 
1986 
5 P E T R I M BocKFNSitDT L C O L M A N J W H I T I N G О K E E F F Q 
F I T Z G S E B A S T I A N A H F I LMANN D Serial asscssmeni of glomer 
ular nitration rate in lupus nephropathy Kidne\ Int 14 832-839 
I98H 
6 B U R G E S S E BLAIR A K R I C H M A N К C U T L E R RE Inhibition of 
renal creatinine secretion by Cimetidine in humans Renal Plnsiol 
5 27-30 1987 
7 D U B B JW S T O I E RM F A M I L I A R RCJ L E F К A L E X A N D F R F 
Effect of Cimetidine on renal function in normal man ( Im Phar 
macol Ther 24 76-83 1978 
8 LARSSON R B O D E M A R G K A C F D A I В W A I A N A The etfects of 
Cimetidine (Tagamet1*) on renal (unction m patients with renal 
failure Ac ta Med Seand 208 27 II 1980 
9 O L S E N NV L A D E F O G E D SD F E L D T RASMUSSEN В F O C H 
A N D E R S F N N JoRDENiNO H M U N C K O The effects of Cimetidine 
on creatinine excretion glomerular filtration rate and tubular fune 
non in renal transplant recipients Scand J Clin Lab lm est 49 I **5— 
159 1989 
10 PACHÓN J L O R B E R M I B I A M J EffeclsofH2 receptor antagonists 
on renal function in cyclosponne treated renal transplant patients 
Tran \plantauon 47 254-259 1989 
11 COCKCROFT DW G A U L T MH Prediction of creatinine clearance 
from serum creatinine Nephron 16 31-41 1976 
12 J A G F N B U R G R A T T M A N PO A U R E L L M B U C H T H Determination 
of glomerular filtration rate in advanced renal insufficiency Stand 
J Urol Nephrol 12 133-117 1978 
13 H A G S T A M KE N O R D E N F E L T I SVENSSON L SVENSSON SE 
Comparison of different methods for détermination of glomerular 
filtration rate in renal disease Scand J Clin Lah I n n i 14 31-36 
1974 
14 FAVRE H Critical study of the value of renal clearances measured 
by the single shot technique Contr \ephrol II 19-21 1978 
15 BROCHNER M O R T E N S E N J RöDBRO Ρ Comparison between total 
and renal plasma clearances of M C r EDTA Scand J Clin Lab 
¡тем 36 247-249 1976 
16 D E C I NAAR C F F R E N K F N I AM ν H O O T F JP Enzymatic method 
for determination of inulin Clin Chem 31 1070-1071 1987 
17 E D W A R D S KDG Creatinine space as a measure of total body water 
in anurie subjects estimated after single injection and haemodial 
ysis Clin Sa 18 455^)64 1959 
18 J O N E S JD B U R N E T T PC Creatinine metabolism in humans wnh 
decreased renal function Creatinine deficit Clin Cium 20 1204-
1212 1974 
19 M I T C H WE C O L L I L R VU WALSER M Creatinine metabolism in 
chronic renal failure Clin Se ι 58 127-33s 1980 
20 С HOW MSS A method for determining the pharmacokinetics of 
endogenous creatinine without exogenous creatinine administra 
Hon Biophatm Drug Dispm 6 201-208 1985 
21 M I T C H WE WALSER M A proposed mechanism for reduced 
creatinine excretion in severe chronic renal failure Nephron 21 
248-254 1978 
22 B U R I A N D WL Gl LADLF RI M I L L S JG S H A R P E PC W E L L S Al 
The effeel of Cimetidine on renal function m Proceedings of The 
Second international S\inpo\ittm on Histamine H receptor Anlag 
onnt\ edited by U U R L A N D WL S I M K I N S MA Amsterdam Ex 
cerpta Medica 1977 ρ 67 
21 LARSSON R B O D F M A R G K Ä G E D A I В The effect of Cimetidine a 
new histamine H2 receptor antagonist on renal function ActtiMed 
Sc and 20^ 87-Я9 1979 
24 S C H U S T E R VL S F L D I N DW Renal clearance in The Ktdne\ 
Ph\siolog\ eind Peiihoph\siolog\ edited by SEI DIN DW G I E B I S C H 
G Ni w YORK RAVEN PRFSS 198s r 36s 
25 V R E F I B H E K S T F R YA H A F K E N S C H F I D JCW V D A L E N R 
F R I E S E N WT The influence of urine flow on renal clearance of 
creatinine in patients with normal and impaired kidney function 
Drug Inlell Clin Plwim 15 194-198 1981 
26 R I C H T E R JM C O L D I T Z GA H U S F DM D E L F A TE O S T F R G 
Cimetidine and adverse reactions A meta analysis of randomized 
clinical trials ol shoiI term therapy Am J Med 87 278-284 1989 
27 N A M N U M Ρ INSOGNA К BAGGISH D H A Y S L E T T J P Evidence for 
bidirectional net movement of creatinine m the rat kidney Am J 
Plnsiol 244 F7I9-F723 1981 
28 R O U B F N O F F R D R F W H MOYER M PF TRI M W H I T I N G O K E E F F 
Q H E I LMANN DB Or.il Cimetidine improves the accuracy and 
precision of creatinine clearance in lupus nephritis Ann Int Med 
111 501-506 1990 
29 ROSMAN JB M F Y F R S T F R W E E PM PIERS B F C H I TPHM 
S I u m R WJ D O N K E R AJM Prospective randomized trial of early 
dietary protein restriction in chronic renal failure Lane et 2 1291-
1296 1984 
10 M I T C H WE W A I SER M B U F F I N G T O N G A L E M A N N J J R Asimple 
method of estimating progression of chronic renal failure Lancet 
2 1326-1328 1976 
108 
CHAPTER 8 
Cyclosporine does not inhibit 
the tubular secretion of creatinine 
L.B. Hilbrands, J.F.M. Wetzels, A.J. Hoitsma, and R.A.P. Koene 
Submitted for publication 

ABSTRACT 
The immunosuppressive drug cyclosporine (CsA) is known to impair renal 
function. The degree of renal dysfunction is usually estimated from the clearance of 
creatinine (CCr). Theoretically however, a fall in CCr can be caused by a decrease 
of GFR, an inhibition of the tubular secretion of creatinine, or the combination of 
both. CsA has convincingly been shown to decrease GFR, but detailed information 
on the effects of CsA on tubular secretion of creatinine is lacking. We performed 
two studies to investigate the influence of CsA on tubular creatinine secretion. In 
study A we simultaneously measured CCr and GFR (using inulin) immediately 
before and 4 weeks after cessation of CsA therapy in 17 renal transplant patients. 
In study B, the rise in serum creatinine after administration of Cimetidine, which 
blocks the tubular secretion of creatinine, was compared in renal transplant patients 
treated with either CsA (in whom secretion might already be inhibited) or 
azathioprine. After cessation of CsA (study A), there was an increase of GFR 
(54±15 vs 63±16 ml/min/1.73m2; P<0.01) and of CCr (71+21 vs 82±23 
ml/min/1.73m2; Ρ < 0.01), but the ratio between CCr and GFR (a measure of the 
relative contribution of tubular secretion to the clearance of creatinine) did not 
change significantly (1.33+0.21 vs 1.32+0.30). In nine couples of patients 
matched for GFR the relative rises in serum creatinine after administration of 
Cimetidine (study B) were 26+21% and 22+7% for the CsA and azathioprine 
treated patients respectively (NS). We conclude that CsA does not substantially 
inhibit the tubular secretion of creatinine. A rise in serum creatinine after admi­
nistration of CsA can thus be attributed completely to a fall in GFR. 
INTRODUCTION 
Impairment of renal function is a well known side effect of the 
immunosuppressive drug cyclosporine (CsA). In clinical practice, as well as in 
many investigational circumstances, CsA-induced renal dysfunction is judged from 
a rise in serum creatinine or a fall in creatinine clearance (CCr) (1-3). Since 
creatinine is not only filtered in the glomerulus but also actively secreted by the 
renal tubule, an increase in the serum creatinine level may result from 1) a 
decrease in GFR, 2) a decrease in tubular creatinine secretion, or 3) a combination 
of 1) and 2). Although CsA has repeatedly been demonstrated to reduce GFR (4), 
its effect on tubular secretion of creatinine is less clear. The practical consequence 
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of inhibition of tubular creatinine secretion by CsA would be that the effect of CsA 
on GFR is overestimated by measuring the change in serum creatinine or CCr. We 
have investigated the influence of CsA on creatinine secretion in recipients of renal 
allografts. The results of our studies indicate that CsA does not affect tubular 
secretion of creatinine. Hence, changes in serum creatinine or CCr during 
administration of CsA are likely to reflect merely changes in GFR. 
SUBJECTS AND METHODS 
We have performed two separate studies in renal transplant patients to 
determine the effects of CsA on tubular secretion of creatinine. The study protocols 
were approved by the Hospital Ethics Committee and informed consent was 
obtained from all patients. 
Study A 
Eighteen renal transplant patients (15 M, 3 F; age 40±12 years) were included 
for simultaneous measurements of GFR and CCr immediately before and four weeks 
after conversion from CsA to azathioprine at three months after renal 
transplantation. The conversion formed part of another study protocol and was 
elective in all cases. Patients were eligible for this study if renal function was 
stable (variation in serum creatinine of less than 15% in two weeks prior to the 
study). Patients who were using diuretics, or drugs that are known to interfere with 
tubular creatinine secretion were excluded. Furthermore, one patient was 
withdrawn during the study period because an acute rejection episode was 
diagnosed. During the first three months after transplantation, immunosuppressive 
treatment consisted of CsA (initial oral dose of 12 mg/kg/d, tapered to 
approximately 4 mg/kg/d in two divided doses) and prednisone (20 mg/d at the 
time of the study) in all patients. In the conversion group, CsA was replaced by 
azathioprine in a dosage of 3 mg/kg/d. The prednisone dosage was temporarily 
increased from 20 to 25 mg/d during the first two weeks after conversion but was 
back on 20 mg/d during the following two weeks. 
Clearance measurements were performed from 9.00 a.m. till noon. A light 
breakfast on study days was allowed. A sufficient diuresis was attained by an initial 
oral water load of 10 ml per kg body weight, followed by i.v. infusion of a 
solution of 0.25% NaCl (to compensate for expected sodium losses in the urine) in 
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3.3% glucose at a rate of 400 ml/hr. Urinary fluid losses in excess of the infused 
volume were replaced orally by tap water. Except for spontaneous voiding in 
upright position, patients remained supine. GFR and renal plasma flow (RPF) were 
measured using a continuous infusion technique. Renal clearances of inulin 
(polyfructosan, InutestR, Laevosan-Gesellschaft, Linz, Austria) and para-
aminohippuric acid (PAH) were used as markers of GFR and RPF, respectively. 
After an equilibration period of 90 min, urine was collected at three 30 min 
intervals. Blood samples were drawn at the midpoint of each urinary collection 
period. Clearances of inulin, PAH, and creatinine were calculated for each of the 
three 30 min intervals and these values were averaged subsequently. AH clearance 
values were adjusted to a standard body surface area of 1.73 m2. The filtration 
fraction (FF) was defined by GFR/RPF * 100%. The tubular clearance of 
creatinine was calculated as CCr-GFR. 
Study В 
In this study, Cimetidine was used as a tool to examine the tubular handling of 
creatinine. Cimetidine has been shown to be able to completely block the tubular 
secretion of creatinine (5,6). Therefore, changes in serum creatinine after 
administration of Cimetidine reflect the level of tubular secretion. The rise in serum 
creatinine after administration of Cimetidine was measured in 36 renal allograft 
recipients at 403±56 (range 325-615) days after transplantation. Renal function had 
to be stable and patients who already used H2-receptor antagonists or drugs known 
to interfere with creatinine secretion were excluded. Immunosuppression consisted 
of CsA with or without prednisone in 21 patients (13 M, 8 F; age 44 + 13 years) 
and of the combination of azathioprine and prednisone in 15 patients (10 M, 5 F; 
age 47 ±11 years). The participants of this study visited the outpatient clinic on two 
separate occasions. During the interval between these visits they used oral 
Cimetidine in a dosage adjusted to renal function as estimated by the formula of 
Cockcroft and Gault (7) (daily dose of 2000 mg in case of estimated CCr > 75 
ml/min), according to a dosage scheme described previously (5). The minimum 
interval required to achieve a new steady state after a rise in serum creatinine was 
calculated from estimated CCr and body weight (5). 
Serum creatinine and urea levels, as well as CsA trough levels in CsA-treated 
patients, were measured on both study days. During the second visit, patients 
received an oral water load of 10 ml/kg and we subsequently measured the 
cimetidine-aided 1.5-hour CCr which we have demonstrated to be a quite accurate 
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measure of GFR (5). 
Analytical procedures 
Inulin and PAH concentrations in serum or urine samples were measured by 
semi-automated techniques. For study A, creatinine concentrations were determined 
by a modified Jaffé technique using an auto-analyzer, while for study В an 
enzymatic method was used (Boehringer Mannheim GmbH, Mannheim, Germany). 
Whole blood CsA levels were measured with a monoclonal antibody against the 
CsA parent molecule using Abbott TDx (Abbott Laboratories, North Chicago, IL, 
USA). 
Statistical analysis 
Data are reported as means ± SD. Results were analyzed with Wilcoxon's test 
for paired or unpaired observations when appropriate. Correlations were assessed 
by calculating Spearman's correlation coefficient. A probability value less than 
0.05 was considered statistically significant. 
RESULTS 
Study A 
Renal function parameters before and after conversion from CsA to azathioprine 
are given in Table 1. As expected, conversion from CsA to azathioprine resulted in 
a rise in GFR (20+21%, P<0.001) and a decrease in serum creatinine (-15+9%, 
Ρ<0.001). During treatment with CsA, CCr overestimated GFR on average by 
33%, reflecting the presence of tubular secretion of creatinine. Neither the ratio 
between CCr and GFR, nor the tubular clearance of creatinine showed any change 
after withdrawal of CsA. In this patient population there was no significant 
correlation between CCr/GFR on the one hand and GFR or FF on the other hand. 
Study В 
In three CsA-treated patients, the creatinine excretion during the 90 min 
collection interval at the second study day differed more than 50% from the value 
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Table 1. Parameters of renal function before and 4 weeks after conversion from CsA to 
azathioprme in 17 renal transplant patients. 
GFR(ml/min/1.73m2) 
RPF (ml/min/ 1.73m2) 
FF (%) 
CCr (ml/min/1.73m2) 
Serum creatinine (μπιοΐ/ΐ) 
CCr / GFR 
Tubular creatinine clearance (ml/min/ 1.73m2) 
Before 
conversion 
54±15 
252 + 101 
23 ±4 
71±21 
129±36 
1.33+0.21 
17 + 12 
After 
conversion 
63 + 16 
292 ±89 
22+4 
82 ±23 
108±29 
1.32±0.30 
19 + 18 
Ρ 
<0.01 
<0.05 
NS 
<0.01 
<0.001 
NS 
NS 
predicted by the formula of Cockcroft and Gault. We assumed that voiding errors 
were made in these patients and excluded them from further analysis. The data of 
the remaining 33 patients are given in Table 2. Compared to azathioprine-treated 
patients, CsA-treated patients had worse renal function which was reflected in a 
higher serum creatinine level before administration of Cimetidine (Ρ < 0.05). 
Administration of Cimetidine resulted in a rise in serum creatinine in all patients 
(CsA group: 23 + 16%, P<0.001; azathioprine group: 2 0 + 7 % , P<0.001). The 
relative increase in serum creatinine did not differ between both groups. There 
were no changes in the serum urea level or the blood CsA concentration. 
In these 33 patients there was an inverse correlation between the cimetidine-
induced rise in serum creatinine on the one hand and GFR, as estimated by the 
cimetidine-aided 1.5-hour CCr, on the other hand (R=-0.41, P<0.05) . 
Consequently, a possible difference between both groups in increment of serum 
creatinine, could have been obscured by a difference in GFR. We therefore re­
analyzed the data after selecting subgroups of patients treated with CsA or 
azathioprine who were matched for GFR (difference in GFR in each pair of 
patients less than 5 ml/min/ 1.73m2; Table 3). Again, there was no difference 
between both groups for the relative rise in serum creatinine (CsA group: 
2 6 + 2 1 % , azathioprine group: 22+7%; NS). 
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DISCUSSION 
Our studies indicate that CsA does not affect the tubular secretion of creatinine 
to a clinical relevant degree, although we had several arguments to suppose an 
inhibitory effect. First, CsA causes well-defined histopathological changes in the 
proximal tubule (8), the site of tubular secretion of creatinine (9). Second, CsA has 
been demonstrated to inhibit the tubular secretion of N'-methylnicotinamide (10), 
which also takes place in the proximal tubule (9). Finally, it has been suggested 
that CsA inhibits urate excretion at the proximal tubular site (11). 
Our conclusions are based on two lines of evidence. In study A, cessation of 
CsA at three months after renal transplantation did not result in an increase in the 
ratio of CCr to GFR, as would have been expected if creatinine secretion was 
inhibited by CsA. In study В we used Cimetidine, a drug that completely abolishes 
the tubular secretion of creatinine when a sufficient dose is given (5,6). Increases 
in serum creatinine after administration of Cimetidine quantitatively reflect the 
tubular secretion process. We observed similar increases in serum creatinine in 
CsA-treated as compared to azathioprine-treated renal transplant patients, while a 
smaller increase in the CsA group would have been expected if creatinine secretion 
already was impeded by CsA. 
It can be argued that a correct interpretation of the data is hampered by the fact 
that tubular secretion of creatinine is influenced by changes in renal hemodynamics. 
Several investigators have provided evidence that the ratio of CCr to GFR increases 
with declining GFR (12-14). In the absence of any influence of CsA on tubular 
creatinine secretion, one might therefore have expected a decrease of CCr/GFR after 
cessation of CsA treatment (and a concurrent increase in GFR) in study A. 
Similarly, after Cimetidine in study B, a more pronounced increase of serum 
creatinine could have been expected in the CsA group (with lower GFR as 
compared to the azathioprine group). Since in our hands CCr/GFR remained 
unchanged (study A) and the increase of serum creatinine was similar in patients on 
CsA or azathioprine (study B), a slight effect of CsA on tubular secretion of 
creatinine might have been present. However, in both studies the differences in 
GFR were small and consequently, if any, the effects on tubular creatinine 
secretion would have been rather limited. Furthermore, in study В we analyzed the 
results again after matching the patients receiving CsA or azathioprine for GFR. In 
these matched groups, we also observed no difference in the increase of serum 
creatinine. Finally, it has been suggested that tubular secretion of creatinine (i.e. 
the CCr/GFR ratio) is more closely associated with the filtration fraction than with 
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GFR per se (15) In study A we measured GFR and RPF and observed no change 
in FF after discontinuation of CsA Taken together, our data are in strong support 
for the conclusion that CsA does not inhibit the tubular secretion of creatinine 
Our results differ from those of Versluis who observed a significant increase of 
CCr/GFR by 28% after conversion from CsA to azathioprme in 17 renal transplant 
recipients (16) However, the mean value of CCr/GFR measured in these patients 
during use of CsA (1 04) seems far too low for the degree of renal dysfunction 
(mean GFR as measured by the clearance of 125I îothalamate 46 ml/min) It seems 
most likely that in these patients 125I îothalamate is not an ideal marker of GFR, 
since îothalamate itself may be subject to tubular secretion (17) Although the topic 
is not specifically addressed, information on the effect of CsA on the tubular 
secretion of creatinine can be found in some other clinical studies In agreement 
with our findings, the degree of overestimation of GFR by creatinine clearance was 
reported to be similar in renal transplant patients treated with CsA or azathioprme 
(18) In that study however, patients in both groups were not matched for GFR In 
diabetics treated with CsA, a reversible increase in the CCr to GFR ratio has been 
observed, suggesting an increase rather than a reduction of tubular creatinine 
secretion, which may have been related to a concurrent decrease in GFR (19) 
In conclusion, we have no evidence for an inhibitory effect of usual dosages of 
CsA on the tubular secretion of creatinine An increase in serum creatinine or a 
decrease in creatinine clearance during treatment with CsA most likely reflect a 
mere decrease in GFR 
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CHAPTER 9 
Acute effects of nifedipine in renal transplant 
recipients treated with cyclosporine or azathioprine 
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Acute Effects of Nifedipine in Renal Transplant Recipients Treated 
With Cyclosporine or Azathioprine 
Lukas В Hilbrands, MD, Andries J. Hoitsma, MD, Henk W. van Hamersvelt, MD, 
Jack F.M Wetzels, MD, Frans Th M Huysmans, MD, and Robert A.P. Koene, MD 
• Cyclosponne (CsA) impairs renal function, probably by preglomerular vasoconstriction. Vasodilating substances 
may therefore be of benefit to ameliorate CsA-induced renal dysfunction. We studied the acute effects on blood 
pressure and renal function of the dlhydropyndine calcium antagonist nifedipine (10 mg orally) in 20 CsA-treated 
renal transplant patients. In addition, we compared the effects of nifedipine when given immediately before and 
4 weeks after elective conversion from CsA to azathlopnne. Compared with placebo (n - 14), administration of 
nifedipine led to a significant decrease in blood pressure and a strong natriuretic and diuretic response. Despite 
the reduction in blood pressure, glomerular filtration rate improved from 60 * 20 (mean * SD) to 69 * 24 ml_/ 
min/1.73 m2 (P < 0.001) and renal plasma flow (RPF) increased from 260 ± 87 to 338 ±120 mL/min/1.73 m2 (P 
• 0.001). The combination of a decreased blood pressure with an increased RPF was reflected In a sharp decrease 
in renal vascular resistance (0.34 · 0 18 units ν 0.23 ± 0.10 units; Ρ < 0.001). The conversion from CsA to 
azathlopnne by itself led to significant increases in glomerular filtration rate (62 ± 15 mL/min/1 73 m2 ν 76 + 18 
mUmin/1.73 m2; Ρ < 0.05) and RPF (280 * 86 mL/min/1.73 m2 ν 334 * 66 тІУтіп/1.73 m2; Ρ < 0.05). Dunng 
treatment with azathlopnne an effect of nifedipine on glomerular filtration rate and RPF was no longer observed, 
although the natriuretic effect was similar on both occasions. The decrease in renal vascular resistance was 
larger dunng treatment with CsA than dunng treatment with azathlopnne (P < 0.05). We conclude that nifedipine 
was able to improve renal hemodynamics in CsA-treated renal transplant patients, while these effects were not 
observed in the same patients off CsA. By this property, nifedipine may be well suited to prevent the renal injury 
that can occur dunng chronic treatment with CsA. 
© f994 by the National Kidney Foundation, Ine 
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THE immunosuppressive drug cyclosponne (CsA) is widely used in the held of organ 
transplantation and autoimmune diseases How­
ever, from the earliest clinical experience with 
CsA in renal transplantation, the drug appeared 
to be nephrotoxic Various reports stress the role 
of renal altèrent arteriolar vasoconstriction in 
CsA-induced acute renal dysfunction ' 2 In addi-
tion, it has been hypothesized that sustained in-
trarenal vasoconstriction with resulting ischemia 
may contribute to the structural histopathologic 
alterations associated with chronic CsA treat-
ment ' 4 Pharmacologic interventions tor the pre-
vention of CsA-induced renal dysfunction should 
therefore aim at improving glomerular perfusion 
Of the different vasodilating drugs, dihydropyn-
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dine calcium antagonists are especially attractive 
because ot their supposed preferential preglomer­
ular vasodilating effects Moreover, the natri­
uretic properties of these drugs may be of specific 
value for blood pressure reduction, since sodium 
retention probably plays an important role in the 
pathogenesis of CsA-induced hypertension 6 
We examined the acute effects ot a single oral 
dose ot Ihe dlhydropyndine calcium antagonist 
nifedipine on blood pressure and renal function 
in CsA-treated renal transplant patients in a pla­
cebo-controlled study To investigate whether 
calcium antagonists specifically counteract the 
renal effects of CsA, we also compared the acute 
effects of nifedipine before and after elective 
conversion trom CsA to azathlopnne 
MATERIALS AND METHODS 
Subjects 
The acute effects of nifedipine were studied in 29 renal 
transplant recipients In 20 of these patients nifedipine was 
administered while placebo measurements were earned out 
in 14 patients (five patients received nifedipine as well as 
placebo with an interval of 4 weeks) In a subgroup of 10 
patients the effects of nifedipine were measured immediately 
before elective conversion from CsA to azathlopnne and 4 
weeks after this conversion had taken place All patients 
underwent one or both measurements between 3 and 5 months 
after their transplantation Patients were eligible for this study 
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if renal function was stable (variation in scrum creatinine of 
< 1 5 % in 2 weeks prior to the study) and diastolic blood 
pressure was below 110 mm Hg Patients who were using 
diuretics xanthine derivatives, nonsteroidal anti-inflamma 
tory drugs or drugs with a known vasodilator action were 
excluded For treatment of hypertension only the use of the 
beta blocker atenolol (50 or 100 mg. taken once daily as a 
morning dose) was allowed Immunosuppressive treatment 
consisted of CsA (initial oral dose 12 mg/kg/d, tapered to 
approximately 4 mg/kg/d in two divided doses at the time of 
the study) and prednisone (10 to 20 mg/d at the lime of 
the study) In 10 patients elective conversion from CsA to 
azalhiopnne was earned out at 3 months after transplantation 
as part of another study protocol In these patients CsA was 
replaced by azathioprme in a dosage of 3 mg/kg/d The pred 
nisone dosage was temporarily increased from 2Ü to 2*1 mg/ 
d during the hrst 2 weeks after conversion, but was returned 
to 20 mg/d during the following 2 weeks, after which the 
second measurements were performed The study was ap 
proved by the hospital ethics committee and all patients gave 
written informed consent 
Study Protocol 
All experiments were performed from 9 00 am until 2 00 
pin The patients were on a regular diet but were advised to 
avoid the use of coffee alcohol liquorice, tir tobacco during 
the last 9 hours preceding the measurements Two 24 hour 
urine samples were collected for measurement of sodium 
excretion The evening preceding each experiment 100 mg 
lithium carbonate (8 l mmol of lithium) was given orally A 
light breakfast on study days was allowed 
On arrival in the ward, a blood sample was drawn for 
determination of the CsA trough level Immediately thereaf-
ter, the patients ingested their regular morning dose of С sA 
A sufficient diuresis was attained by an initial oral water load 
of 10 mL/kg body weight, followed by intravenous infusion 
of a solution of 0 25% NaCl (to compensate for expected 
sodium losses in the urine) in 3 3% glucose at a rale ol 400 
mL/hr Urinary fluid losses in excess of the inlused volume 
were replaced orally by lap water Except for spontaneous 
voiding in the upright position, patients remained supine 
Glomerular filtration rate (GFR) and renal plasma flow 
(RPF) were measured using a continuous infusion technique 7 
Renal clearances of inulin (polyfructosan, Inutcst, Laevosan 
Gesellschaft. Linz, Austria) and para-aminohippunc acid 
were used as markers of GFR and RPF, respectively In the 
absence of renal vein samples, RPF could not be corrected 
for possible changes in the extraction ratios of para-aminohip 
pune acid After an equilibration period of 90 minutes, urine 
was collected at 30-minute intervals Blood samples were 
drawn at the midpoint of each urinary collection period After 
collecting three 30-mmute baseline urine samples, a capsule 
containing 10 mg nifedipine (Adalal, Bayer, Basel, Switzer­
land) or placebo was administered orally (ie, 180 minutes 
after administration of the last dose of CsA) Subsequently,, 
four additional 30 minute blood and urine samples were col­
lected Blood pressure and heart rale were recorded every 3 
minutes with an automatic device (Dinamap model 1846P, 
Cntikon Ine, Tampa, FL) The mean values of five consecu 
ч е readings around the midpoint of each clearance pen od 
were used for analysis The filtration fraction was calculated 
as GFR/RPF x 100% and renal blood flow (RBF) was esti­
mated using the formula RBF = RPF/(I - hematocrit) The 
GFR, RPF, and RBF were adjusted to a standard body surface 
area of 1 71 m' Renal vascular resistance (RVR) was defined 
as mean arterial pressure divided by RBF and expressed in 
arbitrary units Fractional excretions of sodium and potassium 
(FEN j and FEK) were calculated as their respective renal clear­
ances (C N j and CK) divided by GFR x 100% Using lithium 
clearance (CL1) as a marker of proximal tubular sodium and 
water re absorption/ the fractional proximal sodium reabsorp-
tion (FPRN j) and fractional distal sodium reabsorption 
(FPRN j) were estimated by the following calculations 
FPR N j = (I - Сц/GFR) x 100% 
and 
FDR N j - (1 - C»JCLl) x 100% 
Clearances of the various parameters were calculated for each 
of the three 30-mmute intervals of the baseline period and 
averaged to give baseline values During the baseline period 
the intraindtvidual coefficients of variation of GFR and RPF 
were 8 6r/r and 9 3% respectively We assumed the blood 
levels, and thus the eflecls of nifedipine, to be maximal be­
tween 1 and 2 hours after ingestion ч '" Therefore, the values 
of the third and fourth 30 minute interval (60 to 120 minutes) 
after the administration of nifedipine were averaged and sub­
sequently compared with the corresponding baseline value 
Analytical Procedures 
In blood and urine samples para-aminohippunc acid inu­
lin sodium and potassium were measured by standard tech­
niques Lithium was determined by atomic absorption spec­
trophotometry In blood samples the hematocrit was 
determined by routine Coulter counter, and whole blood CsA 
levels were measured with a monoclonal antibody against the 
CsA parent molecule using Abbott TDX (Abbott Labora 
tones, North Chicago, IL) 
Statistical Analysis 
Data arc reported as means ± SD unless stated otherwise 
Results were analyzed with Wilcoxon's lest for paired or 
unpaired observations when appropriate Observations in ihe 
nifedipine and placebo group were regarded as unpaired de 
spite the sharing of hve members by both groups Correlations 
were assessed by calculating Spearman's correlation coeffi­
cient Ρ < 0 05 was considered statistically significant 
RESULTS 
The clinical characteristics of the patients are 
given in Table 1 There were no significant dif­
ferences between the nifedipine and placebo 
group. 
Nifedipine Versus Placebo During Treatment 
With Cyclosporme 
The changes in blood pressure and renal hemo­
dynamics after nifedipine or placebo are shown 
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ТаЫ 1. Characteristics of the Patients Who Received Nifedipine, Placebo, or Nifedipine 
Before and After Conversion From Cyclosponne to Azathioprine 
Niledipine 
Nifedipine During CsA 
Versus Azathioprine* 
N 
Sex (M/F) 
Age (yr)t 
Use of beta blocker 
CsA dosage (mg/d)t 
CsA trough level (ng/mL)+ 
20 
14/6 
38 ± 12 
13 
308 + 66 
168 ± 81 
14 
11/3 
43 ± 12 
14 
308 ί 48 
221 + 76 
10 
8/2 
43 ± 14 
6 
316 ± 78 
167 ± 69 
• Subgroup of the patients presented in the first column 
t Mean values ± SD 
in Table 2 Alter the administration ot nifedipine 
there was a substantial decrease in blood pressure 
with a concomitant increase in heart rate Despite 
the resulting reduction in renal perfusion pres 
sure, GFR increased in all but two patients 
while RPF increased in all patients (GFR + 14% 
± 11% RPF + 3 1 % ± 17%) Since the increase 
in RPF was larger than that in GFR the filtration 
fraction decreased (-12% ± 10%) The combi­
nation of a decreased mean arterial pressure with 
an increased RPF was reflected in a sharp de 
crease in calculated RVR ( - 3 1 % ± 13%) No 
changes in these parameters were observed in 
the placebo group In contrast to the decrease in 
urinary flow rate in the placebo group there was 
a marked increase in diuresis after the adminis 
tration of nifedipine (Table 3) Nifedipine also 
had a strong natriuretic effect with a decrease of 
FPRNa as well as of FDRNj, parallelled by an 
increase in FEK There were significant differ 
enees between nifedipine and placebo for the rel­
ative changes in all parameters given in Tables 
2 and 3 We found no significant correlations 
between nifedipine induced changes in GFR and 
RPF on the one hand and changes in blood pres 
sure or sodium excretion on the other In addi 
tion, relative changes in blood pressure GFR 
RPF RVR, and sodium excretion were not corre­
lated with their respective baseline values CsA 
dosage, or CsA trough levels Higher baseline 
values for mean arterial pressure were associated 
with larger relative decreases after nifedipine 
(r = 0 52, Ρ < 0 2) After nifedipine, but not after 
placebo, there was a small increase in hemato 
cnt (from 0 3S2 ± 0 063 to 0 360 ± 0 061 Ρ 
< 001) 
While all patients in the placebo group used 
atenolol for treatment of hypertension seven ot 
20 patients in the nifedipine group did not Beta-
blockers tend to reduce RBF, and this effect ot 
Table 2. Systemic and Renal Hemodynamic Parameters Before and After the Oral Administration of 10 mg 
Nifedipine or Placebo in Renal Transplant Recipients Treated With Cyclosponne 
MAP (mm Hg) 
Heart rate (beats/mm) 
GFR (mL^min/1 73 m2) 
RPF (mL/min/1 73 m2) 
FF (%) 
RVR (arbitrary units) 
Before' 
115 i 11 
6 1 + 7 
60 ± 20 
260 ± 87 
24 ± 4 
0 34 ± 0 18 
Nifedipine (n 20) 
After 
102 + 9 
6 8 + 1 0 
69 ± 24 
338 ± 120 
2 1 + 4 
0 23 + 0 1 0 
Probability 
Values 
< 0 001 
< 0 001 
< 0 0 0 1 
< 0 001 
< 0 001 
<oooi 
Before* 
116 ± 12 
5 8 + 7 
63 + 25 
262 ± 109 
25 + 7 
0 35 + 0 1 9 
Placebo (n = 14) 
After 
115 ± 13 
58 ± 7 
60 + 23 
243 + 91 
25 + 6 
0 37 + 0 20 
Probability 
Values 
NS 
NS 
NS 
NS 
NS 
NS 
NOTE Data are given as mean values ± SD 
Abbreviations MAP mean arterial pressure FF filtration fraction 
* There were no significant differences in baseline values between the two groups 
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Table 3. Urinary Flow Rate and Renal Tubular Handling of Sodium and Potassium Before and After the Oral 
Administration of 10 mg Nifedipine or Placebo in Cyclosponne-Treated Renal Transplant Recipients 
Nifedipine (n - 20) 
Before" After 
Urinary flow rate (mL/min) 8 3 1 2 2 1 1 9 + 4 4 
FENa (%) 3 6 * 6 2 6 2 1 3 0 
F P R N . (%) 67 * 8 62 1 11 
FDRN. (%) 90 1 4 84 + 5 
FE« (%) 2 0 4 + 8 9 2 6 8 - 1 3 6 
NOTE Data are given as mean values + SD 
' There were no significant differences in baseline values 
atenolol might have influenced our data There­
fore, we compared the effects of nifedipine in the 
13 patients who did use atenolol and the seven 
patients who did not There were no significant 
differences between both subgroups for the 
changes in any parameter given in Tables 2 and 
3 All changes observed after administration of 
nifedipine were present in both subgroups, with 
the exception of a lack of change in FPRNa in 
the patients treated with atenolol, while hltration 
fraction and FEK did not change in the patients 
not using atenolol 
Nifedipine During Treatment With hither 
Cyclosporme or Azathioprine 
Sodium excretion in 24-hour urine samples, a 
measure of dietary sodium intake, did not differ 
before and after conversion trom CsA to azathio-
pnne (197 ± 47 mmol and 221 ± 4 5 mmol, 
respectively, Ρ = NS) Values for blood pressure 
and renal hemodynamics are given in Table 4 
Conversion from CsA to azathiopnne led to sig­
nificant improvements in GFR and RPF The sig­
nificant increases in GFR and RPF after the ad­
ministration of nifedipine during treatment with 
CsA were not observed in the same patients dur­
ing treatment with azathiopnne, and the changes 
in GFR as well as RPF were significantly differ­
ent on both occasions (Fig 1 ) As a consequence, 
the pre-existing differences in GFR and RPF be­
tween treatment with CsA and azathiopnne dis­
appeared after administration of nifedipine Simi­
larly, the nifedipine-induced decreases in systolic 
blood pressure and RVR were more prominent 
dunng treatment with CsA (Fig 1) Values tor 
diuresis and for sodium and potassium excretion 
Placebo (n - 14} 
Probability 
Values 
<0 001 
< 0 001 
< 0 01 
< 0 001 
' Ό 001 
Before' 
8 7 - 2 9 
3 7 * 2 5 
67 * 9 
8 9 + 4 
26 7 + 17 1 
After 
7 4 * 2 6 
3 5 * 1 9 
69 - 8 
89 1 5 
26 7 * 16 1 
Probability 
Values 
-^0 01 
NS 
^ 0 01 
NS 
NS 
between both groups 
are shown in Table 5 Lower baseline urinary 
flow rates dunng treatment with CsA were tol 
lowed by a significant increase after administra­
tion of nifedipine while a significant diuretic ef­
fect of nifedipine was absent dunng treatment 
with azathiopnne Nevertheless nifedipine had a 
similar strong natnuretic effect in both circum­
stances The relative changes after the adminis­
tration of nifedipine in the parameters given in 
Table S did not differ on both occasions 
DISCUSSION 
The acute decrease in GFR after the initiation 
of treatment with CsA is generally attnbuted to 
afferent renal vasoconstnction ' 2 Chronically, 
CsA causes structural vascular changes, con­
sisting of occlusion or obliteration of the arteri­
oles, accompanied by glomerulosclerosis, tubular 
atrophy, and striped interstitial fibrosis Although 
the precise pathogenetic pathway of CsA-associ-
ated chronic renal injury still has to be elucidated, 
it has been proposed that persistent renal vaso­
constriction ultimately leads to the permanent 
structural changes , 4 
In view of the pivotal role of vasoconstnction 
in the pathogenesis of CsA-induced renal dys­
function, the use of the vasodilating calcium 
antagonists in CsA-treated patients has been ad­
vocated " ' 6 In long-term studies, concomitant 
treatment with calcium antagonists resulted in 
improvements in graft survival and renal func­
tion ' 7 Although direct hemodynamic effects may 
have contnbuted to the observed beneficial ef­
fects of calcium antagonists, firm conclusions on 
this subject cannot be drawn from such long-
term studies The reported improvement of graft 
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Table 4. Systemic and Renal Hemodynamic Parameters Before and After the Oral Administration of 10 mg 
Nifedipine During Treatment With Cyclosporin« and 4 Weeks After Elective Conversion 
From Cyclosporins to Azathioprine in 10 Renal Transplant Recipients 
Cyclosponne Azathioprine 
Belore After Probability Before After Probability 
Nifedipine Nifedipine* Values Nifedipine Nifedipine' Values 
MAP (mm Hg) 112 - 12 100 + 9 < 0 05 1 0 9 - 1 1 105 +. 12 NS 
Heart rate (beats/mm) 60 + 7 67 + 10 < 0 01 62 + 7 64 ·. 8 NS 
GFR (mLVmin/1 73 m·) 62 ± 15 73 + 20 < 0 01 76 ± 18+ 80 + 21 NS 
RPF (mL/min/1 73 m2) 280 + 86 3 7 4 + 1 3 2 < 0 01 334 + 6 6 t 385 + 126 NS 
FF (%) 23 + 3 21 + 5 < 0 05 23 + 5 22 ± 5 NS 
RVR (arbitrary units) 0 2 9 1 0 1 4 0 2 0 + 0 0 9 < 0 01 0 23 ± 0 05 0 1 9 ± 0 0 6 <-0 01 
NOTE Data are given as mean values + SD 
Abbreviations MAP mean arterial pressure FF filtration rate 
* There were no significant differences for the values obtained after administration of nifedipine on both occasions 
t Ρ < 0 05 for difference from base-line values during treatment with cyclosponne 
survival mighl be largely related to ihe preven­
tion of delayed graft function In the current 
study, we investigated (he renal hemodynamic 
effects of nifedipine on a short-term basis, ie, 
after (he oral administration of a single dose 
Compared with placebo, nifedipine induced an 
increase in GFR and a pronounced increase in 
RPF despiie a substantial decrease in blood pres 
sure Accordingly, there was a significant de­
crease in calculated RVR The effects on blood 
pressure and renal hemodynamics were accom­
panied by strong natriuretic and diuretic re­
sponses to nifedipine Interestingly, statistically 
significant effects of nifedipine on GFR and RPF 
could no longer be demonstrated after conversion 
from CsA to azathiopnne 
The acute effects of nifedipine on blood pres­
sure are similar to those reported earlier in nor-
motensive and hypertensive subjects '* " Studies 
on the renal hemodynamic effects of nifedipine 
have yielded varying results ' Substantial in 
creases in RPF and GFR have been observed 
after the intravenous infusion of nifedipine in 
human subjects 2 0 However, in many other stud­
ies performed in normotensive'* as well as hyper­
tensive humans, ' 8 " RPF has not always in­
creased, while GFR did no( change or even 
decreased shortly after oral administration of 
nifedipine Compared with these data from the 
literature, the increases of RPF and GFR ob­
served in our study are remarkable and may re­
flect a more specific action of nifedipine in coun­
teracting the effects of CsA on renal vasculature 
Indeed, in experimental animal studies, calcium 
antagonists have been shown to mitigate the dete­
riorating effects of CsA on renal lunction. while 
they did not affect renal function or hemodynam 
ics in animals not treated with CsA 2I In renal 
allograft recipients on CsA, treatment with cal­
cium antagonists has been demonstrated to pre­
vent the reducdon in GFR and RPF that other­
wise occurred acutely after administration ol a 
regular morning dose of CsA l 2 " 
In previous studies ot the acute effects of cal­
cium antagonists on graft function in renal trans­
plant recipients1'*"' it was not investigated 
whether these effects are limited to patients 
treated with CsA or whether they might also 
apply to those not treated with CsA We therefore 
examined 10 subjects before and after elective 
conversion from CsA to azathiopnne The dos­
age of prednisone was equal on both occasions, 
and concomitant antihypertensive therapy with a 
beta-blocker in six patients was not changed The 
significant increases in GFR and RPF after the 
administration of nifedipine that occurred during 
treatment with CsA were not observed during 
treatment with azathiopnne This restnction of 
the action of nifedipine to CsA-trcated patients is 
in agreement with the concept that the beneficial 
effects of calcium antagonists on renal hemody­
namics are more pronounced when resting renal 
vascular tone is increased '' The magnitude of the 
nifedipine-induced mean increases in GFR and 
RPF dunng treatment with CsA equaled that of 
the mean increases in both parameters following 
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Fig 1. Relative changes in GFR, RPF, mean arterial 
blood pressure (MAP), and RVR after oral administra­
tion of 10 mg nifedipine in 10 renal transplant patients. 
The first columns denote values obtained during treat­
ment with CsA and the second columns denote values 
obtained 4 weeks after conversion from CsA to azathi-
oprine (Aza). Data are shown as mean values ± SEM. 
the withdrawal of CsA, although in this rather 
small group of patients we could not demonstrate 
a significant correlation between the effects of 
nifedipine on the one hand and the changes after 
cessation of CsA in the same individual on the 
other. 
A possible artefact that could have contributed 
to the apparent increase in GFR and RPF is a 
sudden increase in urinary flow with consequent 
washdown of clearance markers from the so-
called dead space in the kidney and urinary tract, 
giving a spurious increase in the calculations of 
clearances. Theoretically, this washout phenome­
non would lead to a relationship between a 
change in urinary flow rate on the one hand and 
simultaneously measured differences from base­
line values for GFR and RPF on the other. Such 
a correlation was present for the first of both 
clearance intervals after the administration of 
nifedipine (ie, from 60 to 90 minutes afterward; 
for GFR: r = 0.69. Ρ < 0.001: for RPF: r 
= 0.53. Ρ < 0.05). In the next clearance interval 
(from 90 to 120 minutes after nifedipine), how­
ever, there was no significant increase in urinary 
flow rate while GFR and RPF remained signifi­
cantly higher than baseline levels, which resulted 
in a lack of correlation between the respective 
parameters. In addition, the rather high urinary 
flow rates during the entire measurements should 
have minimized the bias of the urinary dead 
space. This makes it unlikely that the washout 
phenomenon substantially influenced the results 
obtained. 
The natriuretic and diuretic effects of nifedi­
pine have been well documented in healthy vol­
unteers4 and patients with hypertension." How­
ever, we are not aware of studies directed at the 
acute effects of nifedipine on renal handling of 
sodium and water in renal transplant patients 
treated with CsA or azathioprine. The present 
study showed a strong natriuretic response to 
nifedipine during treatment with CsA as well as 
during treatment with azathioprine. There was 
no correlation between the increase in fractional 
excretion of sodium and the increases in GFR 
and RPF. Moreover, there was a similar increase 
in fractional sodium excretion before and after 
conversion from CsA to azathioprine, while GFR 
and RPF only increased on the first occasion. 
Taken together, these findings confirm that the 
natriuretic effects of nifedipine are probably not 
due to its influence on renal hemodynamics.21 
The exact mechanism and tubular site of the na­
triuretic effects of calcium antagonists are still 
to be elucidated. Using the lithium clearance 
technique to assess segmental tubular handling 
of sodium, we found similar relative decreases 
in proximal and distal fractional reabsorption of 
sodium. However, limitations on the validity of 
the lithium clearance as a marker for the output 
of sodium from the proximal tubule24 do not per­
mit firm conclusions regarding this subject. 
In both CsA- and azathioprine-treated patients, 
the administration of nifedipine was followed by 
a marked increase in urinary potassium excretion, 
which was significantly correlated with the in­
crease in sodium excretion (r = 0.62; Ρ < 0.01). 
In previous studies, a lack of this increase in 
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ТаЫе 5 Urinary Flow Rate and Renal Tubular Handling of Sodium and Potassium Before and After the Oral 
Administration of 10 mg Nifedipine Dunng Treatment With Cyclosponne and 4 Weeks After Elective Conversion 
From Cyclosponne to Azathioprine in 10 Renal Transplant Recipients 
Unnary flow rale (mL/mm) 
FE„. (%) 
FPU*. (%) 
FDFU (%) 
FEK (%) 
Before 
Nifedipine 
8 6 i 
3 5 î 
65 ΐ 
90 i 
188 i 
2 3 
0Θ 
7 
3 
7 5 
Cyclosponne 
After 
Nifedipine 
125 
6 2 
62 
84 
26 1 
» 4 4 
» 2 7 
» 12 
i 6 
+ 139 
Probability 
Values 
^ o o i 
< 0 05 
NS 
< 0 01 
^•0 05 
Before 
Nifedipine 
1 0 6 
3 1 
62 
92 
1 6 4 
± 2 4 t 
* 1 2 
» 13 
» 3 
* 1 0 0 
Azathioprine 
After 
Nifedipine' 
123 ± 3 9 
5 2 * 2 5 
60 + 10 
87 * 4 
21 1 + 11 6 
Probability 
Values 
NS 
•-0 01 
NS 
- 0 01 
< 0 05 
' There were no significant differences for the values obtained after administration of nifedipine on both occasions 
t Ρ -' 0 05 for difference from baseline values dunng treatment with cyclosponne 
kaliuresis after nifedipine was a rather uniform 
finding' " and might be caused by a direct effect 
of nifedipine on Na*-K + exchange in the distal 
tubule Alternatively, calcium antagonists could 
specifically counteract the local action of aldoste 
rone or they could inhibit aldosterone release by 
the adrenal glands We recently demonstrated 
that calcium antagonists induce kaliuresis in 
healthy volunteers only if sufficient amounts of 
(exogenous) aldosterone are present2Ч Although 
aldosterone levels were reported to be low in 
renal transplant recipients, especially those 
treated with CsA,26 the mineraloconiLOid action 
of prednisone may have played a permissive role 
m the kaliuretic response to an increased distal 
tubular load of sodium in our patients 
Both the natriuretic and kaliuretic effects of 
nifedipine (and other nifedipine-hke calcium an 
tagonists) might be of special value in the clinical 
practice of transplantation Sodium retention is 
supposed lo play an important role in the patho 
genesis of CsA induced hypertension,'1 and (he 
acute sodium losses with calcium antagonists ap­
pear to be maintained in the long term, as indi­
cated by sodium balance studies after initiation or 
discontinuation of these drugs 2 7 Hyperkalemia is 
a common problem with the use of CsA after 
renal transplantation, and antihypertensive agents 
with kaliuretic properties in this setting may 
therefore be preferred over drugs that lack this 
quality or even aggravate the risk of hyperka 
lemia, such as angiotensin converting enzyme in­
hibitors In a previous study, we demonstrated 
that dihydropyndine calcium antagonists are also 
effective antihypertensive agents in case of mod 
crate renal insufficiency,№ as can be expected in 
CsA-treatcd renal transplant patients 
In summary this study demonstrates that the 
oral administration of a single dose of nifedipine 
has favorable acute effects on renal hemodynam­
ics in renal transplant patients who are treated 
with CsA, while these effects were not observed 
in the same patients off CsA Since vasoconstric­
tion appears to play a pivotal role in acute as 
well as chronic CsA-induced renal dysfunction 
calcium antagonists may be well suited to miti­
gate these serious events In addition, the known 
effects of nifedipine on blood pressure, diuresis, 
and natnuresis also apply in renal transplant pa­
tients treated with CsA or azathiopnne The ob 
served effects of nifedipine in this and other stud­
ies support the combined use of CsA and 
nifedipine Prospective randomized placebo-con­
trolled studies on the chronic use of dihydropyn­
dine calcium antagonists in CsA treated renal 
transplant recipients are desired 
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CHAPTER 10 
Summary and discussion 

Summary 
Although the immunosuppressive drugs cyclosporine (CsA), azathioprine and 
prednisone are of proven value after renal transplantation, controversy remains 
about the optimal drug regimen for long term use. In selecting a treatment 
regimen, one has to search for an optimal compromise between sufficient 
immunosuppressive action on the one hand and side-effects and costs of the various 
drugs on the other hand. Especially during the first months after renal 
transplantation, when the risk of rejection is highest, many patients are successfully 
treated with the combination of CsA and prednisone. However, concern exists 
about the potential complications of these drugs when they are used chronically. 
The major side-effect of CsA is nephrotoxicity, and chronic use of CsA has been 
associated with irreversible loss of renal function. Prednisone has a wide array of 
adverse effects, of which steroid diabetes, cataract, Cushingoid appearance, and 
changes in bone metabolism and skin are the most notorious. Both CsA and 
prednisone have been implicated in the pathogenesis of post-transplant hypertension 
and hyperlipidaemia. To minimize the long term side-effects of these drugs, several 
strategies may be followed. One is to withdraw the steroids at some time after 
transplantation, resulting in CsA monotherapy. Another option is to replace CsA by 
azathioprine with continuation of prednisone. We performed a randomized 
prospective trial to compare these two treatment regimens. 
Our study population consisted of 127 patients who received a first or second 
cadaveric renal allograft. All patients received CsA and prednisone during the first 
three months after transplantation. Then, they were allocated to CsA monotherapy 
(n=64) or to the combination of azathioprine and prednisone (n=63). In chapter 2 
we report the results with regard to patient and graft survival, rejection incidence, 
and graft function after a follow-up ranging from 2.7 to 5.6 years. In addition, 
treatment related costs were calculated for the first year after transplantation. 
Although the originally assigned treatment was changed for various reasons in a 
considerable number of patients (about 40% at the end of the second year after 
transplantation), all data were analyzed according to the intention-to-treat principle. 
Estimated five-year patient survivals, departing from 100% at three months after 
transplantation (i.e. the time of randomization), were 92% and 95% in the CsA and 
azathioprine-prednisone group respectively (NS). Estimated graft survival rates 
(death with a functioning graft considered as graft failure) were equally satisfying 
in both groups: 78% in the CsA group and 87% in the azathioprine-prednisone 
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group at five years after transplantation (NS). A rather disappointing finding 
however, was the high incidence of acute rejections after both steroid withdrawal 
and conversion from CsA to azathioprine. Within three months after allocation to 
either therapy, the incidence of acute rejection was 30% in the CsA group and 
25% in the azathioprine-prednisone group. During follow-up, eleven grafts have 
been lost to the progressive course of rejection (8 in CsA group, 3 in azathioprine-
prednisone group; NS). In nine of these cases, the patient had been free of 
rejection episodes at the time of conversion from CsA to azathioprine or start of 
steroid withdrawal. This suggests that the reductions in immunosuppressive therapy 
may have contributed to graft loss in a number of cases. Regarding graft function, 
conversion from CsA to azathioprine resulted in an expected improvement of 
creatinine clearance by 19+20% after three months. In contrast, withdrawal of 
steroids was followed by a slight increase in serum creatinine, even when the 
analysis was restricted to patients without rejections or overt signs of CsA 
nephrotoxicity (rise in serum creatinine between 3 and 6 months after 
transplantation 7.5 + 13.9%). On the other hand, we did not observe a progressive 
decline in graft function in the patients who received CsA chronically. To our 
surprise, the reduction in blood pressure following withdrawal of steroids equalled 
that observed after conversion from CsA to azathioprine. Health care costs during 
the first year after transplantation were significantly lower in the azathioprine-
prednisone group. The difference was partly explained by lower drug costs during 
the period after randomization (months 4 to 12). Nevertheless, when costs of CsA, 
azathioprine, and prednisone as well as of CsA level measurements were not 
considered, there remained a tendency for lower costs in the azathioprine-
prednisone group. Summarizing these data, we conclude that with regard to graft 
survival, CsA monotherapy and azathioprine-prednisone are comparably effective 
immunosuppressive regimens from three months after transplantation. However, 
both regimens carry a substantial risk of rejection which may negatively influence 
graft survival rates during longer follow-up. Azathioprine-prednisone has the 
advantages of better graft function and lower costs. 
When two treatment strategies do not differ with respect to their influence on 
patient and graft survival, the quality of life of the patients becomes an extra 
important outcome variable. We evaluated quality of life during the first year after 
transplantation in 120 participants of our trial on CsA monotherapy versus 
azathioprine-prednisone, and the results are described in chapter 3. To assess 
quality of life, we used the Sickness Impact Profile (SIP), the Affect Balance Scale 
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(ABS), the Center for Epidemiological Studies Depression Scale (CES-D), 
measures of satisfaction with several domains of life experience, and a population-
specific physical symptoms questionnaire. In both treatment groups, the overall SIP 
score as well as the scores on its physical and psychosocial dimensions improved 
during the first year after transplantation, reaching levels that are comparable to 
those found in the general Dutch population. Intention-to-treat analysis showed no 
differences between the groups for scores on SIP, ABS, CES-D, and satisfaction 
measures. After exclusion of 41 patients who did not strictly adhere to their 
originally designated therapy (per-protocol analysis) we observed a tendency for 
better psychosocial SIP scores in CsA-treated patients, which mainly resulted from 
a difference on the category social interaction. It seems likely that the high level of 
quality of life in our study population has impaired the discriminative capacity of 
our quality of life measures. In combination with the limited sample size, this may 
have obscured additional differences between the treatment groups. Nevertheless, 
we conclude from this study that, if successfully completed, steroid withdrawal at 
three months after transplantation leads to a higher degree of psychosocial well-
being as compared to replacement of CsA by azathioprine with continuation of 
prednisone. Measurement of quality of life appeared a useful adjunct to evaluation 
by outcome measures that are traditionally used in the field of transplantation. 
In chapter 4 we provide data on the compliance with immunosuppressive and 
antihypertensive medication in the participants of our trial. We addressed this issue 
because compliance is an important determinant of long term graft survival. 
Moreover, we aimed to investigate whether adherence to the therapeutic regimen 
might be associated with the patient's psychosocial functioning as assessed by the 
quality of life measures described in the previous chapter. Using the pill count 
method we found a high degree of medication compliance during the first year after 
transplantation, although there was considerable variability within and between 
subjects. Scores for immunosuppressive drugs were superior to those for 
antihypertensive medication, possibly reflecting the patient's awareness of the risks 
of noncompliance with the immunosuppressants. Defining compliance arbitrarily as 
adhering to the prescribed regimen at least 80% of the time, the following 
frequencies of noncompliance were observed for the various drugs: CsA: 23%, 
azathioprine: 13%, prednisone: 23%, atenolol: 36%, and nifedipine: 32%. We 
were not able to demonstrate a consistent relationship between compliance on the 
one hand and several demographic variables or quality of life scores on the other 
hand. There was however a bidirectional relationship between compliance and the 
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occurrence of acute rejections: noncompliance was more frequent in patients with 
one or more rejections, and a rejection episode appeared to correct noncompliant 
behaviour. Thus, noncompliance was not a striking problem in our patient 
population although it may have contributed to the occurrence of rejection in some 
cases. 
Hyperlipidaemia is a frequent complication in renal transplant recipients and it 
may add to the high incidence of cardiovascular morbidity and mortality in this 
population. In chapter 5 we describe the effects of CsA and prednisone on serum 
lipid and (apo)lipoprotein levels. Measurements were carried out just before 
randomization to CsA monotherapy or azathioprine-prednisone at three months 
after transplantation, and at regular intervals during the remainder of the first post-
transplant year. Because azathioprine is not known to influence lipid metabolism, 
this study-design allowed direct comparison of the effects of CsA and prednisone. 
Withdrawal of prednisone in the CsA monotherapy group was followed by a 
considerable decrease in high-density lipoprotein (HDL) cholesterol (-27+30% at 5 
months after transplantation) and a rise in serum triglyceride levels (49 ±73% at 6 
months). Although conversion from CsA to azathioprine, with concomitant 
reduction in the daily dose of prednisone from 20 mg to 10 mg, also resulted in a 
decrease in HDL cholesterol (-13+25% at 6 months), the changes differed 
significantly between both groups for HDL cholesterol (a larger decrease with 
complete withdrawal of steroids) and for triglycerides (an increase in the CsA 
group versus no change in the azathioprine-prednisone group). Levels of total and 
LDL cholesterol did not change in either group. At one year after transplantation, 
CsA-treated patients had significantly higher lipoprotein(a) levels than patients 
receiving azathioprine-prednisone. Multiple linear regression analysis, which was 
applied to control for the influence of confounding variables, confirmed 
independent correlations between the use of prednisone and the HDL cholesterol 
level and between the use of CsA and the concentration of lipoprotein(a). In 
patients who were retreated with prednisone after prior steroid withdrawal, we 
observed a reversion of the decrease in HDL cholesterol and of the rise in 
triglycerides. Since a low HDL cholesterol level, high serum triglycerides, and a 
high lipoprotein(a) concentration all have been associated with an increased risk for 
coronary heart disease, we consider CsA monotherapy less favorable than the 
combination of azathioprine and prednisone in this regard. In contrast to our 
expectations (and to general belief) our data strongly indicate that withdrawal of 
steroids in CsA-treated renal transplant patients impairs rather than improves the 
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serum lipid and lipoprotein profile. 
The remaining studies of this thesis were performed to expand the knowledge 
on the renal effects of CsA. Chapter 6 gives the results of detailed examination of 
changes in various parameters of renal function after conversion from CsA to 
azathioprine. Twelve patients were studied immediately before and 1, 2, and 4 
weeks after replacement of CsA by azathioprine at three months after renal 
transplantation. An improvement in GFR by 15% was already observed during the 
first week after conversion. In the ensuing weeks only a minor further increase was 
noticed. Measurement of the renal (tubular) handling of sodium, lithium, 
potassium, bicarbonate, magnesium, and urate showed that the serum levels of 
magnesium and urate were the most sensitive markers of the reversible renal 
effects of CsA. During the first week after conversion, the serum magnesium level 
rose in all patients whereas the urate concentration decreased in all but one patient. 
These findings led us to conclude that with regard to renal function, the outcome of 
CsA withdrawal can be evaluated definitely as early as after one to two weeks. 
In routine clinical practice, serum creatinine is commonly used to asses the 
degree of CsA-induced renal dysfunction. However, the use of creatinine as a 
marker of the GFR has some pitfalls. Since creatinine is not only filtered in the 
glomerulus but also secreted by the renal tubule, the ratio of creatinine clearance to 
GFR will exceed 1.0 to an unpredictable degree. Moreover, an increase in serum 
creatinine during treatment with CsA may theoretically result from a decrease in 
glomerular filtration, a decrease in tubular secretion, or both. While the effects of 
CsA on GFR are well-known, we searched for an additional effect of CsA on the 
tubular secretion of creatinine. To this end, we utilized the ability of the drug 
Cimetidine to inhibit the tubular creatinine secretion. Whether this property of 
Cimetidine might indeed be used to improve the validity of creatinine as a marker 
of glomerular filtration was first investigated in a separate study, presented in 
chapter 7. In 10 healthy subjects and 29 patients with varying degrees of renal 
dysfunction, we compared the clearance of creatinine to that of the true filtration 
markers 51Cr-EDTA and inulin. After the administration of Cimetidine, the mean 
ratio of the clearance of creatinine to the clearance of 51Cr-EDTA was 1.02 ±0.13, 
whereas the ratio of creatinine clearance to inulin clearance was 1.01+0.13. Mean 
ratios did not differ between three subgroups of subjects, composed according to 
renal function. Thus, after oral administration of Cimetidine the creatinine clearance 
appears to be a reliable measure of GFR within a broad range of renal function. At 
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the same time, it can be inferred that the increase in serum creatinine after 
administration of Cimetidine provides information on the degree of tubular 
creatinine secretion in a given subject. 
Chapter 8 contains the results of two studies which were performed to 
determine the influence of CsA on the tubular secretion of creatinine. In one of 
these studies, the cimetidine-induced rise in serum creatinine was compared in 
renal transplant patients treated with either CsA or azathioprine. Administration of 
Cimetidine led to similar increases of creatinine in CsA and in azathioprine 
receiving patients. If creatinine secretion was already impeded by CsA, a smaller 
increase in the CsA group would have been expected. In the second study, the 
clearance of creatinine and of inulin were measured immediately before and 4 
weeks after cessation of CsA therapy in 17 renal allograft recipients. The ratio 
between these clearances did not change after discontinuation of CsA, while an 
increase would have been expected if creatinine secretion had been inhibited by 
CsA. The results of both studies therefore indicate that CsA does not affect the 
tubular secretion of creatinine. The practical consequence of this conclusion is that 
a rise in serum creatinine after administration of CsA can be attributed completely 
to a fall in GFR. 
Awareness of the important role of afferent vasoconstriction in the pathogenesis 
of the CsA-induced fall in GFR, has stimulated the use of vasodilating calcium 
antagonists in CsA-treated patients. We investigated the ability of nifedipine to 
counteract the renal effects of CsA in a placebo-controlled study (chapter 9). 
Administration of a single oral dose of nifedipine to 20 CsA-treated renal transplant 
patients led to an increase in GFR and renal plasma flow by 14% and 31% 
respectively. In addition, nifedipine had a strong diuretic and natriuretic effect. In a 
subgroup of patients, measurements were repeated after conversion from CsA to 
azathioprine. The significant increases in GFR that occurred after ingestion of 
nifedipine during treatment with CsA were not observed during treatment with 
azathioprine, which indicates that the beneficial renal hemodynamic effects of 
nifedipine are restricted to CsA-treated patients. Probably, this reflects a specific 
action of nifedipine in counteracting the renal vasoconstrictive effects of CsA. The 
fact that the natriuretic response to nifedipine was present during treatment with 
azathioprine as well, agrees with the concept that the natriuretic effects of calcium 
antagonists cannot be explained solely by their influence on renal hemodynamics. 
Based on the effects of nifedipine observed in this study, we suppose that calcium 
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antagonists may be well-suited to reduce or prevent the renal injury that can occur 
during chronic treatment with CsA. 
Unresolved questions and future prospects 
Many studies in the field of transplantation have focused on developing drugs 
which are able to reduce the incidence of rejections and prolong graft survival. 
However, current graft survival rates after renal transplantation have reached a 
level that will be hard to surpass. More powerful immunosuppressive drug 
regimens will certainly take their toll by a higher incidence of complications. It can 
be questioned whether the improvement in graft survival will outweigh the 
increased frequency of infections, malignancies, and other adverse effects. 
Therefore, many research efforts are directed to find more specific ways to prevent 
an immune response e.g. by induction of tolerance to allo-antigens. Pre-transplant 
blood transfusions are thought to act in this manner, and more sophisticated 
methods of tolerance induction are on their way from experimental transplantation 
to clinical application. In the meantime, we will have to design non-specific 
immunosuppressive drug regimens that combine adequate immunosuppressive 
action with an acceptable array of side-effects. In view of the prolonged survival of 
renal allograft recipients, special attention should be paid to those complications 
which can result from chronic immunosuppressive drug treatment (1). Since 
individual patients may differ with regard to immunological characteristics as well 
as risk factors for long-term complications, it appears unlikely that a single 
treatment regimen will suffice in all cases. Perhaps, we will once succeed in 
employing clinical-decision making models to compose patient-tailored 
immunosuppressive therapy on the basis of several demographic, clinical, and 
immunological variables. 
One of the limitations of our randomized comparison between CsA monotherapy 
and azathioprine-prednisone is the as yet rather short duration of follow-up. 
Although all patients were at least two years after their transplantation at the time 
of analysis, the consequences of the different treatment strategies regarding graft 
survival may only become manifest after still longer follow-up. Quality of life and 
expenditure to health care were measured during the first year after transplantation. 
It is evident that longer use of the various drugs may lead to additional 
complications with concomitant changes in quality of life and costs. Similarly, it 
would be relevant to measure medication compliance at a later stage after 
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transplantation, since late allograft failure has particularly been related to 
noncompliance. We presume that the follow-up was long enough to evaluate the 
effect of CsA and prednisone on lipid and (apo)lipoprotein metabolism. However, 
for optimal interpretation of the unfavorable serum lipid profile in patients on CsA 
monotherapy, it would have been helpful to have a control group of patients who 
had continued both CsA and prednisone. Currently, we are performing a trial to 
compare the effects on serum lipids and lipoproteins of treatment with CsA-
prednisone to that of treatment with CsA-azathioprine. In this regard, the latter 
combination can be considered as CsA monotherapy, since azathioprine is not 
known to influence lipid metabolism. Prolonged follow-up is necessary to 
investigate whether the divergent effects of various immunosuppressants on lipid 
metabolism are reflected in different incidences of clinical signs of atherosclerosis. 
In comparing the long-term complications of various immunosuppressive drug 
regimens, notice should be given to the occurrence of malignancies as well as to 
problems with bone and skin (1). In the present studies we did not address these 
issues in detail, but our patients on CsA monotherapy continue to be a valuable 
source of information to investigate the advantages of a steroid-free regimen in this 
regard. Additional studies on the pathogenesis, prevention, and therapy of post-
transplantation disorders of bone and skin are at various stages of preparation and 
progress in our centre. 
Although knowledge on the mechanism by which CsA impairs renal function is 
gradually growing, more research on this topic is still required. Because practically 
all immunosuppressive regimens that are used in renal transplant patients are based 
on CsA, attenuation of the renal side-effects of this drug would be a meaningful 
advancement. Concurrent treatment with calcium-antagonists seems the most 
promising approach to reach this goal. In addition to the beneficial renal 
hemodynamic effects as described in this thesis, calcium antagonists have been 
demonstrated to reduce the incidence of delayed graft function in CsA-treated renal 
transplant patients. Currently, we are involved in a prospective placebo-controlled 
trial to evaluate the effect of adding the calcium antagonist isradipine to the 
standard CsA-based immunosuppressive regimen. Primary endpoints are the 
incidence of delayed graft function and the ultimate level of graft function. 
One of the main findings from our comparison of CsA monotherapy and 
azathioprine-prednisone was the rather high rate of acute rejections in both groups. 
We therefore concluded that neither treatment regimen can be recommended as 
first-choice therapy for general use. On the other hand, indefinite continuation of 
both CsA and prednisone to reduce the incidence of rejections may unnecessarily 
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expose a certain number of patients to the long-term adverse effects of these drugs. 
Until now, it has not been possible to identify patients in whom reduction of the 
immunosuppressive therapy is likely to be successful. Therefore, other strategies to 
minimize the long term side-effects of CsA or prednisone have to be explored. 
Based on these considerations, we have initiated a randomized prospective trial to 
compare CsA-prednisone to CsA-azathioprine from six months after renal 
transplantation. The latter regimen was recently shown to provide excellent long 
term graft survival (2) and the side-effects of azathioprine are less feared. 
In the past few years, several new immunosuppressive drugs have been 
investigated for their potential to couple excellent immunosuppressive properties to 
less impressive side-effects. Tacrolimus, also known as FK 506, acts in a similar 
way as CsA and is an equally effective immunosuppressive agent (3). 
Unfortunately, nephrotoxicity comparable to that caused by CsA appeared to be a 
side-effect as well (4). This drug has therefore not gained wide acceptance in the 
field of renal transplantation. IMM 125 is a derivative of CsA which was supposed 
to possess equal immunosuppressive activity while being less nephrotoxic as 
compared to CsA itself. We participated in a European multicentre trial to examine 
the change in renal allograft function after replacement of CsA by IMM-125. The 
results of this trial showed no evidence for a meaningful improvement in renal 
function after switching to IMM-125, whereas liver function disturbances occurred 
in a substantial number of patients (unpublished observations). Mycophenolate 
mofetil (RS 61443) inhibits the de novo purine synthesis of lymphocytes. Several 
studies have confirmed its capacity to reduce the rejection incidence when added to 
conventional immunosuppressive therapy (5). Drag-specific adverse effects are 
mainly confined to the gastro-intestinal tract and bone marrow, although the 
frequency of leucopenia is markedly lower than is seen with the use of 
azathioprine. Mycophenolate mofetil appears to be the first drug since the 
introduction of CsA that holds the promise to add to an immunosuppressive drug 
regimen combining the current standard of immunosuppressive effectiveness with 
less side-effects. As many others, our centre is involved in clinical trials to explore 
the role of mycophenolate mofetil containing drug combinations in baseline 
immunosuppression. In due course, quality of life and costs should be used 
amongst other outcome measures to evaluate the appropriateness of these novel 
therapeutic approaches. 
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IMMUNOSUPPRESSIVE BEHANDELING NA EEN NIERTRANSPLANTATIE: 
TEGEN ELKAAR AFWEGEN VAN NUTTIGE EN SCHADELIJKE EFFECTEN 
SAMENVATTING 
Voor patiënten met zeer slecht functionerende nieren bestaan drie vormen van 
nierfunctievervangende therapie: hemodialyse, peritoneale dialyse en 
niertransplantatie. In het algemeen verdient niertransplantatie de voorkeur omdat dit 
tot een betere kwaliteit van leven leidt en uiteindelijk minder kostbaar is dan 
chronische dialysebehandeling. De resultaten van niertransplantatie zijn bovendien 
geleidelijk verbeterd; tegenwoordig heeft circa 85% van de patiënten een voldoende 
functionerende nier op één jaar na de transplantatie. Vijf jaar na de transplantatie 
bedraagt de transplantaatoverleving ongeveer 70%. 
Doordat een transplantaatnier als lichaamsvreemd herkend wordt kan er een 
afstotingsreactie (=rejectie) ontstaan. Een snel verlopende, acute, rejectie kan 
meestal met medicijnen die het natuurlijke afweersysteem zeer sterk onderdrukken 
succesvol behandeld worden, terwijl een chronische rejectie uiteindelijk vaak tot 
verlies van de transplantaatfunctie leidt. Om het optreden van rejecties te 
voorkomen worden ontvangers van een transplantaatnier levenslang behandeld met 
medicijnen die de afweer verzwakken (immunosuppressieve middelen). 
Ciclosporine (Sandimmune*, Neoral*) is hiervan een voorbeeld. Met het gebruik 
van dit middel, sinds ± 1980, is de transplantaatoverleving enorm verbeterd. 
Andere medicamenten die veel worden gebruikt zijn azathioprine (Imuran*) en 
Prednison. Gedurende de eerste maanden na de transplantatie worden de meeste 
patiënten behandeld met Ciclosporine en prednison. Welk behandelschema op de 
lange duur de beste resultaten oplevert is echter niet precies bekend. Bij het 
vaststellen van de optimale aanpak moet een compromis worden gezocht tussen een 
voldoende immunosuppressief effect van de behandeling enerzijds en zo weinig 
mogelijk bijwerkingen en kosten van de betrokken medicamenten anderzijds. 
Langdurig gebruik van welk immunosuppressief medicijn dan ook resulteert in een 
verhoogde kans op het krijgen van infecties en kwaadaardige ziekten. Daarnaast 
kent ieder middel zijn eigen specifieke nadelen. Ciclosporine is relatief duur, en 
heeft als belangrijke bijwerkingen remming van de nierfunctie (uiteraard zeer 
ongewenst na een niertransplantatie), hoge bloeddruk en verstoring van de 
vetstofwisseling. De laatste twee effecten zijn ook bekend van prednison en dit 
middel kan daarnaast nog aanleiding geven tot suikerziekte, botontkalking, staar en 
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een dunne huid. De voornaamste bijwerkingen van azathioprine zijn nadelige 
effecten op beenmerg- en leverfuncties. 
Om de, vaak op lange termijn optredende, schadelijke effecten van de 
immunosuppressiva zoveel mogelijk te beperken kunnen verschillende wegen 
worden gevolgd. Eén mogelijkheid is het slechts tijdelijk toedienen van prednison 
en daarna alleen met Ciclosporine doorgaan. Een andere optie is het vervangen van 
Ciclosporine door azathioprine (waarvan de bijwerkingen minder gevreesd worden), 
en de behandeling met prednison voortzetten. In dit proefschrift wordt verslag 
gedaan van een prospectief onderzoek waarbij een veelomvattende vergelijking van 
deze twee behandelmethoden is gemaakt. 
De onderzoekspopulatie bestond uit 127 patiënten die voor de eerste of tweede 
keer een niertransplantatie hadden ondergaan. Tijdens de eerste drie maanden na de 
transplantatie werden alle patiënten behandeld met Ciclosporine en prednison. 
Daarna werden ze door loting verdeeld in twee groepen; een groep waarin 
behandeling met alleen Ciclosporine plaatsvond (n=64) en een groep waarin 
Ciclosporine werd vervangen door azathioprine (n=63). In hoofdstuk 2 beschrijven 
wij de resultaten met betrekking tot overleving van de patiënten, 
transplantaatverliezen, het optreden van rejecties, en de transplantaatfunctie, na een 
vervolgperiode van 2,7 tot 5,6 jaar. Bovendien verschaffen wij gegevens over de 
kosten van de gezondheidszorg tijdens het eerste jaar na de transplantatie bij deze 
patiënten. Hoewel bij een groot aantal patiënten de behandeling in de loop der tijd 
om diverse redenen gewijzigd moest worden (oplopend tot ongeveer 40% op het 
einde van het tweede jaar na transplantatie), werden de gegevens geanalyseerd op 
basis van het oorspronkelijk toegewezen behandelschema. 
De geschatte vijf-jaars patiëntoverleving (met als uitgangspunt 100% op 3 
maanden) bedroeg in de Ciclosporine en azathioprine-prednison groep 
respectievelijk 92% en 95%. De transplantaatoverleving (sterfte met een 
functionerend transplantaat telde als transplantaatverlies) was eveneens bevredigend 
in beide groepen: 78% in de Ciclosporine groep en 87% in de azathioprine-
prednison groep op vijfjaar na de transplantatie. Een teleurstellende bevinding was 
het veelvuldig optreden van een acute rejectie, zowel na stoppen van prednison als 
na vervanging van Ciclosporine door azathioprine. In de eerste drie maanden na 
deze veranderingen in de therapie ontstond bij 30% van de patiënten in de 
Ciclosporine groep en bij 25% van de patiënten in de azathioprine-prednison groep 
een acute rejectie, terwijl rond dit tijdstip na transplantatie veel minder acute 
rejecties te verwachten zijn. Gedurende de vervolgperiode ging bij 11 patiënten (8 
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in de Ciclosporine groep en 3 in de azathioprine-prednison groep) de functie van de 
transplantaatnier verloren. Negen van deze patiënten hadden nog geen acute rejectie 
meegemaakt toen drie maanden na transplantatie hun behandeling werd gewijzigd. 
Dit betekent dat de verlichting van de immunosuppressieve therapie in een aantal 
gevallen bijgedragen zou kunnen hebben aan het transplantaatverlies. 
Vervanging van Ciclosporine door azathioprine leidde, zoals verwacht, tot een 
duidelijke verbetering van de nierfunctie. Het stoppen met prednison in de 
Ciclosporine groep werd daarentegen gevolgd door een lichte achteruitgang van de 
transplantaatfunctie. Wij vonden echter geen aanwijzingen voor een (gevreesde) 
progressieve verslechtering van de nierfunctie bij de patiënten die aanhoudend met 
Ciclosporine werden behandeld. Stoppen met prednison en vervanging van 
Ciclosporine door azathioprine resulteerden in een vergelijkbare verbetering van de 
bloeddruk. De kosten van gezondheidszorg in het eerste jaar na de transplantatie 
waren duidelijk lager in de azathioprine-prednison groep. Het verschil was slechts 
gedeeltelijk te verklaren uit het feit dat azathioprine en prednison minder kostbare 
medicijnen zijn dan Ciclosporine. 
Samenvattend concluderen wij uit onze bevindingen dat Ciclosporine en de 
combinatie azathioprine-prednison vanaf drie maanden na transplantatie 
gelijkwaardige immunosuppressieve behandelingen zijn met betrekking tot de 
transplantaatoverleving. De relatief hoge kans op een acute rejectie verbonden aan 
beide behandelschema's zou de transplantaatoverleving op de langere termijn echter 
wel eens ongunstig kunnen beïnvloedden. De behandeling met azathioprine-
prednison heeft als voordelen een betere nierfunctie en lagere kosten. 
Bij het beoordelen van de doelmatigheid van chronische behandelingen wordt de 
laatste jaren steeds meer aandacht besteed aan de zogenaamde kwaliteit-van-leven 
als belangrijke uitkomstvariabele. Wij evalueerden de kwaliteit-van-leven bij 120 
deelnemers van het eerder genoemde onderzoek (hoofdstuk 3). Voor het meten 
hiervan werd gebruik gemaakt van Nederlandse vertalingen van de volgende 
gestandaardiseerde vragenlijsten: Sickness Impact Profile (SIP), Affect Balance 
Scale (ABS) en Center for Epidemiological Studies Depression Scale (CES-D). 
Daar aan toegevoegd werden vragen over de tevredenheid met diverse aspecten van 
het leven en vragen naar lichamelijke klachten die bij deze patiëntengroep verwacht 
kunnen worden. In zowel de Ciclosporine als azathioprine-prednison groep was er 
een verbetering van de SIP-scores tot waarden die door anderen werden gevonden 
in een steekproef uit de Nederlandse bevolking. Voor geen van de vragenlijsten 
waren er verschillen tussen de scores in beide groepen. Na uitsluiting van 41 
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patiënten bij wie het oorspronkelijk toegewezen behandelschema niet precies werd 
gevolgd, vonden wij met de SIP een duidelijke tendens tot beter psychosociaal 
functioneren in de Ciclosporine groep. Dit werd voornamelijk veroorzaakt door 
gunstiger scores in de categorie vragen over sociale interacties. De bevindingen 
wijzen er dus op, dat als het lukt de behandeling met prednison vanaf drie maanden 
na transplantatie te staken, dit tot een hogere graad van psychosociaal welbevinden 
leidt dan in geval van vervanging van ciclosporine-prednison door azathioprine-
prednison. 
In hoofdstuk 4 beschrijven wij de mate van therapietrouw met betrekking tot 
immunosuppressiva en medicijnen tegen hoge bloeddruk (antihypertensiva; bijv. 
atenolol en nifedipine) in onze onderzoekspopulatie. Wij waren hier in 
geïnteresseerd omdat is aangetoond dat geringe therapietrouw één van de meest 
voorkomende oorzaken is van transplantaatverlies. Bovendien wilden wij 
onderzoeken of de therapietrouw samenhangt met aspecten van de kwaliteit-van-
leven. De therapietrouw werd beoordeeld door gedurende het eerste jaar na de 
niertransplantatie maandelijks de overgebleven tabletten te tellen. Wij vonden in het 
algemeen een hoge graad van therapietrouw hoewel er nogal wat variatie aanwezig 
was in de loop van de tijd en ook tussen verschillende patiënten. De scores voor 
immunosuppressiva waren beter dan die voor antihypertensiva, wat mogelijk 
samenhangt met de aard van de consequenties van het niet zorgvuldig innemen van 
beide groepen middelen. Wanneer therapietrouw werd gedefinieerd als het 
gedurende meer dan 80% van de tijd volgens voorschrift innemen van de 
medicijnen, dan stelden wij bij de volgende percentages patiënten gebrek aan 
therapietrouw vast voor de verschillende middelen: Ciclosporine 23%, azathioprine 
13%, prednison 23%, atenolol 36%, en nifedipine 32%. Wij konden geen verband 
aantonen tussen de mate van therapietrouw enerzijds en verschillende 
demografische variabelen of scores op de kwaliteit-van-leven vragenlijsten 
anderzijds. Er was wel een duidelijke relatie tussen therapietrouw en het 
voorkomen van rejecties: a) de therapietrouw was geringer bij patiënten met één of 
meer rejecties, en b) het optreden van een rejectie werd gevolgd door toename van 
de therapietrouw. Hoewel de therapietrouw globaal beschouwd dus wel goed was, 
heeft tekort aan therapietrouw bij een aantal patiënten waarschijnlijk toch 
bijgedragen aan het optreden van een rejectie. 
Stoornissen in de vetstofwisseling komen regelmatig voor na een 
niertransplantatie en dragen mogelijk bij aan het veelvuldig optreden van hart- en 
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vaatziekten bij deze categorie patiënten. In hoofdstuk 5 beschrijven wij de effecten 
van Ciclosporine en prednison op de bloedspiegels van lipiden (zoals cholesterol en 
triglyceriden) en lipoproteïnen (samengesteld uit lipiden en eiwitten). De metingen 
werden in onze onderzoekspopulatie uitgevoerd tijdens behandeling met 
ciclosporine-prednison en vervolgens tijdens het gebruik van óf alleen Ciclosporine 
óf de combinatie van azathioprine en prednison. Omdat van azathioprine geen 
invloed op de vetstofwisseling bekend is, vergeleken wij op die manier in feite de 
effecten van Ciclosporine en prednison. Staken van de behandeling met prednison in 
de Ciclosporine groep resulteerde in een sterke daling van de 'high-density 
lipoprotein' (HDL)-cholesterolconcentratie en een stijging van het 
triglyceridengehalte. In de andere groep trad na vervanging van Ciclosporine door 
azathioprine ook een daling van HDL-cholesterol op, maar deze daling was 
geringer dan na stoppen met prednison. De concentraties van totaal cholesterol en 
'low-density lipoprotein' (LDL)-cholesterol bleven onveranderd in beide groepen. 
Eén jaar na de transplantatie werden in de Ciclosporine groep hogere waarden 
gevonden voor lipoproteïne(a) dan in de azathioprine-prednison groep. Ook na 
rekenkundige correctie voor eventuele verstorende factoren bleek gebruik van 
prednison samen te gaan met een hoger HDL-cholesterolgehalte en inname van 
Ciclosporine met een hogere concentratie van lipoproteïne(a). 
In grote onderzoeken is aangetoond dat een laag HDL-cholesterolgehalte, een 
hoge triglyceridenconcentratie, en een hoge waarde voor lipoproteïne(a) ieder het 
risico op het krijgen van kransslagadervernauwing verhogen. Vanuit dat 
gezichtspunt verdient azathioprine-prednison dus de voorkeur boven Ciclosporine. 
In tegenstelling tot wat algemeen verondersteld wordt, geven onze bevindingen aan 
dat staken van het gebruik van prednison bij patiënten die met de combinatie 
ciclosporine-prednison behandeld worden, eerder een verslechtering dan een 
verbetering van de vetstofwisseling tot gevolg heeft. 
De resultaten van de voorgaande hoofdstukken overziend, kan worden gesteld 
dat ten aanzien van de transplantaatoverleving het stoppen met prednison en 
vervanging van Ciclosporine door azathioprine gelijkwaardige behandelingen zijn. 
Bij de meerderheid van de patiënten is verlichting van de immunosuppressieve 
therapie zonder grote problemen realiseerbaar. Behandeling met azathioprine-
prednison leidt tot een betere nierfunctie, minder verstoring van de vetstofwisseling 
en lagere kosten. Succesvol staken van prednison lijkt echter (voor het onderzochte 
tijdvak) beter voor de kwaliteit-van-leven. Een nadeel van beide behandelschema's 
is de relatief hoge kans op het optreden van een rejectie. Wij beschouwen deze 
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wijzen van aanpak daarom nog niet als ideaal en wij zijn op zoek naar mogelijke 
verbeteringen. 
De overige onderzoeken uit dit proefschrift werden uitgevoerd om meer kennis 
te verkrijgen over de wijze waarop Ciclosporine de nierfunctie negatief beïnvloedt. 
Hoofdstuk 6 bevat een gedetailleerde beschrijving van de veranderingen in diverse 
parameters van de nierfunctie na vervanging van Ciclosporine door azathioprine bij 
12 van de patiënten die deelnamen aan bovenstaande studie. Een toename van de 
filtratiesnelheid van bloed in de nier (gemiddeld 15%) was al na één week 
waarneembaar, terwijl daarna slechts een geringe verdere stijging optrad. Van 
diverse stoffen onderzochten wij de heropname in het bloed uit de voorurine en/of 
de uitscheiding uit het bloed naar de urine door de nierbuisjes. Het bleek dat deze 
processen voor wat betreft magnesium en uraat waarschijnlijk in belangrijke mate 
beïnvloed worden door Ciclosporine omdat reeds één week na staken van 
Ciclosporine het magnesiumgehalte in het bloed bij alle patiënten was gestegen en 
de uraatspiegel bij 11 patiënten was gedaald. 
In de dagelijkse praktijk wordt het kreatininegehalte in het bloed gebruikt als 
graadmeter voor de nierfunctie en op basis hiervan wordt meestal ook de mate van 
remming van de nierfunctie door Ciclosporine vastgesteld. Voor wat betreft de 
nierfunctie zijn wij eigenlijk vooral geïnteresseerd in de filtratiesnelheid van het 
bloed in de nier ('glomerular filtration rate'; GFR). Kreatinine wordt echter niet 
alleen door filtratie uit het bloed verwijderd, maar wordt daarnaast ook door de 
nierbuisjes van het bloed naar de urine overgebracht (tubulaire secretie). Een 
stijging van het kreatininegehalte tijdens behandeling met Ciclosporine kan 
theoretisch dus veroorzaakt worden door een afname van de GFR, een afname van 
de tubulaire secretie, of door beide processen samen. Dat Ciclosporine de GFR 
vermindert is algemeen bekend, maar over de invloed van Ciclosporine op de 
tubulaire kreatinine secretie was eigenlijk geen informatie beschikbaar. Om dit 
laatste te kunnen bestuderen onderzochten wij eerst de mogelijkheid om de 
tubulaire secretie van kreatinine volledig te blokkeren met Cimetidine (een 
medicament dat veel gebruikt wordt om de maagzuurproduktie te remmen). 
In hoofdstuk 7 staat beschreven hoe wij bij 10 gezonde proefpersonen en 29 
patiënten met diverse nieraandoeningen de verwijdering uit het bloed (klaring) van 
kreatinine vergeleken met de klaring van stoffen die louter gefiltreerd worden en 
geen tubulaire secretie ondergaan (inuline en 51Cr-EDTA). Nadat Cimetidine 
gedurende enkele dagen was ingenomen bleek de klaring van kreatinine gelijk te 
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zijn aan die van de zuivere filtratiemerkstoffen Cimetidine had de tubulaire 
secretie van kreatinine blijkbaar voldoende geblokkeerd 
Wij analyseerden vervolgens op twee manieren de invloed van Ciclosporine op 
de tubulaire secretie van kreatinine (hoofdstuk 8) Op de eerste plaats maten wij de 
stijging van het kreatininegehalte na toediemng van Cimetidine bij patiënten die al 
of niet Ciclosporine gebruikten na een mertransplantatie Indien de tubulaire secretie 
door Ciclosporine geremd wordt, zou de toediemng van Cimetidine bij Ciclosporine 
gebruikende patiënten een geringere stijging van het kreatinine tot gevolg moeten 
hebben dan bij patiënten die geen Ciclosporine innemen Wij vonden in beide 
groepen echter een even grote toename van het kreatininegehalte 
Ten tweede bepaalden wij gelijktijdig de klaring van kreatinine en van inuline 
direct vóór, en 4 weken na het staken van Ciclosporine, bij 17 ontvangers van een 
transplantaatruer Uitgaande van beëindiging van de door Ciclosporine 
teweeggebrachte remming van de tubulaire kreatinine secretie, zou er een stijging 
op moeten treden van de verhouding kreatinineklanng inulineklaring Deze ratio 
veranderde echter niet bij de onderzochte patiënten De resultaten van beide 
onderzoeken pleiten dus sterk tegen een remmende invloed van Ciclosporine op de 
tubulaire secretie van kreatinine De betekenis daarvan is dat een stijging van het 
kreatininegehalte tijdens behandeling met Ciclosporine geheel kan worden 
toegeschreven aan een daling van de glomerulaire filtratiesnelheid 
De daling van de GFR tijdens gebruik van Ciclosporine berust waarschijnlijk 
grotendeels op vernauwing van de aanvoerende bloedvaten in de mer Wij 
onderzochten daarom of het vaatverwijdende middel nifedipine (Adalat*) in staat is 
de ongewenste effecten van Ciclosporine op de nierfunctie tegen te gaan (hoofdstuk 
9) Toediemng van een enkele dosis nifedipine aan met Ciclosporine behandelde 
niertransplantatiepatienten, leidde in de daarop volgende uren tot een toename van 
zowel de bloeddoorstroming van de nier als van de GFR met respectievelijk 31% 
en 14% Daarnaast maten wij een toegenomen uitscheiding van water en zout in de 
urine Omdat met uitgesloten was dat nifedipine dezelfde werking zou vertonen bij 
patiënten die geen Ciclosporine gebruikten, herhaalden wij bij een aantal patiënten 
de metingen vier weken nadat bij hen Ciclosporine vervangen was door 
azathiopnne De toename van de GFR die waargenomen werd na inname van 
nifedipine tijdens behandeling met Ciclosporine trad met meer op tijdens 
behandeling met azathiopnne Blijkbaar kan nifedipine de effecten van Ciclosporine 
op de bloedvaten in de nier tenietdoen De toegenomen water- en zoutuitscheidmg 
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was wel in beide situaties aanwezig, hetgeen past bij de veronderstelling dat de 
toename van de zoutuitscheiding door nifedipine niet verklaard kan worden door 
bloedvatverwijding in de nier. Gebaseerd op de bevindingen in dit onderzoek 
verwachten wij dat de nierbeschadiging die bij langdurig gebruik van Ciclosporine 
op kan treden verminderd zou kunnen worden door gelijktijdige behandeling met 
nifedipine of soortgelijke middelen. 
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Het verpleegkundige en overige personeel van de niertransplantatie-afdeling en de 
medewerkers van de polikliniek inwendige ziekten (toen nog post A), krijgen een 
pluim voor de prettige wijze van omgang met de patiënten. Bovendien heb ik de 
regelmatig door hen getoonde belangstelling voor mijn onderzoek altijd zeer 
gewaardeerd. 
Ik onderschrijf de stelling dat de kwaliteit-van-leven in belangrijke mate wordt 
bepaald door het karakter van de mensen met wie men dagelijks omgaat. Uit dat 
oogpunt had ik het de afgelopen jaren niet beter kunnen treffen. Op de afdeling 
Nierziekten heerst een volwassen attitude die omschreven kan worden als oprecht, 
kritisch en stimulerend. Overigens valt er gelukkig ook voldoende te lachen. 
Thuis zorgden het blijmoedige karakter en de nuchtere instelling van Anique voor 
aangename afleiding en relativering. 
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STELLINGEN 
1 Het is niet hard te maken dat het leven van patiënten met een terminale 
niennsufficientie meer wordt verlengd door een niertransplantatie dan door 
behandeling met chronische hemodialyse of continue ambulante peritoneale dialyse 
2 Bij de evaluatie van immunosuppressieve behandelschema's na een niertransplantatie 
ligt het accent doorgaans teveel op de behaalde transplantaatoverlevingspercentages 
en is er relatief weinig aandacht voor de bijwerkingen en kosten van de 
verschillende alternatieven 
3 Het optreden van een rejectie na een niertransplantatie kan een corrigerend eftect 
sorteren op enige mate van therapie-ontrouw welke mogelijk aan deze rejectie heeft 
bijgedragen (dit proefschrift) 
4 Bij niertransplantatiepatienten die worden behandeld met Ciclosporine en prednison, 
leidt staken van de prednisonbehandeling tot ongunstige veranderingen in de 
serumconcentraties van lipiden en lipoproteinen (dit proefschrift) 
5. BIJ de toeneming van het lichaamsgewicht na een niertransplantatie, speelt het 
gebruik van prednison geen belangrijke rol, tijdens het eerste jaar na de 
transplantatie is de gewichtstoeneming bij patiënten die na drie maanden stoppen 
met prednison hetzelfde als bij hen die dit middel gedurende het gehele jaar 
gebruiken (eigen waarnemingen) 
6. Nadat enkele dagen Cimetidine is gebruikt, vormt het meten van de kreatinineklaring 
met behulp van de gedurende 90 minuten gespaarde urine, een betrouwbaar 
alternatief voor de klassieke GFR-meting die gebruik maakt van intraveneuze 
toediening van inuline of 51Cr-EDTA (dit proefschrift). 
7 Er moet ernstig rekening mee worden gehouden dat poly-ethyleen glycol, dat als 
oplosmiddel deel uitmaakt van de intraveneuze toedieningsvorm van een aantal 
geneesmiddelen, de kans op trombose in een transplantaatnier verhoogt (eigen 
waarnemingen). 
8. Op het moment dat een chronische vasculaire rejectie van een transplantaatnier zich 
uit in verslechtering van de transplantaatfunctie, is intensivering van de 
immunosuppressieve therapie waarschijnlijk niet meer zinvol. 
9. Indien er bij een transplantatie-kandidaat een indicatie bestaat voor secundaire 
tuberculose-profylaxe met isoniazide, is het, in verband met de potentiële interacties 
en bijwerkingen van dit middel, aan te bevelen deze behandeling uit te voeren 
tijdens de wachttijd voor de transplantatie in plaats van erna 
10. Om het dysfunctioneren binnen de medische beroepsgroep zoveel mogelijk te 
beperken, behoren artsen naast het percuteren ook het elkaar op de vingers tikken te 
beheersen. Van belang daarbij is verder dat men niet alleen patiënten maar ook 
elkaar de waarheid durft te vertellen 
11. In de geneeskunde leidt een defensieve houding vaak juist tot een offensief van 
diagnostische en therapeutische handelingen. 
12. Op een compact-disc met populaire muziek ligt het vijfde nummer dikwijls het best 
in het gehoor 
13 Mensen die met de leeftijd rechtser worden, laten hun verleden links liggen 
14. Het geforceerd zoeken naar 'geslachtsneutrale' woorden zoals menskracht en 
timmerpersoon kan toepasselijk worden betiteld als kul 
19 januari 1996 
Luuk Hilbrands 


